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ABSTRACT 
Congenital cytomegalovirus (CMV) infection is responsible for long-term morbidity 
in the form of sensorineural hearing loss and neurodevelopmental impairment in a 
high proportion of those with symptomatic infection at birth but only around 14% of 
those without symptoms.  In contrast newborns acquiring infection posnatally, 
generally from maternal breast milk, do not seem to have any associated long-term 
sequelae.  These differing clinical outcomes remain to be explained.   
In immunocompromised adults, quantitative CMV DNA PCR has given valuable 
insight into viral dynamics.  Such data have informed treatment, particularly in the 
transplant setting, where CMV disease has been shown to be directly correlated with 
various measures of viral load in both blood and urine.  Pre-emptive therapy has been 
adopted in many units as a direct result.  Newer immunological techniques have also 
led to the realisation that a large proportion of the human host's cellular immune 
response is directed towards maintaining CMV in a latent state lifelong following 
primary acquisition of this virus.  No equivalent data exist for the natural history, 
viral response to treatment or associated immune responses in neonates. 
This thesis therefore aimed to apply quantitative, virological and immunological 
techniques already successfully employed in adult patient groups to help define 
natural history and immune responses along with other measures of treatment 
response in this neonatal patient group through multicentre collaboration. 
The results presented give the first calculations of virus dynamics in response to 
antiviral treatment in this age group.   The possibility is raised of suboptimal drug 
exposure in the clinical setting and data presented on both viral load and CMV-
specific immunological responses have potentially important implications for 
treatment in these infants and for optimal sampling times which will inform future 
clinical trials and the continued search for biomarkers of treatment efficacy.  
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CHAPTER 1. 
1. INTRODUCTION 
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1.1. DESCRIPTION OF THE VIRUS 
Cytomegalovirus (CMV) derives its name (cyto-megalo-virus) from the typical 
histological appearance of enlarged cells with intranuclear (Owl’s eye) inclusions 
first observed in post mortem specimens in the late 19
th
 and early 20
th
 Century. It 
was some years after initial histopathological changes were observed in post mortem 
specimens from newborns, however, that they were identified as being viral in origin 
and that CMV was named as the aetiological infective agent (Weller et al. 1960).  
CMV is now known as a member of the betaherpes virus sub-family (Human Herpes 
Virus 5) and is ubiquitous in humans.   As with other herpesviruses, infection is 
characterised by a primary infection, establishment of latency and subsequent 
reactivation throughout the hosts’ lifetime.  Virus is detectable in most human body 
fluids during active infection.  More recently it has been established as the most 
common congenital infection in the developed world (Cannon 2009). 
What follows below is an overview of the aspects of CMV most relevant to the focus 
of this thesis. 
1.1.1. CMV structure 
Electron microscopy of CMV shows the characteristic herpesvirus appearance 
including a central icosahedral capsid encasing the DNA core, surrounded by a layer 
of amorphous tegument and an outer, lipid bilayer, envelope.   
The genome of CMV is the largest of all herpes viruses.  Its linear, double-stranded, 
genome was demonstrated to be 230kb on sequencing of strain AD169 in the early 
90’s (Chee et al. 1990).  Some years later, however, it became apparent that this 
highly passaged strain of CMV lacked a large portion of the genome present in 
‘wild-type’ human CMV (HCMV), containing around 22 additional genes.  In 2004 
Dolan et al proposed that Merlin, a low-passage clinical virus strain, 235 kb in size 
and encoding 165 genes was closer to wild-type virus (Dolan et al. 2004).  Some of 
the mutations present in AD169, and other laboratory strains of human CMV, are 
likely to facilitate the high production of virus observed following infection of 
fibroblasts in traditional laboratory tissue culture systems.  The difference between 
laboratory and clinical isolates therefore has implications for translational research 
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into the pathogenesis of CMV and has led to recent debate regarding the most 
relevant cell lines to be used in laboratory-based research (Gerna et al. 2008).       
Proteins are produced in sequence with immediate early genes being transcribed first 
(alpha), followed by early (beta) and late (gamma) genes, which are mainly 
transcribed after DNA replication has occurred.  Immediate early proteins e.g. IE1 
and IE2 regulate cellular functions, early proteins generally have enzymatic functions 
within the cell e.g. pUL54 is a DNA polymerase and pUL97 is a protein kinase 
essential for CMV replication and involved with the first phosphorylation step 
necessary for activation of ganciclovir (GCV).  Late proteins are generally structural 
e.g. surface glycoproteins.   
Envelope is derived from budding from the inner nuclear membrane of the host cell, 
which has been modified by insertion of herpesvirus glycoproteins (gp).  These 
glycoproteins are therefore of importance due to their early interaction with the host 
immune system. One of the most abundant envelope components is glycoprotein B 
(gB).  This protein can be detected on both infected cells and virions and has been 
found to be one of the major targets of neutralising antibody in the host response to 
CMV infection (Britt et al. 1990). It is also the fragility of this envelope which leaves 
the virus susceptible to damage and renders CMV sensitive to drying, acids, 
detergents and organic solvents.   
CMV is often divided into distinct genotypes based on these envelope glycoproteins 
with gB, for example, having four main genotypes (Pignatelli et al. 2004). The more 
detailed subtyping of distinct CMV strains is traditionally derived from restriction 
endonuclease analysis (RFLP). Whole genome sequencing is now leading to a full 
appreciation of the extensive genetic variation exhibited by HCMV. 
1.1.2. CMV replication (including permissive cell types) 
Following virus entry a multitude of factors regulate expression of genes necessary 
for CMV to complete its replicative cycle.  These are likely to be dependent both on 
the cell type infected and the virus strain involved along with corresponding host 
immunological regulatory mechanisms.  Although wild-type virus can be propagated 
in a wide range of cell lines only human fibroblasts give rise to high-titres of virus 
production in vitro (Spiller et al. 1997).  Cultures of placental cytotrophoblasts have 
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been shown to be fully permissive to infection; enhanced replication and more virus 
is released in first trimester trophoblast infections when compared to term in these in 
vitro models (Halwachs-Baumann et al. 1998;Halwachs-Baumann 2006).  
In vivo, CMV is found in a multitude of cells (Bissinger et al. 2002;Sinzger and Jahn 
1996).  CMV DNA has also been detected in placentas at post mortem (McDonagh et 
al. 2004).  During active CMV infection the predominant cell types expressing CMV 
DNA are, however, endothelial cells, granulocytes, monocytes, B cells and T cells 
(Emery 2001a;Hassan-Walker et al. 2001).   
The differences in cell types allowing for infection in vitro when compared to in vivo 
observations highlights the need for caution when extrapolating results from 
laboratory-based systems to the human host.   
1.2. PATHOGENESIS 
1.2.1. Incubation period, viral dissemination and proposed mechanisms of 
tissue damage  
The period between infection of a new host and the onset of detectable virus 
excretion has been estimated to be around 4-8 weeks from data derived from 
transplant recipients and perinatally infected neonates (Hamprecht et al. 2001;Stagno 
et al. 1975).  This is based on cell culture data and may be shortened in light of data 
emerging from studies using polymerase chain reaction (PCR).    
Historical concepts of viral spread postulate that initial entry into the host leads to 
establishment of local viral infection followed by primary viraemia enabling 
subsequent virus transmission to the liver and spleen.  Further virus propagation in 
these organs leads to a secondary viraemia followed by generalised virus 
dissemination.  There is some experimental evidence in animal models of CMV 
infection to support this theory, however, recent data using novel experimental 
methods have challenged this mode of spread (Lockridge et al. 1999;Sacher et al. 
2008).  There are no corresponding data in humans and the factors involved with 
virus spread within the human host following initial virus entry therefore remain 
elusive.  Although cell free virus has been proposed to have a role in the initial 
spread of community acquired HCMV this is supported by limited data.  Spread 
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within the host is possibly predominantly by cell associated virus.  Certainly 
infectivity in the blood compartment has been shown to be mediated mainly by 
PBMCs and endothelial cells (Emery 2001a;Percivalle et al. 1993).  PBMCs, 
although not being fully permissive to viral replication themselves, can transmit virus 
from infected endothelial cells or fibroblasts to infect further susceptible fibroblasts 
(Gerna et al. 2000).  The production of chemokine-like proteins along with activation 
of pathways which increase PBMC recruitment to sites of inflammation are also 
likely to enhance virus dissemination as summarised in a recent review (Goodrum et 
al. 2012).  Further understanding of the key events involved with early establishment 
of infection and dissemination to multiple organs might give crucial insight into why 
disease in neonates so readily involves the central nervous system (CNS).       
The delayed detection of virus in fetuses of mothers with primary infection is 
consistent with placental infection preceding transmission to the unborn baby.  
Placental infection, without fetal involvement, has also been reported (McDonagh et 
al. 2006).  In experimental models using explants of first trimester placenta CMV 
replication in trophoblasts is likely followed by subsequent transmission to the 
stromal fibroblasts and then on to fetal endothelial capillary cells (Gabrielli et al. 
2001).  Stromal fibroblasts are therefore thought important in propagating placental 
infection.   
The lack of detectable viraemia in many women transmitting CMV to their unborn 
child, however, raises uncertainty regarding the exact mechanism of fetal 
transmission. Despite this uncertainty a number of proposals have been made 
including the possibility that antibody-coated virus is transcytosed using placental Fc 
receptors or that cell-associated virus is reactivated from latency in placental 
monocytes with subsequent infection of different layers of the syncytiotrophoblast as 
reviewed by Revello and Gerna (2004).  Whatever events precede it is likely that the 
final step in fetal infection involves infection of fetal endothelial cells and 
subsequent haematogenous dissemination. 
Both lytic and non-lytic productive infections have been described dependent on the 
source of cells and infecting virus.  Acute tissue damage due to direct viral 
cytopathogenic effect has been directly associated with viral copy number in 
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individual organs (Mattes et al. 2000).  Indirect damage is also proposed through 
inflammatory responses, chemokine alterations and cell apoptosis induced by CMV 
infection (Britt 2007).           
1.2.2. Possible mechanisms for pathogenesis associated with congenital 
infection 
In keeping with the observation that intrauterine growth retardation (IUGR) occurs in 
both congenital infection and other maternal conditions affecting placental function 
recent data have implicated changes in placental vasculature induced by HCMV as 
contributing to placental insufficiency and subsequent fetal hypoxia (Maidji et al. 
2010). 
Although the exact mechanisms of CMV-induced sensorineural hearing loss (SNHL) 
remain unknown, CMV has been detected in non-neuroepithelial cells of both the 
cochlear and vestibular apparatus of the inner ear on post mortem examination of 
temporal bones (Strauss 1990).  CMV inclusion bodies have been noted in the stria 
vascularis and vestibular (Reissner’s) membrane but not other critical structures in 
post mortem studies.  However, a wider distribution of viral antigen, including the 
organ of Corti and spiral ganglia, have been reported using immunofluorescent 
staining for viral antigen (Strauss 1990).  Studies in animal models have raised the 
possibility that hearing loss is more likely a result of CMV-induced inflammation in 
the inner ear than of direct cytopathic effect (Darmstadt et al. 1990;Keithley et al. 
1989).   
CMV infection in mouse models has been shown to alter the expression of factors 
important in differentiating neural stem/progenitor cells and may thus disturb 
neuronal cell migration (Kosugi et al. 2000).  These models have also suggested that 
acute infection is characterised by a ventriculo-encephalitis and lytic infection with 
subsequent chronic infection being sustained both by neuron-specific activation of 
the early CMV promoters along with evasion of innate host immunity and possible 
anti-apoptotic mechanisms as reviewed by Tsutsui et al (2005).  Reactivation of 
infection has been observed in mouse brain slice cultures with the possibility that 
differentiation of neural stem cells into progenitor cells reactivates latent virus in a 
similar way to that reported during differentiation of haematopoietic stem cells 
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(Tsutsui et al. 2002).  This proposed model for chronic neurotropic infection might 
explain the neurological sequelae and progression of clinical findings noted during 
the first few years of postnatal life which are characterised by rapid brain growth and 
neuronal differentiation. 
1.2.3. Viral persistence and latency 
Persistent virus excretion is common in HCMV and may either arise from chronic 
low-level virus production following primary infection or following intermittent 
reactivation of virus from sites of proposed latency, whereby viral genomic DNA is 
detectable with no associated early gene products.  
In congenitally infected infants a median duration of virus excretion in urine of 3.9 
years has been reported (Noyola et al. 2000).  It is likely that this results from 
persistent infection of glandular epithelial cells although the mechanisms behind this 
remain elusive.  Urinary excretion of up to a year has also been reported in healthy 
adult hosts (Klemola et al. 1969). 
Latency is established primarily in cells of the myeloid lineage and in dendritic cells 
(Hahn et al. 1998;Soderberg-Naucler et al. 1997).  Differentiation of monocytes to 
macrophages has been proposed as an important trigger for subsequent reactivation 
from this latent state, resulting in intermittent low level detection of virus.  As 
mentioned earlier reactivation in neural stem or progenitor cells has also been 
proposed in mouse models of infection.  It is likely that the associated cytokine 
milieu and host immune status play an important role in the balance between virus 
latency and reactivation (Soderberg-Naucler et al. 2001;Tsutsui, Kawasaki, & 
Kosugi 2002).     
1.3. EPIDEMIOLOGY AND TRANSMISSION  
1.3.1. Determinants of population seroprevalence 
CMV is endemic with maternal seroprevalence ranging from 60–100% in different 
populations studied (Embil et al. 1969;Miles et al. 2007;Staras et al. 2006;Tookey et 
al. 1992;Vyse et al. 2009).  Seroprevalence increases with age although in many 
populations, particularly those studied from low-income countries, a high proportion 
of individuals seroconvert early in life, presumably due to high rates of seropositivity 
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in maternal groups and concomitant early postnatal or childhood transmission (Miles 
et al 2007).  In the UK seroprevalence is estimated at only around 15% in those aged 
1-4 years of age increasing to 80% by ≥65 years of age with a relatively high 
proportion of children acquiring CMV infection in early life (Peckham et al. 
1987;Vyse, Hesketh, & Pebody 2009).  
Studies in various Western populations have also shown large variations within 
populations according to ethnicity and socio-economic status (Colugnati et al. 
2007;Staras et al. 2006).  A large US study showed a 10-15% higher seroprevalence 
in low- and middle-income households compared to high-income households (Staras 
et al. 2006).  Consistent with this finding, higher seroprevalence was observed in 
women from lower social class in a study of women attending antenatal clinics in 
West London (Tookey, Ades, & Peckham 1992).  Increased seropositivity was also 
noted in women with Asian and African/Caribbean ethnic origin compared to white 
women in both this and a more recent South West London cohort (Khare et al. 
2004;Tookey, Ades, & Peckham 1992). 
Working in daycare settings with toddlers has also been associated with an increased 
seroconversion rate but not work within healthcare settings (Adler 1989;Dworsky et 
al. 1983).   
1.3.2. Route of acquisition 
As outlined above congenital infection is thought most likely to follow placental 
infection following either haematogenous spread or possibly ascending infection via 
the maternal genital tract (Fisher et al. 2000).  The delayed detection of CMV DNA 
in amniotic fluid, of around 6-8 weeks after the estimated date of maternal primary 
infection, is consistent with the incubation period for CMV and supports placental 
infection as the main route of acquisition in this group (Revello and Gerna 2004).      
Postnatal infection either follows ingestion of infected vaginal secretions during 
passage through the birth canal or via breast milk soon after delivery (Hamprecht et 
al. 2001;Reynolds et al. 1973). CMV is detectable in breast milk at some stage 
during lactation in 96% of seropositive mothers, and acquisition via breast milk is 
likely to be the predominant mode of transmission during the first year of life 
(Hamprecht et al. 2001).  As many mothers shed no virus from other body fluids 
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localised reactivation of CMV infection in breast epithelium is most likely 
responsible for the virus excretion observed in these women (Hamprecht et al. 2008). 
Thereafter infection probably results from direct contact with infected body fluids.  
The high burden of virus excreted in saliva and urine in toddlers has been implicated 
as a significant source of infection in this age group (Adler 1985).  This is supported 
by studies whereby saliva containing CMV has been found contaminating toys in 
daycare centres (Hutto et al. 1986).  In teenage years, where CMV has been 
occasionally found to cause an infectious-mononucleosis like illness, similar to EBV, 
saliva has likewise been implicated as a significant mode of transmission.  Although 
CMV has been isolated in large titres in both vaginal secretions and semen whether 
CMV is truly sexually transmitted remains debated.  Importantly for this thesis, 
population analyses suggest that women of childbearing age are more likely to 
acquire primary CMV infection from their children than from sexual contacts (Pass 
et al. 1986;Staras et al. 2008).  Transmission via blood transfusions was a common 
route of acquisition, particularly in transplant recipients and premature babies, prior 
to the introduction of measures to limit this mode of transmission by use of CMV-
negative red cells and leucocyte depletion using white cell filters during transfusion.  
Likewise CMV seronegative solid organ recipients are at particular risk of acquiring 
infection from seropositive organ donors with virtually no risk if they receive an 
organ from a seronegative donor (Atabani et al. 2012).  Seropositive recipients may 
also be reinfected following acquisition of new strains of CMV from the organ 
donor.  It is hypothesised that infection is transmitted either via CMV-infected 
parenchymal cells or leucocytes infiltrating the donated organs.  
1.3.3. Factors associated with intrauterine transmission 
In mothers with primary infection around 33% have been found to transfer infection 
to their unborn fetus (Kenneson and Cannon 2007).  Natural maternal immunity prior 
to conception has been shown to provide 69% protection against delivering a neonate 
with cCMV infection compared to seronegative women in the same population 
(Fowler, Stagno & Pass 2003).  Transmission of infection is still reported, however, 
in 1% of fetuses born to women with pre-existing immunity to CMV (Fowler, 
Stagno, & Pass 2003).  Infections in women with pre-existing immunity are proposed 
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to follow either reinfection with a new strain of CMV or reactivation of pre-existing 
infection from sites of latency.  Epidemiologically it is difficult to prove the exact 
origin of infecting virus and to ascertain relative significance of these two routes.  
Mothers with pre-existing immunity nonetheless remain a significant source of 
transmission in many populations, with 90% of all cCMV cases being born to 
seropositive mothers in populations with a high underlying maternal seroprevalence 
(Kenneson and Cannon 2007;Mussi-Pinhata et al. 2009).    
Risk of transmission also seems to be greatest in women acquiring CMV in later 
stages of pregnancy (Griffiths and Baboonian 1984), perhaps explained by the 
proposed role of Fc receptors in transcytosis of antibody-coated virus across the 
maternal and fetal placental interfaces (Fisher et al. 2000).  Transmission to the 
unborn fetus is increased in the presence of maternal antibody with both low avidity 
and poor neutralising activity (Boppana and Britt 1995;Lazzarotto et al. 1999).  Up to 
the 18
th
 week of pregnancy a low avidity index is 100% sensitive in identifying 
women who will have an infected newborn (Lazzarotto et al. 2000).  
Correspondingly, women with impaired cellular immune responses (such as in HIV 
infection) are more likely to transmit infection antenatally (Guibert et al. 2009;Rola-
Pleszczynski et al. 1977).  
1.4. DIAGNOSIS 
For many years CMV was diagnosed using its cytopathic effect (CPE) on fibroblast 
cultures.  Subsequently electron microscopy enabled the virion to be visualised.  
These ‘direct’ methods are labour intensive, and generally require a high virus 
burden or prolonged periods of cell culture to enable detection.  Furthermore it can 
be difficult to differentiate between CMV and other, related, herpes viruses (Mattes 
et al. 2000).   
Modern diagnostic techniques now enable direct detection of CMV viral DNA using 
small amounts of body fluid or tissue.  Owing to its capacity for high throughput, 
high sensitivity and ability to quantify viral DNA, PCR has now largely superseded 
these older tissue-culture based methods in combination with the use of indirect 
detection using serological measures of detectable anti-CMV antibody.     
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1.4.1. Serological  (Indirect measures) 
o IgG; IgM; IgG Avidity 
IgM is, as with other infections, the first detectable antibody produced in response to 
CMV infection.  CMV IgM is generally positive within 4 weeks of infection and 
persists for around 2-3 months.  Sensitivity is poor, however, with at best only 70% 
of congenitally infected newborns having detectable IgM antibody (Donner et al. 
1993;Revello et al. 1999).  False positives are commonly reported, particularly 
during pregnancy, from cross-reactivity with rheumatoid factor IgM, and with EBV.  
Furthermore IgM can persist for up to one year, even in immunocompetent hosts, and 
IgM detection during reinfection with new CMV strains or reactivation has also been 
reported as reviewed by Revello and Gerna (2002).  IgM assays are therefore rarely 
helpful on their own in confirming primary infection. 
IgG sensitivity and specificity varies, as with IgM, dependent on the commercial 
assay being used but all assays are generally acceptable in immunocompetent 
patients.  Unless seroconversion is observed CMV IgG measurement is of limited 
value in identifying primary CMV infection.  Given the absence of any screening 
programmes for CMV in the UK CMV IgG is therefore only of value in excluding 
CMV infection, with a negative result 4-8 weeks after potential exposure giving 
reasonable confidence that a mother has not acquired infection.  CMV IgG is 
transplacentally transferred and, as with other congenital infections, is therefore of no 
value in diagnosing CMV infection in the newborn.    
In recent years the development of CMV IgG avidity assays has assisted in 
differentiating between primary and non-primary CMV infections.  Data show that a 
low CMV IgG avidity index is associated with infection within the preceding 3 
months and maturation to high avidity usually occurs over a period of 6 months  
(Lazzarotto et al. 1997) (Figure 1-1).  The presence of low avidity CMV IgG in 
pregnant women has been reported to be highly sensitive for identifying women who 
will have an offspring with CMV infection (Lazzarotto et al. 2000). 
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Figure 1-1  Correlation between CMV Avidity Index and number of weeks after 
primary HCMV infection in pregnant women  
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Reproduced from Lazzarotto et al. (1997) 
 
Each data point represents the avidity index measured at different time points, in weeks, after 
a CMV-infected pregnant woman reported symptoms of primary HCMV infection.  
Correlation analysis gives a correlation coefficient of 0.8726, indicating a strong association 
between the two parameters.  
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1.4.2. Culture vs PCR (Direct measures) 
o Culture 
Historically the gold standard for diagnosis was tissue culture based methods such as 
the DEAFF (detection of early antigen fluorescent foci) test, often referred to as shell 
vial assay in the US.  By detecting proteins produced early in the replicative cycle of 
CMV using fluorescent-labelled monoclonal antibody, virus is detected earlier than 
waiting for cytopathic effect.  This method remains labour intensive, however and 
cultures still need to be left up to 21 days in order to be able to report a negative 
result.   
o PCR detection  
QUALITATIVE 
Over recent years PCR of both tissues and various body fluids has been shown valid 
for the diagnosis of CMV disease (de Vries et al. 2012;Demmler et al. 1988).  
Sensitivity and specificity of this method of detection depends on the area of the 
CMV genome being probed with higher sensitivity reported when areas with low 
genetic variability between strains are targeted (Boeckh and Boivin 1998).  There are 
no other significant differences between different PCR assays with regards to test 
performance.  Nested PCR, while more sensitive, has associated disadvantages of 
both increased labour and risk of background contamination.  A further disadvantage 
of PCR is that CMV does not need to be actively replicating in order to be detected. 
It is therefore important that the amount of DNA extracted from clinical samples is 
not sufficient to detect latent infection. Once this is done, many clinical studies have 
shown correlation between CMV detection by PCR and active disease leading to this 
being adopted as the new ‘gold standard’ according to updated virological texts (de 
Vries et al. 2012;Griffiths et al. 2008).  Where urine is being assayed, inhibition of 
the enzymes used in the PCR mixture is a potential cause of false negative results.  
Virus is generally sufficiently abundant in urine of congenitally infected infants for 
this to have little impact on diagnostic utility and can additionally be controlled for 
by using an internal laboratory control.   
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QUANTITATIVE (REAL TIME) PCR. 
Real-time PCR (RT-PCR) has led to the development of assays which give an 
estimate of the virus burden in a given body compartment, “viral load” (VL).  These 
assays generally involve an oligonucleotide probe with an associated fluorescent dye 
and ‘quencher’ meaning that fluorescence is only detected if the DNA sequence of 
interest is recognised.  The fluorescence generated during consecutive cycles of 
amplification directly relates to the amount of DNA present in a sample and is 
reported in relation to a standard curve generated during each diagnostic run from 
serial dilutions of a known amount of target DNA.  During the log linear phase of 
DNA amplification this provides an accurate reflection of the DNA content of the 
input sample but due to the non-linearity at either end of this curve accuracy 
correspondingly decreases at very low or very high VL.   
Inter-lab variations up to 4.3 log10 have also been reported and in one study only 
58% of all samples came within a proposed acceptable variation of 0.5 log10 from the 
‘expected’ value (Pang et al. 2009).  This has historically prevented comparison of 
quantitative results derived from different laboratories.   
1.4.3. Differentiation of congenital vs postnatal infection 
The diagnosis of congenital infection currently relies on the availability of clinical 
samples taken within the first 21 days of life.  This proposed cut-off is derived from 
historical studies of congenitally and postnatally infected babies using tissue culture 
(Stagno et al. 1975).  The increased sensitivity of PCR detection raises the possibility 
of earlier virus detection, thus potentially decreasing this diagnostic cut-off to around 
14 days (de Vries et al. 2012).  CMV DNA is detectable in blood before viruria in a 
proportion of postnatally infected neonates with further implications for defining 
congenital infection if this body fluid is used diagnostically (Hamprecht et al. 2001).  
o Diagnostic utility of different body fluids 
CMV is not uniformly detectable in the blood and is therefore not the specimen of 
choice for diagnosis of cCMV (Bradford et al. 2005;Kimberlin et al. 2008).  Urine 
has been the gold standard for diagnosis but it is not always easy to obtain such 
specimens in infants, particularly in the out-patient setting.  Virus detection in 
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salivary samples has been shown to be comparable to that in urine, particularly in the 
setting of large scale screening studies (Warren et al. 1992;Yamamoto et al. 2006). 
Although there are no published data regarding false positive results, concerns exist 
regarding contamination of neonatal saliva with maternally derived CMV-DNA, 
particularly in samples obtained from breastfed neonates.  Diagnosis should therefore 
always be subsequently confirmed using another body fluid.   
CSF is not part of the routine assessment of the neonate with cCMV infection in 
most institutions as there are insufficient data that this adds anything to less invasive 
investigations and clinical examination.  CMV detection in CSF has been associated 
with cCMV disease and correlated with poor outcome (Halwachs-Baumann et al. 
2002;Troendle Atkins et al. 1994).  However, CMV was also weakly detectable in 
2/100 controls being evaluated for other diagnoses in one of these studies (Troendle 
Atkins et al. 1994).  Larger studies including adequate numbers of both symptomatic 
and asymptomatic infants along with long-term follow-up are needed before the role 
of testing CSF can be fully defined.   
CMV has been detected in perilymph in children undergoing cochlear implantation 
up to 7 years of age (Bauer et al. 2005;Di et al. 2009).  Obtaining a diagnosis at this 
stage has limited value, however, other than for epidemiological purposes and might 
purely be reflecting CMV detection in the perilymph following a recent acquisition 
of CMV (Di et al. 2011).   
Amniotic fluid is often obtained antenatally from women with suspected primary 
CMV infection, or with fetal findings consistent with a diagnosis of congenital 
infection.  To maximise virus detection, samples need to be taken at least 6-8 weeks 
after maternal primary infection and >21 weeks gestation to ensure sufficient fetal 
urinary production (Donner et al. 1994;Enders et al. 2001;Guerra et al. 2000).  If 
samples are taken in accordance with this guidance then specificity is reported to be 
around 100% (Guerra et al. 2000).  Sensitivity of around 80% is reported if high load 
virus detection is taken to indicate a positive result but increases to 100% if lower 
quantities of virus detection are used to indicate positivity or if amniotic fluid PCR is 
combined with other diagnostic tests (Enders et al. 2001;Guerra et al. 2000).  A 
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positive result indicates infection only, however, and is not diagnostic of fetal 
disease.    
o Retrospective diagnosis using dried blood spots (DBS) 
Detecting clinical symptoms and signs of cCMV and obtaining relevant samples 
within the narrow time frame necessary to make a definitive diagnosis of cCMV is 
challenging and likely contributes to underdiagnosis (Townsend et al. 2011).  The 
availability of DBS, taken on all babies shortly after birth, has therefore raised 
interest in the use of these clinical specimens to aid retrospective diagnosis of 
congenital infection.  CMV DNA was first successfully extracted and detected from 
DBS in the late 1990s (Barbi et al. 1996b;Shibata et al. 1994).  Since that time there 
have been many further reports on the retrospective diagnosis of cCMV using DBS 
in babies exhibiting clinical features of disease and, more recently, as a possible 
screening tool for detecting cCMV in large cohorts of asymptomatic neonates (Barbi 
Binda, & Caroppo 2006;Boppana et al. 2010). 
Specificity is generally close to 100% but sensitivity has been reported variably as 
30-100% (Barbi et al. 2008;Boppana et al. 2010).  Variations in sensitivity depend 
not only on the specific patient group being tested but also on the method of DNA 
extraction and the region of CMV being targeted as summarised in Barbi’s review 
(2006) of this methodology.  The lack of detectable CMV DNA in the blood of many 
congenitally infected infants further limits the sensitivity of this test and although a 
positive result is of benefit in confirming cCMV a negative result by no means 
excludes the diagnosis.    
1.4.4. Defining virus dynamics using quantitative PCR  
The basic model of virus dynamics is similar to epidemiological models of 
infectivity, albeit at a cellular level.  A number of nonlinear differential equations can 
be used to mathematically explain the interactions between uninfected cells and free 
virus leading to infection of cells and subsequent production and release of further 
virion as shown in Figure 1-2.  These equations in active infection are difficult to 
interpret and subject to many variables with many of the rates involved being time 
dependent (Herz et al. 1996). 
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Figure 1-2 Cartoon of basic model of virus dynamics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
γ = rate of repletion of uninfected cells (constant rate) 
δ= rate of cell death of uninfected cells 
β = rate of free virus infecting uninfected cells 
κ = rate of virion production by infected cells 
µ = rate of death/clearance of free virus 
a= rate of death of infected cells 
 
Cartoon showing the basic model of virus dynamics as described in more detail by Perelson 
et al. (2002).  Uninfected cells (x) are infected with free virus at rate β.  Infection leads to 
productively infected cells which produce new virions at a rate, κ.  Uninfected cells, infected 
cells and free virus die at the rates δ, a, and µ, respectively.  Uninfected cells are replenished 
at a constant rate (γ).    
This model can be further described by a number of inter-related differential equations which 
have been used to estimate virus half-life (T1/2) and other parameters.       
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The stable VL observed in chronic HIV infection had for many years been assumed 
to imply slow virus replication which was discrepant with laboratory observations of 
rapid virus mutation.  Studies in the 1990’s led to the observation that antiviral 
treatment with protease inhibitors effectively inhibited virion production resulting in 
a rapid logarithmic decline in HIV VL within the first few weeks of treatment (Ho et 
al. 1995;Wei et al. 1995).  By preventing infection of new cells the normal cycle of 
virus production was disrupted allowing mathematical biologists to break down the 
complex equations describing virus dynamics into linear differential equations as 
reviewed by Perelson (2002).  These differential equations were subsequently used to 
estimate upper limits of half-life (T1/2) of plasma virions using the equation ln2/c, 
where c is the rate of clearance from plasma; c can be derived from measuring the 
slope of the curve of VL during the phase of exponential decline (phase 3 in Figure 
1-3) (Perelson 2002).  Serial VL measurements obtained during these treatment 
studies confirmed that HIV was, in fact, a rapidly replicating virus with a T1/2 of 
around 6 hours (Ho et al. 1995;Perelson et al. 1996;Wei et al. 1995).  These models 
have been used to further describe the phases of viral decline observed when 
measuring quantitative VL during antiviral treatment (Figure 1-3).        
Similarly the slow appearance of CMV cytopathic effect in fibroblast cell culture of 
around 7-20 days had led to the assumption that CMV was a slowly replicating virus.  
Applying the models of virus dynamics deployed for HIV, and assuming GCV 
efficacy to be 100%, Emery et al (1999) established that the T1/2 of CMV in HIV-
infected patients was around 2.56 ± 0.36 days.  Similar calculations in liver and bone 
marrow transplant recipients receiving IV GCV gave T1/2 values of 2.36 ± 1.2 days 
and 1.52 ± 0.67 days respectively thus proving that CMV was also a more rapidly 
replicating virus than had been previously appreciated.  By carrying out more 
frequent sampling in a number of patients during early treatment these estimates 
were further refined to give estimates of T1/2 of around 1.0 ± 0.3 days during early 
stages of treatment (Emery et al. 1999).     
Subsequently these authors, using similar models of exponential decay, confirmed 
that GCV had an efficacy of close to 100% (91.5%) in adult patients (Emery and 
Griffiths 2000).  In contrast oral GCV, due to its poor oral bioavailability, had a 
corresponding efficacy of only 46.5%.  Oral valganciclovir (VGCV), with its 
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Figure 1-3: Schematic of classical phases of plasma virus decline following 
antiviral treatment   
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Stationary phase reflecting pharmacological and intracellular delay 
2. Transition phase reflecting decay of free virus and productively infected cells  
3. Rapid decline reflecting decay of productively infected cells (exponential) 
4. Levelling off due to: non-optimal drug dose, emergence of drug resistant virus, 
reservoirs of virus-producing cells that are not affected by drug 
 
In the initial phase the plasma virus load stays constant.  The duration of this phase is 
dependent on the pharmacological delay (defined as the time the drug needs to reach an 
effective concentration) and the intracellular delay (defined as the time between infection of 
a cell and production of new virus particles).  Subsequently there is a smooth transition to an 
approximately exponential decline that primarily reflects the decay of productively infected 
cells.  The length and smoothness of the transition phase is determined by a combination of 
the half-lives of free virus and productively infected cells.  Finally, decline levels off due to 
the reasons stated in 4, above.  
 
  
Adapted from Herz et al. (1996)  
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enhanced oral bioavailability, has been shown to have a similar efficacy to that of i.v. 
GCV and in a group of solid organ transplant patients treated pre-emptively with oral 
VGCV T1/2 was estimated at 2.16 days compared to 1.73 days in those receiving i.v. 
GCV (P=0.63) (Mattes et al. 2005).  Oral VGCV can thus be considered equivalent 
to GCV for the purposes of calculations of viral dynamics in this patient group. 
1.5. CLINICAL DISEASE ATTRIBUTED TO CMV 
1.5.1. Adult disease  
Disease in immunocompetent hosts is rare and generally mild although occasionally 
primary infections are associated with an infectious mononucleosis-type illness 
(Klemola et al. 1969).  In immunocompromised hosts, however, CMV is a leading 
cause of morbidity and mortality.  Prospective studies in patients post-transplantation 
show that viraemia always precedes all forms of end organ disease and that a high 
VL is a pre-requisite (Emery et al. 2000).  In these patients a ‘CMV syndrome’ has 
been described in which a spiking pyrexia accompanies viraemia and leucopenia.    
Patterns of acute disease often involve specific organs dependent on the patient 
group affected as shown in Table 1-1.  The factors determining these different 
manifestations, such as the predominance for significant eye involvement in HIV co-
infected subjects, and pneumonitis following bone marrow transplantation, are 
currently unknown but are likely to involve a complex interplay between viral factors 
(including genetic variations between different strains) and host adaptive and innate 
immune responses together with the known viral immune modulatory functions. 
Encephalopathy is also observed in HIV-infected patients although it usually only 
occurs in the most severely immunocompromised (<50 CD4 cells/mm
3
) (Cinque et 
al. 1997).  This can be either subacute with progressive dementia or an acute 
presentation associated with necrotising ventriculitis and high mortality, despite 
antiviral therapy.  Polyradiculopathy and peripheral neuropathies have also been 
described.  CNS disease is only rarely described in non-HIV immunosuppressed 
patients or immunocompetent individuals (Schober and Herman 1973). 
CMV itself may cause immunosuppression and morbidity from associated secondary 
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Table 1-1  Pathology associated with CMV disease in different patient groups 
 
Symptoms Solid 
organ 
recipients 
Bone 
marrow 
recipients 
AIDS 
patients 
Congenital 
infection 
Premature 
babies/ 
postnatal 
infection 
Fever + + +  + 
Hepatitis ++ +  ++ ++ 
Gastrointestinal + + +  ++ 
Retinitis + + ++ ++  
Pneumonitis + ++  + ++ 
Encephalopathy/ 
CNS 
  + ++  
Polyradiculopathy   +   
Myelosuppression  ++  ++ + 
Immunosuppression +     
Rejection +     
Addisonian  +    
Audiological    ++  
 
Adapted from Emery (2001a) 
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bacterial or fungal superinfection and graft rejection are described (Ljungman et al. 
2002). The evidence supporting a causal role for CMV in these diverse conditions is 
their reduction in double-blind, randomised, placebo-controlled trials of anti-CMV 
prophylaxis in transplant patients (Lowance et al. 1999). CMV has also been 
associated with other conditions such as immunosenescence, extended stay in 
intensive care and excess mortality in the whole USA population although whether 
CMV is causative in these conditions remains unclear (Koch et al. 2006;Limaye and 
Boeckh 2010).  
1.5.2. Postnatally acquired CMV in neonates 
Pneumonitis, lymphadenopathy, hepatitis, enterocolitis and aseptic mengingitis have 
all been associated with postnatal acquisition of CMV infection although antiviral 
treatment has not shown consistent symptomatic improvement (Barampouti et al. 
2002;Cheong et al. 2004;Kumar et al. 1984;Rongkavilit et al. 2004).  A ‘sepsis-like 
syndrome’ has also been reported in up to 25% of premature babies closely 
associated with the first detection of CMV in body fluids (Hamprecht et al. 2001).  
Current evidence does not support any concerns regarding neurological morbidity or 
SNHL associated with such postnatally acquired infections as reviewed by Luck and 
Sharland (2009).     
1.5.3. Symptomatic congenital CMV (CMV inclusion disease) 
CMV inclusion disease historically describes the multiorgan pathology observed in 
the most severely affected newborns with congenital infection.  Symptomatic disease 
at birth is detected in only 13% of all CMV-infected neonates according to a recent 
meta-analysis (Dollard et al. 2007).  Many authors consider only those with 
observable manifestations of cCMV disease to be symptomatic, thus excluding those 
babies identified as having SNHL at birth alone.  Similarly whether babies with 
isolated neuro-radiological abnormalities should be considered to have symptomatic 
disease is contentious with the role of MRI in particular remaining uncertain.   Such 
differences in definitions are partly responsible for the variable figures of 
symptomatic infection at birth and may have significance when considering long-
term follow-up data. 
The most common manifestations of symptomatic cCMV at birth are 
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Table 1-2  Frequency of clinical and laboratory abnormalities in babies born 
with congenital CMV disease 
 
CLINICAL FEATURES OF CONGENITAL CMV 
 
CLINICAL 
  
 IUGR 26-50% 
 Microcephaly 20-53% 
 Hepato-splenomegaly 45-70% 
 Petechiae 45-75% 
 Jaundice 41-70% 
 Pneumonitis 7.30% 
 Chorioretinitis 14-17% 
 Seizures 7-13% 
 Other neurological abnormalities 19-37% 
 Dental enamel defects 11% 
    
LABORATORY: 
  
 Thrombocytopenia 50-77% 
 Anaemia 7% 
 Raised ALT/AST 48-83% 
 Conjugated hyperbilirubinaemia 47-81% 
 CSF abnormalities 46% 
    
IMAGING:  
  
 Abnormal Cr USS 56% 
 Abnormal CT 71-80% 
 Abnormal MRI 89% 
    
OTHER 
  
 Abnormal VEP* 43% 
 Abnormal SSEP* 71% 
 Abnormal EEG* 67% 
 
* = only reported in Kylat, Kelly, & Ford-Jones (2006) 
 
VEP   = Visual Evoked Potential 
SSEP  = Somatosensory Evoked Potentials 
EEG   = Electroencephalogram 
 
Data Taken From:  
Kylat, Kelly & Ford-Jones (2006)  
Boppana et al (1992)  
Noyola et al (2001)  
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hepatosplenomegaly, jaundice, petechiae (associated with underlying 
thrombocytopenia), blueberry muffin rash (due to extramedullary haematopoiesis), 
microcephaly and IUGR with variable frequencies (Table 1-2).  Pneumonitis and 
myocarditis are less common.  Mortality is reported in 4-12% of those symptomatic 
at birth (Boppana et al. 1992;Fowler et al. 1999;Kylat, Kelly, & Ford-Jones 2006).  
Although non-specific for cCMV, a combination of the above clinical findings 
should certainly raise the suspicion of a congenital infection.  IUGR alone, however, 
can arise following a multitude of antenatal challenges to placental function and 
whether babies should be considered to have CMV disease with this finding alone is 
contentious.   
CNS features include seizures, focal neurological findings and abnormalities in tone 
and posture which may be difficult to appreciate clinically in the newborn.  Ocular 
pathology includes chorioretinitis, optic atrophy, pigmentary retinopathy and 
strabismus (Stagno et al. 1977).  The manifestations of cCMV-associated SNHL are 
described in more detail below.  
o Long term sequelae 
Many of the non-CNS symptoms and signs of cCMV resolve over the first few 
months of life although liver involvement has been reported to persist for some 
months (Kimberlin et al. 2003).  Approximately 50% of those with early signs of 
disease will exhibit long-term sequelae in some form (Dollard, Grosse, & Ross 
2007).  Most commonly these manifest as SNHL and developmental delay in one or 
more areas resulting in significant disability.  Visual loss from early chorioretinitis 
has also been reported along with dental abnormalities and slow growth.  Importantly 
large cohort studies have also reported development of sequelae, particularly SNHL, 
in 13% of babies considered asymptomatic at birth (Dollard, Grosse, & Ross 2007).      
o Sensorineural hearing loss 
Second only to genetic mutations, cCMV is a leading cause of SNHL at birth and 
accounts for around 25% of all SNHL at 4 years of age (Nance et al. 2006).  
Although the risk is greatest in those symptomatic at birth the ‘asymptomatic’ group 
account for up to 2/3 of the overall burden of CMV-associated SNHL due to the 
higher absolute numbers of babies in this group (Figure 1-4)(Dahle et al. 2000). 
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Figure 1-4  Estimated frequency of sequelae in 1000 children born with congenital CMV infecion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures from Dollard, Grosse, & Ross (2007) 
SNHL = Sensorineural hearing loss 
69-71% of babies destined to have CMV-attributable SNHL will be asymptomatic at birth 
1000 
Children born with 
congenital CMV infection 
 
127 
Symptomatic at birth 
873 
Asymptomatic at birth 
5 (4%) 
Deaths 
122 
Survivors 
118 (13.5%) 
Permanent disabilities 
(96-104 SNHL (11-12%)) 
755 
No sequelae 
51-73 
No sequelae 
49-71 (40-58%) 
Permanent disabilities 
(43 SNHL (35%)) 
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A number of large cohort studies from Birmingham Alabama provide the most 
comprehensive data of SNHL in congenitally infected babies to date.  These studies 
found hearing loss in 22-65% of babies with symptomatic CMV compared to 6-23% 
of those asymptomatic at birth (Fowler and Boppana 2006).  Although the Alabama 
population may not be representative of the situation worldwide, a recent meta-
analysis reported overall hearing loss in around 35% compared to 11-12% of those 
born with symptomatic and asymptomatic cCMV at birth respectively, which would 
be consistent with these earlier data (Dollard, Grosse, & Ross 2007).   
These cohort studies have demonstrated that SNHL can be of any type and severity 
with severe or profound hearing loss documented in around 70% of those with 
symptomatic or asymptomatic infection (Figure 1-5) (Dahle et al. 2000); bilateral 
hearing loss is reported in 67% of those with symptomatic infection, however, 
compared to 48% of asymptomatic babies.  Late (delayed) onset hearing loss is also 
described in approximately 27% and 38% of those symptomatic and asymptomatic at 
birth respectively with cCMV-associated SNHL.  Significantly this means that less 
than half of individuals destined to have SNHL attributable to cCMV will have 
deficits detectable on newborn hearing screening at birth (Fowler et al. 1999).  Also 
characteristic of cCMV is the progressive loss observed in around 50% of affected 
babies (Dahle et al. 2000).  The pathogenesis of this delayed and progressive loss 
remains unknown.  Fluctuations in hearing are also reported (defined as deterioration 
in hearing assessment followed by subsequent improvement with no other obvious 
cause) with this phenomenon being more frequently described in asymptomatic 
babies (54% vs 29% in symptomatic) (Dahle et al. 2000).     
If cumulative hearing loss is plotted, the majority of SNHL presents in the prelingual 
phase of development with symptomatic babies having a slightly earlier onset of 
hearing loss when compared to those that are asymptomatic (median onset 33 months 
compared to 44 months) (Dahle et al. 2000)(Figure 1-6). 
o Neurological progression 
Long-term cognitive deficit has been documented in around 42% of symptomatic 
babies and 6.5% of asymptomatic babies on meta-analysis (Dollard, Grosse, & Ross 
2007).  Seizures are common and have been reported in 13% of babies <6 months of 
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Figure 1-5: Severity of SNHL reported at last hearing test in babies with 
'symptomatic' or 'asymptomatic' congenital CMV at birth 
 
 
Degree of SNHL based on average pure-tone thresholds at last audiologic evaluation 
(percentage of ears) in babies with (‘symptomatic’) and without (‘asymptomatic’) clinically 
evident CMV disease at birth.  If SNHL was determined by auditory brainstem response, 
hearing thresholds were calculated based on nHL as follows:  mild (30-45 dB), moderate 
(50-70 dB), severe (>70 dB).  Chronological age at last evaluation ranged from 1month to 19 
years (median 5 years). 
 
Data taken from Dahle et al. (2000) 
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Figure 1-6:  Cumulative hearing loss over time in 85 babies with 'symptomatic' 
and 48 with 'asymptomatic' congenital CMV infection at birth 
 
 
 
Hearing was measured by either auditory brainstem response or pure-tone audiometry 
depending on the child’s age and developmental level.  The criteria for hearing loss for pure-
tone audiometry was the presence of thresholds greater than 20 dB HL at one or more 
frequencies.  For ABR, hearing loss consisted of thresholds greater than 25 dB nHL.  
Chronological age at last evaluation range 1month – 19 years; Median 5 years 
 
Data taken from Dahle et al. (2000)  
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age and a further 16% later in childhood (Kylat, Kelly, & Ford-Jones 2006).  Some 
studies have reported delayed detection of neurological manifestations although it is 
unclear whether this is due to true clinical progression or difficulties in detecting 
subtle neurological impairments in newborns (Conboy et al. 1986;Pass et al. 
1980;Reynolds et al. 1974;Stagno et al. 1977).      
o Visual loss  
Early studies reported chorioretinitis associated with both symptomatic and 
asymptomatic cCMV infection (Stagno et al. 1977).  As with other sequelae, 
symptomatic babies are more likely to have long-term visual impairment than those 
asymptomatic at birth (22-50%) (Anderson et al. 1996;Coats et al. 2000).  Although 
generally thought to be stable in immunocompetent children case studies reporting 
delayed onset, reactivation and progression of CMV chorioretinitis in those 
congenitally infected would seem to refute this (Barampouti, Rajan, & Aclimandos 
2002;Boppana et al. 1994).  
1.6. RISK FACTORS FOR SYMPTOMATIC DISEASE  
There has been much interest in finding markers present at birth which predict long-
term sequelae of CMV disease.  Studies are generally weakened by the inclusion of 
only small numbers of asymptomatic babies that subsequently develop sequelae.  It is 
arguably this group of babies that present the biggest management challenge and that 
early treatment might be hypothesised to benefit. 
1.6.1. Antenatal factors  
Severity of placental pathology has been associated with the severity of 
manifestations in the newborn (Mostoufi-zadeh et al. 1984). 
In addition to increasing likelihood of CMV transmission, primary rather than non-
primary infection during pregnancy has been shown to be associated with more 
frequent and more severe neonatal disease (Foulon et al. 2008;Fowler et al. 
1992;Ross et al. 2006;Yamamoto et al. 2011).  However, symptomatic cCMV is still 
reported in women with pre-existing immunity and in populations with a high 
seroprevalence the majority of affected babies are born to women with previous 
exposure to CMV (Ahlfors et al. 1983;Colugnati et al. 2007;Yamamoto et al. 2011). 
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In keeping with observations in other congenital infections it is now generally 
accepted that infection in the third trimester, although associated with increased 
transmission, is likely to carry a smaller risk of severe symptomatic disease 
(Daiminger et al. 2005;Liesnard et al. 2000;Revello and Gerna 2004).  This might 
relate to enhanced concomitant transfer of maternal anti-CMV antibody at these later 
gestations or to the more advanced development of the CNS and/or immune system 
in these more mature fetuses. 
Babies with abnormal antenatal ultrasound scan (USS) findings are more likely to be 
born with symptomatic infection.  However, one Italian study reported symptomatic 
infection in 68/131 (52%) congenitally infected babies with normal USS (Guerra et 
al. 2008). Another, more recent, study reported enhanced sensitivity of detection of 
cerebral lesions with prenatal MRI with a sensitivity of 83% for predicting 
symptomatic infection and a corresponding negative predictive value (NPV) of 94% 
(Doneda et al. 2010).  Other authors have proposed additional prognostic value in 
conducting fetal blood sampling (FBS) to determine fetal platelet counts in addition 
to serial USS, despite the associated 1-3% risk of fetal loss with this procedure 
(Benoist et al. 2008;Fabbri et al. 2011).   
The utility of measuring amniotic fluid VL is discussed further below (see 1.6.4).  
1.6.2. Clinical findings at birth as predictors for long term sequelae  
Petechiae and IUGR at birth have been shown to be independent risk factors for 
subsequent hearing impairment and petechiae have additionally been associated with 
abnormal CT findings (Boppana et al. 1997;Rivera et al. 2002).  Other studies have 
reported microcephaly (taking into account whether head circumference (OFC) was 
appropriate for weight) as being the most specific predictor for poor neurological 
outcome with the combination of normal CT and head circumference being 
associated with a good prognosis in those with symptoms at birth (Noyola et al. 
2001).   
1.6.3. Neuroimaging and long term sequelae 
Cranial USS has a good positive predictive value (PPV) and NPV with regards to 
subsequent neurological abnormalities in all CMV infected neonates (Ancora et al. 
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2007).  Conversely in symptomatic infection CT scan has been shown to have a good 
NPV but only 50% PPV in identifying a poor neurodevelopmental outcome (Noyola 
et al. 2001).  Although CT has a better sensitivity for detecting intracerebral 
calcifications in one recent study it added nothing diagnostically to cranial USS 
(Ancora et al. 2007).  MRI has, however, been found to identify additional 
information in 6/8 children in 2 unrelated studies (Ancora et al. 2007;de Vries et al. 
2004).     
There is currently no literature evaluating the prognostic benefit of carrying out MRI 
in large cohorts of asymptomatic babies in addition to cranial USS.  It also remains 
largely unknown whether more subtle changes, such as lentriculostriatal 
vasculopathy, should be considered indicative of symptomatic CNS disease. 
1.6.4. Viral load (threshold concept) 
o Adult transplant patients (threshold concept) 
A series of studies conducted in adult transplant patients have shown that risk of 
CMV disease is associated with blood VL independent of donor seropositivity (Cope 
et al. 1997a;Gor et al. 1998;Hassan-Walker et al. 1999).  VL in urine was also shown 
to be associated with disease in renal transplant patients independent of presence of 
viraemia (Cope et al. 1997b).  Indeed, VL seemed to fully account for the increased 
risk of disease in seronegative patients.  Both peak VL and rate of increase are 
associated with increased risk of CMV disease in these transplant recipients (Cope et 
al. 1997a;Emery et al. 2000). 
These observations led to the proposal of a ‘threshold’ effect with a defined level of 
viraemia being significantly associated with risk of disease; such was this association 
that many transplant centres have since adopted a ‘pre-emptive’ strategy to CMV 
prophylaxis (Figure 1-7)(Cope et al. 1997a).  Such treatment strategies have 
proposed benefits in decreasing both subsequent ‘late-onset’ CMV complications and 
healthcare costs (Emery 2001b).  Similarly VL has been shown to be of predictive 
value in those with HIV that develop CMV disease (Bowen et al. 1997). 
These observations have led to interest in whether a similar threshold for disease 
exists in those congenitally infected. 
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Figure 1-7  Blood viral load and association with probability of CMV disease in 
liver transplant patients 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease probability curves computed from univariate logistic regression analysis of 
blood virus load in liver transplant recipients.  CMV viral load was measured using 
quantitative CMV DNA PCR.    
 
Reproduced from Cope et al. (1997a) 
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o Congenital CMV   
Stagno et al (1975) showed in their early studies of the natural history of 
cytomegalovirus infection that the amount of virus detectable in urine using tissue 
culture was significantly higher in those babies with symptomatic infection over the 
first 6 months of life when compared to those without clinically evident infection 
(Figure 1-8).  Furthermore virus titer was higher in congenitally infected babies when 
compared to those postnatally infected up to 9 months of life.   
More recent studies have not only associated the detection of CMV in the blood with 
symptomatic infection but have also found similar quantitative associations between 
CMV DNA PCR in blood, urine and DBS and clinical severity of disease (Boppana 
et al. 2005;Bradford et al. 2005;Lanari et al. 2006;Rivera et al. 2002;Walter et al. 
2008).  Amniotic fluid VL similarly correlates with symptomatic cCMV in the 
newborn although the overlap between groups limits utility of this finding in clinical 
practice (Revello and Gerna 2002).  Asymptomatic babies are generally under-
represented in these cohorts and many babies without symptoms have comparable 
VL to those with disease.  Low/undetectable virus, however, is consistently reported 
to be associated with a good overall prognosis and a good NPV for disease; research 
in this area is ongoing. 
There are conflicting data reporting on the duration of CMV excretion and symptoms 
with viruria being variably reported as decreased and increased in congenitally 
infected neonates developing SNHL (Noyola et al. 2000;Rosenthal et al. 2009).  
Noyola et al. (2000) reported no significant difference, however, in duration of 
viruria in symptomatic compared to asymptomatic neonates.   
As discussed in 1.4.3 above the value of obtaining CSF and perilymph in CMV-
infected newborns has not been fully evaluated in asymptomatic babies.  Whether 
detection of virus or VL in these samples is predictive of subsequent neurological 
sequelae is therefore currently unknown.     
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Figure 1-8  Quantitative viruria over time in babies infected with 
cytomegalovirus congenitally (symptomatic and asymptomatic) and postnatally  
  
 
 
 
Data shown are from 38 infants with congenital infection (8 with symptoms of disease at 
birth) and 17 with postnatal infection.  Congenital infection was confirmed by the presence 
of viruria within the first week of life.   
Viruia was quantified using titration of tissue cultures of human skin fibroblasts. 
 
   
Redrawn from Stagno et al. (1975)  
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1.6.5. Role of genetic polymorphisms  
It has been demonstrated by a number of authors that multiple strains of CMV may 
coexist in congenitally infected infants (Arav-Boger et al. 2002;Ross et al. 2011). 
There has been interest in whether specific genetic subtypes predict symptomatic 
infection.  Studies have failed to show an association between subtypes of US28, gB 
or UL146 and UL147 despite demonstrating an unexpectedly diverse genetic 
variation in the UL146 gene locus which encodes for an chemokine homolog 
(Arav-Boger et al. 2006b).  Arav-Boger et al described an association between 
UL144 subtype C and risk of symptomatic infection (Arav-Boger et al. 2002;Arav-
Boger et al. 2006a;Arav-Boger et al. 2006b).  This has not, however, been confirmed 
by other researchers (Picone et al. 2005).   
1.7. IMMUNE RESPONSE 
Many CMV gene products have a proposed role in evading usual host immune 
responses which include the down regulation of MHC Class I and II expression, 
production of MHC Class I-related decoy molecules, production of chemokine and 
chemokine receptor homologues along with the ability to alter cell signalling 
pathways as reviewed in detail elsewhere (Mocarski 2004;Ploegh 1998).  A full 
understanding of these interactions is further complicated by the discrepancies often 
reported between data derived from animal models, in vitro systems and in vivo 
observations (Goodrum, Caviness, & Zagallo 2012).  
Despite these diverse immune evasive strategies a large proportion of the T-cell 
repertoire in CMV-infected hosts has been shown to be directed towards CMV 
peptides and immune evasion genes themselves can be targets of CD8+ T cells 
(Elkington et al. 2003;Sylwester et al. 2005).  
The decreased need for antiviral treatment for CMV in HIV infected patients 
associated with use of highly active anti-retroviral therapy signifies the importance of 
host immunological responses in the overall control of CMV in this situation.  A 
complex balance therefore exists between virus, host immune responses and virus 
immunomodulation.   
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1.7.1. Innate immunity 
CMV has been reported to employ multiple strategies to decrease NK cell receptor 
activity including encoding genes which interfere with NK cell receptor binding with 
activation ligands along with enhanced signalling through inhibitory NK receptors as 
reviewed by Jackson et al (2011).  The process of CMV binding to and entering cells 
also activates production of interferon and inflammatory cytokines through TLR-2 
recognition of gB and gH (Isaacson et al. 2008). 
1.7.2. Adaptive immunity - antibody mediated 
The envelope glycoprotein, gB (gpUL55), has been proposed as the predominant 
target for neutralising antibodies, accounting for 40-70% of the total serum 
neutralising response (Britt et al. 1990).  Recent studies evaluating CMV 
hyperimmune globulin, however, have implicated pentameric gH/gL/UL128-131A 
complexes as the predominant target for neutralising antibodies and in vitro studies 
using endothelial cell lines (the cell line predominantly infected in vivo) have also 
challenged the role of gB as the major neutralising epitope (Macagno et al. 2010). 
Clinical studies would infer that antibodies are important in preventing infection 
based on decreased transmission from seropositive mothers and in seropositive 
transplant recipients as described earlier.  Passive transfer of maternal antibody has 
also been proposed as a contributory factor to the lack of disease associated with 
postnatally transmitted infection and as an explanation for the altered CMV–specific 
antibody responses observed in postnatally compared to congenitally infected babies 
(Stagno et al. 1975).  Recent studies investigating the use of a recombinant gB 
vaccine have correspondingly shown some promising initial results (Griffiths et al. 
2011;Pass et al. 2009).  The contribution of antibody to overall virus control remains 
undefined, however, and intact cellular immune responses are also likely to be 
necessary to minimise symptomatic infection and maintain CMV in a latent state 
following primary infection.  
1.7.3. Adaptive immunity – cellular immune responses 
In adults symptomatic patients have been observed to have impaired cellular 
immunity with both functional and phenotypic differences in T cells.  Broadly 
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speaking chronic CMV infection induces phenotypic changes favouring a CD28-
/CD27- CD8+ “late” T-cell phenotype and cells characteristically express perforin, 
granzyme and other cytotoxic effectors but lack the chemokine receptor CCR7.  This 
pattern is distinct when compared to other chronic viral infections (Appay et al. 
2002).  Given the asymptomatic nature of infection, responses during primary 
infection in immunocompetent adults are not easy to define.  During primary 
infection in renal transplant recipients, however, CD8+ T cells are detectable shortly 
after CMV antibody responses and show a similar activated phenotype with high 
expression of Ki67, granzyme B, perforin and CD45RO+, CCR7-, CD28-; they are 
predominantly CD27+, however (Gamadia et al. 2003;van de Berg et al. 2008).   
Immune therapy with reconstitution of CMV-specific CD8+ lymphocytes has been 
shown to decrease active disease and reactivation of infection in mice and humans 
highlighting the important role of this component of host immunity in 
immunocompromised individuals (Riddell et al. 1992;Steffens et al. 1998;Walter et 
al. 1995).  The appearance of late onset CMV disease has similarly been proposed to 
be due to the intense viral suppression accompanying prophylactic antiviral treatment 
strategies and a consequent delay in reconstitution of CMV-specific immune 
responses (Boeckh et al. 2003;Li et al. 1994).   
Studies using HLA-matched Class I tetramers incorporating overlapping peptides 
from 213 known or predicted HCMV open reading frames (ORFs) have shown that 
10% of the overall CD8+ and CD4+ memory T-cell pool is able to recognise CMV 
(Sylwester et al. 2005).  Although these studies demonstrated T-cell responses to a 
diverse range of CMV epitopes in individual hosts, responses to pp65 and IE1 are 
consistently present and remain relatively immunodominant between subjects.  
Responses to pp65 and IE1, however, only represent ~40% of all T-cell responses to 
CMV.  Detail of other known Class I and Class II T lymphocyte epitopes are 
reviewed elsewhere (Gandhi and Khanna 2004).  A direct correlation between viral 
load and virus specific CD8+ve T cells has been shown in HIV (Ogg et al. 1998).  
Similar correlations have also now been shown between the calculated proportion of 
pp65-specific CD8+ T-cells secreting IFNg and CMV VL (Mattes et al. 2008).  No 
association was demonstrated between CD8+ T-cell responses and virus shedding, 
however, in healthy children (Chen et al. 2004). 
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Other authors have proposed a more pivotal role for IFN-g secreting CD4+ cells with 
CD8+ effector cells and CMV-specific antibody alone being ineffective in 
controlling virus in renal transplant and allogeneic stem cell transplant patients 
(Gamadia et al. 2003;Widmann et al. 2008).  Consistent with this observation a 
longer duration of virus shedding has been observed in healthy children associated 
with deficient CD4+ T cell immunity (Tu et al. 2004).   
High numbers of CD57+ T cells have been found associated with CMV 
seropositivity in a number of situations and are proposed to result from chronic 
antigenic stimulation (Brenchley et al. 2003;Wang et al. 1997;Wang and 
Borysiewicz 1995).  CD57+ve lymphocytes have been shown to have decreased 
proliferative capacity and expression of CD57 is thought to be independently 
associated with replicative senescence and an increased susceptibility to cell 
apoptosis on activation along with decreased telomere length (Brenchley et al. 2003).  
This may have relevance when considering the “immune risk” phenotype also 
recently described in elderly CMV seropositive subjects (Pawelec et al. 2009).    
1.7.4. Differences in immune responses to CMV in congenitally infected 
babies 
Previous studies have suggested various abnormalities in the immune response to 
CMV in young children and between those with symptomatic and asymptomatic 
infection. 
Activated NK cells are decreased in symptomatic compared to asymptomatic 
congenitally infected infants with low numbers of activated CD16+ NK cells being 
significantly correlated with decreased killing of CMV-infected fibroblasts (Cauda et 
al. 1987).   
Studies in neonates suggest similar phenotypic changes in lymphocyte populations 
during acute CMV infection to adults with loss of CD28 and CD27 along with 
expression of Ki67 and RA to RO+ shift (Marchant et al. 2003;Miles et al. 2008).  
These changes are distinct in infected neonates compared to healthy, uninfected 
controls (Elbou Ould et al. 2004).  However, lymphocyte proliferation and IFN-g 
production have been shown to be decreased in both congenitally and postnatally 
infected infants compared to adults (Elbou Ould et al. 2004;Pass et al. 1983b).  These 
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deficits are more evident in younger infants (less than 1-2 years of age) and seem to 
be a selective defect in response to stimulation with CMV antigens as other stimuli 
do produce responses (Elbou Ould et al. 2004;Gehrz et al. 1982;Hayashi et al. 
2003;Pass et al. 1983b).  Indeed, enhanced activation has been observed following 
non-specific antigen stimulation in CMV-infected infants compared to healthy 
neonatal controls (Elbou Ould et al. 2004).  Correspondingly Hayashi et al, also 
found decreased CMV specific CD8+ lymphocyte frequencies in HLA-A24-positive 
babies with symptomatic cCMV compared to postnatally infected infants or adults 
(Hayashi et al. 2003).  Others have demonstrated T-cell responses but propose that 
younger infants might respond preferentially to IE1, rather than pp65 as seen in 
adults, particularly in those that were not HLA-A2 positive (Gibson et al. 2004).   
Results comparing asymptomatic and symptomatic populations are conflicting with 
authors variably reporting increased and decreased markers of T cell activation and 
cytotoxic killing in asymptomatic compared to symptomatic babies (Cauda et al. 
1987;Rola-Pleszczynski et al. 1977).  Decreased numbers and activation of CD4+ T 
cells have been demonstrated in symptomatic compared to asymptomatic 
congenitally infected infants (mean age 4 years) and uninfected controls (Cauda et al. 
1987;Elbou Ould et al. 2004). 
In contradiction to speculation that immune tolerance might play a role in these 
observations are studies of fetal immune responses which have shown CMV-specific 
responses in fetuses as young as 28 weeks gestation (Elbou Ould et al. 
2004;Marchant et al. 2003).   
1.8. ANTIVIRAL TREATMENT 
There are currently only four licensed drugs for the systemic treatment of CMV, all 
of which act on the viral DNA polymerase and have major side effects which limit 
their use.  The two drugs most commonly used for the treatment of cCMV are GCV 
and its oral prodrug VGCV.  These drugs and their clinical utility in the treatment of 
cCMV are therefore discussed in more detail below.  Cidofovir and foscarnet are 
rarely used in the treatment of cCMV and data are sparse; these drugs are therefore 
not discussed further here.   
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1.8.1. Ganciclovir  
2’-deoxyguanosine, GCV, has been used in children since 1989 (Fan-Havard et al. 
1989).  It is a synthetic guanosine analogue which undergoes phosphorylation in 
infected cells to its triphosphorylated form (Figure 1-9).  The first phosphorylation is 
initiated by a protein kinase homolog encoded by HCMV pUL97, meaning that 
phosphorylation occurs preferentially in infected cells, thus ensuring high levels of 
active drug in these cells (Biron et al. 1985;Sullivan et al. 1992).  Intracellular GCV-
triphosphate has a half-life of around 16.5 hours making it additionally effective in 
inhibiting CMV replication (Crumpacker 1996).  Although GCV-triphosphate is a 
competitive inhibitor of the viral DNA polymerase unlike acyclovir triphosphate it is 
not an obligate chain terminator meaning that synthesis of viral DNA continues, 
albeit at a slower rate, with an associated risk of side effects including mutagenicity 
if drug is activated in non-infected cells.    
o Formulation and dose, pharmacokinetics 
The drug is excreted by the kidneys, with almost 100% of drug eliminated 
unchanged in the urine (Jacobson et al. 1987); dose must therefore be adjusted in 
renal impairment.  There is minimal protein binding.    
In vitro minimum inhibitory concentration (MIC) and 50% inhibition of virus 
replication (IC50) for GCV are reported to be 0.31-1.63 mcg/ml and 0.02-3.48 
mcg/mL respectively (Fishman et al. 2000).  Peak concentrations of GCV of 4.5-
10mcg/mL and trough levels of 0.8mcg/mL have been reported in adults receiving 
doses of 7.5-10mg/kg/day i.v. GCV in two divided doses (Crumpacker 1996).  Oral 
doses of 1000mg GCV three times daily were recommended for prophylaxis but due 
to the low bioavailability (~6%) and correspondingly low peak levels achieved the 
use of this drug has been superseded by oral VGCV and oral GCV is not currently 
available.  Bioavailability in children has been reported to be even more problematic 
(Frenkel et al. 2000).       
Levels of 0.7 mcg/mL have been detected in the CSF 3.5 hours after a 2.5mg/kg dose 
of i.v. GCV where simultaneous serum concentrations were 2.2mcg/mL (Fletcher et 
al. 1986).  These levels only just reach the MIC for GCV and may thus limit efficacy 
in this body compartment.  
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Figure 1-9  Structure of ganciclovir and valganciclovir and steps to tri-phosphorylated, active drug  
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Reports of the use of GCV in children emerged in the late eighties; over the 
subsequent two decades there have been very few further pharmacological studies in 
the paediatric age group and even fewer involving neonates.  Rapid changes in many 
parameters impacting on pharmacokinetics (PK), including renal function, make 
dosing in the neonatal age group particularly challenging.  In neonates plasma levels 
comparable to those found in adults can be achieved with i.v. GCV doses of 6mg/kg 
twice daily although some studies report two-fold higher levels in adults compared to 
neonates (Table 1-3)(Pacifici 2005;Trang et al. 1993;Zhou et al. 1996).  Changes in 
body weight and age have been correlated with changes in the volume of distribution 
(Vd) and creatinine clearance (Cl) of GCV respectively (Trang et al. 1993;Zhou et al. 
1996).  A more recent study in congenitally infected infants aged 30 days or less at 
onset of treatment demonstrated a 73% increase in renal excretion of GCV from 
3.8mL/min/kg to 6.8mL/min/kg between days 4 and 34 of treatment, and a 
corresponding decrease in area under curve (AUC) of 41% over the same time 
period, following a dose of 6mg/kg i.v. GCV (Kimberlin et al. 2008).  Furthermore in 
contrast to the multicompartmental PK reported in adults, neonatal studies have 
shown that PK is adequately described by a single-compartment model with zero-
order input and first-order elimination (Trang et al. 1993).     
o Toxicity 
Toxicity limits the use of most antivirals effective against CMV with one of the 
commonest side effects of GCV being bone marrow suppression.  Grade 3-4  
neutropenia (based on NIAID DMID toxicity definitions) has been reported in 
around 65% of babies undergoing treatment with i.v. GCV often necessitating a 
decrease in dose (Kimberlin et al. 2003;Whitley et al. 1997).  This is in contrast to 
levels of neutropenia of around 15% quoted in adult studies.   Neurotoxicity has been 
rarely reported in adults, generally in association with decreased renal function 
(Ernst and Franey 1998).  Although uncommon this emphasizes the need for close 
monitoring of both haematological and biochemical parameters during treatment.   
Animal models have shown decreases in spermatogenesis causing infertility 
associated with treatment.  Increased tumours, lymphoma cell mutagenesis and DNA 
damage have also been reported in rodent models with less drug exposure than  
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Table 1-3: Pharmacokinetics of ganciclovir in neonates and adults 
 
 
Age Single 
dose
+
 
Cl 
(l/h/kg) 
Vd 
(l/kg) 
Cmax 
(µg/ml) 
T1/2 (h) Ref 
No. 
cases 
4-49 days 4mg/kg 
0.19 ± 
0.03 
0.67 ± 
0.07 
5.5 ± 
0.4 
2.4 ± 
0.4 
Trang, 1993  14 
2-30 days 6mg/kg 
0.21 ± 
0.02 
0.75 ± 
0.07 
7.0 ± 
0.5 
2.4 ± 
0.4 
Trang, 1993  13 
n.a. 
(newborns) 
4-6mg/kg 0.42 ± 
0.08 
1.8 ± 
0.32 
n.a. n.a. Zhou, 1996  27 
Adult 5mg/kg 0.28 ± 
0.11 
1.1 ± 
0.30 
6.6 ± 
0.8‡ 
4.3 ± 
1.6 
Pacifici, 2005  n.a. 
 
Figures are mean ± SEM 
+      = Ganciclovir was administered by an intravenous infusion over 1 hour 
‡      = Following a single 6mg/kg dose over 1 hour of infusion. 
 
n.a.  = not available 
Cl     =  clearance  
Cmax  =  Maximum drug concentration 
SEM = Standard error of mean 
T1/2      = drug half-life  
Vd    = Volume of distribution. 
  
Table adapted from Pacifici (2005) 
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anticipated in humans (Genentech 2013;Tomicic et al. 2002).  Data show that GCV 
crosses the placenta, probably by simple diffusion, resulting in both embryotoxicity 
and teratogenicity in animal models (Genentech 2013). 
In view of the concerns relating to carcinogenesis and gonadal toxicity, long-term 
follow-up has been conducted of 47 children enrolled as neonates into a phase II trial 
(NCT 00031421).  Although unpublished no adverse effects have been noted in 
relation to cancer incidence, sexual development or pubertal development in this 
small number of subjects (personal communication). 
o Resistance 
Resistance to GCV can be secondary to mutations in pUL97 or in the viral 
polymerase encoded by the UL54 gene.  Recent studies have detected a number of 
mutations in pUL97 with only a small number conferring GCV resistance (Chou 
2010). Resistance in adult studies is associated with low plasma levels of GCV; the 
use of oral GCV for prolonged periods was correspondingly proposed to select for 
resistance (Emery and Griffiths 2000).   
1.8.2. Valganciclovir  
VGCV is the L-valyl-ester prodrug of GCV and after oral administration it is rapidly 
converted to GCV by hepatic and gastrointestinal esterases (Figure 1-9) (Razonable 
and Paya 2004).  Unlike GCV, VGCV is a substrate for peptide transporters in the 
intestinal wall, thus explaining its enhanced bioavailability.  It was licensed for use in 
adult transplant recipients in 2001 in the USA and a few years later gained a 
European marketing authorisation for use as prophylaxis against CMV disease in 
solid organ transplant recipients.  
o Formulation and dose, PK 
At around 60%, oral bioavailability in adults is around 10 times greater than for oral 
GCV (Sugawara et al. 2000).  More recently, oral bioavailability in neonates and 
children has been shown to be around 50% with an increased bioavailability reported 
over time in neonates sampled over a 6 week treatment period (Acosta et al. 
2007;Burri et al. 2004). 
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Adult studies have shown GCV Cmax following oral VGCV administration is 
comparable to that achieved with iv GCV (Razonable and Paya 2004).  VGCV was 
originally available only as tablets with subsequent reports of extemporaneously 
produced VGCV solution being used in the paediatric age group (Anaizi et al. 
2002;Henkin et al. 2003).  Oral VGCV solution gained marketing authorisation in 
the UK in 2009.  At the onset of this thesis uncertainty therefore existed regarding 
dosing of VGCV in infants.   
There is no published literature regarding CSF concentrations of GCV following oral 
VGCV administration. Data from studies of oral valaciclovir, however, show stable 
levels of aciclovir in the CSF when compared to serum with data indicating slow 
passive diffusion into this compartment and active transport out (Lycke et al. 2003).  
This might imply that peak serum levels of nucleoside drugs are not as important for 
CSF penetration as AUC.   
o Toxicity 
Side effects are essentially those of GCV with some reported increase in 
gastrointestinal side effects (Martin et al. 2002).  Neurotoxicity has been reported in 
one child treated with VGCV (Peyriere et al. 2006). The same cautions regarding 
possible long-term carcinogenicity and impaired fertility need to be taken into 
consideration although no long term data currently exist for humans.   
1.8.3. Treatment efficacy and pharmacodynamics  
o Clinical efficacy in adults 
In adults GCV has been used to treat and prevent CMV disease in transplant patients 
and those with HIV with variable efficacy dependent on the underlying condition,  
drug used (including formulation and dose) and clinical stage at time of treatment 
initiation (Griffiths 2009).  Once clinical manifestations of disease are present 
treatment is of limited efficacy in preventing long term morbidity in either of these 
patient groups.  Where disease processes have already been initiated the host immune 
response to CMV is therefore likely critical in continuing to cause tissue damage 
even once virus burden is decreased by antiviral treatment.  Treatment strategies in 
transplant patients therefore consist of either prophylactic therapy (antiviral agents 
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commenced dependent on certain risk factors irrespective of virus detection) or pre-
emptive therapy (antiviral therapy commenced at an asymptomatic stage generally 
dependent on predetermined levels of virus detection) with advocates for both 
strategies (Singh 2006a;Snydman 2006).  The main proposed benefit of pre-emptive 
strategies is a decrease in late-onset disease which has emerged as a significant 
problem with the prophylactic use of potent antivirals (Singh 2006b).  Studies to date 
have generally reported comparable efficacy between oral VGCV and i.v. GCV, 
including small studies in children, with the exception of liver transplant recipients 
(Clark et al. 2004;Jain et al. 2005;Paya et al. 2004).   
Antiviral treatment for CMV retinitis is generally successful in preventing sight-loss 
in those with AIDS and it may be of some benefit in treating CMV polyradiculitis 
and other CMV-related peripheral neuropathies but is rarely efficacious in treating 
CMV ventriculoencephalitis (Cinque, Marenzi, & Ceresa 1997).  It is speculated that 
this might be due to the low levels of GCV detectable in the CSF which are close to 
the in vitro MIC for CMV.  In support of this CMV has been detected in CSF, with 
no associated pp65 antigenaemia, at the end of 3 weeks treatment with GCV and at 
autopsy in HIV patients with diffuse encephalopathy that subsequently died (Cinque 
et al. 1995).         
The majority of studies of clinical efficacy in adults focus on acute CMV-related 
morbidity and mortality post-transplantation or the clinically visible manifestations 
of HIV retinitis.  The ongoing uncertainty regarding the best therapeutic options to 
prevent late-onset disease post-transplantation highlight the difficulties of obtaining 
longer term follow-up data of less clearly defined morbidities and the need for early 
biomarkers for such morbidities. 
o Virological efficacy in adults 
Virological efficacy has been described in adult patient groups with 71% of 
transplant patients with a median starting VL of 4.3 log10 (range 2.7-5.9) clearing 
viraemia within 14 days of starting pre-emptive i.v. GCV treatment;  none of 24 
failed to clear viraemia within 50 days of treatment (Mattes et al. 2004).  Similarly 
median duration of detectable viraemia of 14 and 15 days were observed in patients 
treated with GCV and oral VGCV respectively in a subsequent study in transplant 
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recipients with similar viral dynamics reported in both treatment groups.  A number 
of subjects failed to become CMV PCR negative, however, even after treatment 
courses of up to 49 days (Mattes et al. 2005).  Likewise 85% of 45 patients with HIV 
and CMV retinitis who were CMV PCR positive at treatment onset had no viraemia 
21 days after commencing i.v. GCV (Bowen et al. 1996).  Those that remained 
viraemic had a higher starting VL and a shorter time to disease progression and death 
(Bowen et al. 1996).  
o Congenital CMV clinical efficacy 
The Collaborative Antiviral Study Group (CASG) has conducted a series of studies 
evaluating the optimal treatment for babies with cCMV. The first of these studies 
compared 6mg/kg i.v. GCV twice daily (bd) with a lower dose of 4mg/kg bd and 
showed the higher dose suppressed virus more effectively with no significant 
increase in side effects (Whitley et al. 1997).  Improved clinical outcome was also 
reported compared to historical data.  A subsequent randomised controlled trial 
(RCT) found that 6 weeks treatment with this higher dose of GCV decreased long-
term sequelae in babies with cCMV and CNS disease (Kimberlin et al. 2003).  
Although treatment was randomized there was no placebo arm, as this would have 
necessitated central line insertion which was not thought ethical.  Results were 
further confounded by the availability of follow-up data in only 42 of the 100 
subjects initially enrolled.  Despite these limitations a significant treatment advantage 
was shown with 0/25 treated babies having hearing deterioration from baseline at 6 
months compared to 7/17 (41%) of controls (p <0.01); this difference remained 
significant at one year follow-up.  Short-term benefits were also reported in growth 
and resolution of liver function.  Subsequent neurological follow-up of these babies 
also showed fewer neurodevelopmental delays in the treated cohort (Oliver et al. 
2009).      
Other, uncontrolled, case cohort studies have reported a benefit from antiviral 
treatment of symptomatic babies at birth (Halwachs-Baumann et al. 2002;Michaels et 
al. 2003;Nigro et al. 1994;Rojo and Ramos 2004;Tanaka-Kitajima et al. 
2005;Whitley et al. 1997).  Duration of treatment and dose of medication varies 
greatly in these cohorts, however, as summarised by Luck et al. (2006).  Recent 
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studies have reported clinical benefit with higher drug doses and longer treatment 
courses, particularly with the availability of oral VGCV solutions (Amir et al. 
2010;Baquero-Artigao and Romero Gomez 2009;Meine Jansen et al. 2005).  
Publication bias is obviously of concern and the need for placebo-controlled RCTs is 
further highlighted by the fluctuations in SNHL described earlier (Dahle et al. 2000).   
o Congenital CMV virological efficacy 
An association between clinical efficacy and suppression of viruria at treatment 
termination was shown in early studies but virus was seen to subsequently rebound 
after treatment cessation (Nigro, Scholz, & Bartmann 1994;Whitley et al. 1997).  
There were no large studies reporting on virological efficacy with treatment for 
cCMV at the start of my work.  
1.9. AIMS OF THESIS 
The aims of this thesis were primarily to apply modern virological and 
immunological techniques to further define the natural history of disease in 
congenitally infected babies and to inform treatment strategies in the neonatal age 
group.   
Specific objectives were to:- 
1) Evaluate PK in neonates and correlate with drug efficacy. 
2) Describe pharmacodynamics (PD) of antiviral treatment in neonates.  
3) Apply VL measurements and calculations of virus dynamics to infected 
neonates (including VL measurements in different body fluids) 
4) Establish collaborations within the UK and European Union to facilitate 
multicentre studies and data collection.   
5) Evaluate sequential immunological responses in the neonatal age group 
using methodology validated in adult patients. 
6) Define optimal time points at which sampling should be conducted to                                      
facilitate correlation of PK with PD. 
 
One or more of these objectives are addressed in each of the following Chapters.  
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CHAPTER 2. 
2. GENERAL METHODS
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2.1. INTRODUCTION 
This chapter describes methods developed by others and used during work in a 
number of different chapters of this thesis. 
2.2. QUANTITATIVE CMV PCR 
2.2.1. Outline 
Most DNA extractions and CMV PCR analyses were carried out by the diagnostic 
team in the laboratory at the Royal Free Hospital alongside samples received for 
routine clinical analysis.  DNA was extracted according to manufacturer’s 
instructions and standard laboratory protocols in place at the time from 110uL of 
blood or urine or 1mL of viral transport medium (VTM) from salivary swabs into 
110uL phosphate buffered saline (PBS) using either the semi-automated easyMag™ 
or the fully automated QIAsymphony™ system (which work on the same 
technology).  Quantitative VL was then measured using an in-house real-time 
TaqMan PCR detecting a target within the highly conserved glycoprotein B (gB) 
gene of HCMV (primer 1 5’-GAGGACAACGAAATCCTGTTGGGCA-3’ [gB1] 
and primer 2 5’- TCGACGGTGGAGATACTGCTGAGG-3’ [gB2]). The 150 base 
pair product was detected in real time by use of a 29-mer TaqMan probe (5’-
CAATCATGCGTTTGAAGAGGTAGTCCACG-3’ [gb-P3]), with PCR and cycling 
conditions as described elsewhere and using 5uL of input purified or control DNA 
(Mattes et al. 2005). Each TaqMan PCR run contained a dilution series of cloned 
HCMV gB plasmid from 200-200x10
6 
copies/ml.  CMV VL was calculated using the 
ABI TaqMan sequence detection system software.  The limit of detection was 1 copy 
per 5uL input (200 copies/mL).    
2.2.2. Limitations  
Urine can inhibit the PCR reaction.  Extraction of DNA prior to PCR analysis 
minimises this risk and inhibition has not been problematic during routine diagnostic 
analysis within our laboratory.   
For samples received in the Royal Free diagnostic laboratory VL results are likely to 
be reasonably consistent over time despite the long study period involved due to the 
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internal controls and similar PCR conditions used.  Results from different labs are 
not, however, comparable although log changes should, nonetheless, be meaningful 
as intra-assay variation is low. 
2.3. GANCICLOVIR LEVELS 
All samples were assayed by the United Kingdom Antimicrobial Reference 
laboratory (BCARE) using a validated high performance liquid chromatography 
(HPLC) assay and following the standard protocol in use at the time of analysis. In 
brief, chromatography was performed on a Techsphere C8 column using a mobile 
phase of 1% phosphoric acid in a 10g/L solution of octane sulphonic acid, with 
sample preparation by 1:1 dilution with perchloric acid and quantification by the 
external standard method. Both the intra- and inter-assay precision, coefficient of 
variation (CV), were below 10% and the limit of detection ranged from 0.5 down to 
0.1 mg/L depending on the instrumentation used over the period of the study. 
2.4. CMV IGG AVIDITY ASSAYS 
IgG avidity was measured using diagnostic equipment and protocols available at the 
time and were conducted by laboratory staff alongside samples being processed for 
diagnostic purposes.  Some earlier samples were analysed using the VIDAS® 
(Biomerieux) system which measures avidity using a denaturing agent to remove low 
avidity antibody.  Most samples, however, were analysed using the completely 
automated Abbott ARCHITECT® system which in contrast uses a two-step 
chemiluminescent microparticle immunoassay (CMIA) utilising the finding that 
high, but not low, avidity antibody binds to antigen in a liquid phase to remove high 
avidity antibody prior to measuring remaining low avidity antibody (Curdt et al. 
2009)(Figure 2-1).  CMV IgG avidity index is subsequently calculated as a 
percentage using the relative light units (RLUs) of paired samples: 100 – [ratio (RLU 
with liquid phase antigen (Assay 1))/(RLU without liquid phase antigen (Assay 2))] 
x 100.           
To enable the most appropriate dilution protocol to be selected it is necessary for a 
total CMV IgG to first be measured on the ARCHITECT® system.  If samples have 
a total IgG concentration of >250IU then a 1:10 dilution of the serum is
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Figure 2-1 Cartoon showing steps in Abbott ARCHITECT® IgG avidity assay 
 
Two aliquots of sample are used.  Assay 1 is pretreated with liquid CMV antigen which 
binds to high avidity antibody in the sample.  Assay 2 is pretreated with buffer only leaving 
both high and low avidity antibody unbound in the sample.  Solid phase CMV antigen (CMV 
lysate-coated paramagnetic microparticles) is then added to both samples.  The samples are 
incubated and washed, removing high avidity antibody bound to the liquid phase antigen in 
Assay 1 but leaving both high and low antibody bound to the solid phase antibody in Assay 
2.  An acridinium-labelled mouse anti-human IgG is then added to both samples followed by 
a pre-trigger (hydrogen peroxide) and a trigger agent (sodium hydroxide) which results in 
chemiluminescence, the amount of which is measurably related to the amount of antibody 
bound to the solid phase antigen in both samples.  IgG avidity is then calculated using the 
relative light units (RLU’s) measured in the 2 assays. 
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automatically conducted in keeping with evidence that this improves avidity 
accuracy (Dangel et al. 2006).  
Values of <50.0% and ≥60.0% are interpreted as indicating a low and high CMV IgG 
avidity respectively with results between 50 and 60% representing an equivocal ‘grey 
zone’ which cannot be interpreted. 
2.4.1. Limitations 
Using this commercial platform it is possible that more serum was needed than if 
manual assays had been conducted.  Minimum serum recommended by the 
manufacturer is ~150uL.  There were only two samples where serum was insufficient 
for avidity analysis so this had minimal impact on my studies.   
2.5. PBMC EXTRACTION, EX-VIVO STAINING AND CYTOKINE 
ASSAYS 
I spent some time adapting and refining adult protocols, developed previously by 
others in the laboratories at the Royal Free Department of Virology, to maximise 
buffy coat and PBMC yield from the smaller blood samples obtainable from 
neonates.  Data from our lab demonstrated a marked decrease in viable PBMCs and 
cytokine production following freezing and thawing processes, it was therefore 
decided that fresh samples would provide the most reliable source of material in my 
studies particularly with additional restricted sample sizes.  Most of the assays were 
then conducted by me, with some assistance by others in the lab towards the end of 
the studies.    
2.5.1. PBMC extraction 
EDTA blood (~1.0-1.5mls) was diluted with an approximately equal volume of 
RPMI-1640 (Gibco, UK) and carefully layered over an approximately equal volume 
(2-4mls) of Ficoll-Paque (GE Healthcare, UK) solution in a 15ml Falcon tube, to 
prevent mixing.  The tube was centrifuged with no brake (778g for 20 minutes) to 
separate the PBMC-containing buffy coat.  PBMCs were then harvested using a 
pipette, ensuring no Ficoll or blood contamination, and placed in a clean 15ml Falcon 
tube.  10mls RPMI was added and mixed gently with the harvested PBMC to wash.  
After further centrifugation with the brake on (15mins at 600g) supernatant was 
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removed and the cell pellet resuspended in a further 10mls RPMI.  10uL of this 
solution was removed, diluted 1:1 with trypan blue, inserted into a FastRead 102™ 
haemocytometer and viable PBMCs counted.  Cell count/ml of blood was calculated 
using the formula: No. of cells per grid x 10
4 
x dilution factor.  At least 3 different 
grids were counted and the average number of PBMCs per grid calculated.  Whilst 
cells were being counted, remaining cells were centrifuged (500g, 5min) then 
resuspended in warmed 10% FCS/RPMI to give ~2x10
6
 PBMCs/ml and then stained 
according to either the ex-vivo or stimulation protocols below. 
2.5.2. Ex-vivo staining 
~1x10
6
 PBMCs were placed in a FACS tube and centrifuged (500g, 5min) to pellet.  
Supernatant was discarded and cells resuspended in residual fluid. If subjects had 
been identified as being HLA-A2 positive cells were incubated for 10 minutes at 
room temperature, protected from light, with 10μl of R-PE labelled 
A*02:01/NLVPMVATV (CMV) pentamer (Proimmune); if HLA-A2 negative, cells 
were incubated with 10uL CD28-R-PE (BD Pharmingen) in place of pentamer.  Cells 
were washed in 2mls 0.1% sodium azide in PBS (PBS/0.1% NaN3) and centrifuged 
at (500g, 5 minutes).  
Pellets were resuspended in residual fluid and incubated at room temperature for 15 
minutes protected from light with 10μl CD8 PerCP Cy5.5 and 10μl CD57 FITC (BD 
biosciences). Cells were washed as before, pellets resuspended, and 100μl Caltag A 
(Fixative) (Invitrogen) added while vortexing. Cells were then incubated at room 
temperature for 15 minutes protected from light before washing again.  
Following centrifugation, pellet was again resuspended in supernatant and 100μl 
Caltag B (Permeabilising solution) (Invitrogen) added while vortexing along with 
10μl Granzyme B APC (APC Invitrogen). Cells were incubated at room temperature 
for a further 15 minutes, protected from light before washing as before and 
resuspending in 100μl of 4% paraformaldehyde.  Samples were stored at 4°C, 
protected from light, until acquisition (maximum of 24 hours). 
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2.5.3. PBMC overnight cultures for cytokine detection   
CD4 and CD8 positive PBMC production of the cytokines IFNγ, TNFα and IL-2 
following stimulation of PBMCs was conducted by me using protocols developed by 
others in our laboratory as follows.   
Essentially ~1x10
6
 PBMC in 500μl of 10%FCS in RPMI were added to sterile 
polypropylene FACS compatible culture tubes.  Dependent on the number of cells 
available stimulation was conducted with reagents as shown below.    
1. Matched pp65 MHC class I peptide: 5μl of CMV pp65 NLVPMVATV, 
Proimmune peptide (i.e. corresponding to peptide folded with MHC Class I 
HLA-A2 specific pentamers used in ex-vivo assays described earlier).    
2. CMV lysate: 2.5μl of HCMV AD169 purified whole-virus lysate (Autogen 
Bioclear cat no.10-144-000).   
3. IE-1 pool/pp65 pool: 2μl of appropriate peptide pool (JPT Technologies 
PepMix containing a mix of 15-aa overlapping peptides spanning the HCMV-
pp65 and IE-1 proteins)  
4. SEB: 1ul of 1mg/ml Staphylococcal aureus enterotoxin B stock. 
5. No antigen (background): 2μl of DMSO only. 
5μl of pure anti-CD28 (BD bioscience) was added as a costimulatory antibody to 
CMV lysate, pp65/IE-1 pools and no antigen controls.  Previous work by others had 
shown that adding this reagent to SEB and matched pp65 MHC class I peptides did 
not further increase cytokine production (data not shown). 
Where cell numbers were limited stimulations were prioritised, as detailed below:- 
1. If <3x106 PBMC and subject HLA-A2 positive ex-vivo pentamer staining 
and matched peptide stimulation were conducted along with positive (SEB) 
and no antigen background control.  Although fewer than <1x10
6
 cells were 
present in each tube this was felt to be an acceptable compromise to ensure 
that there were no obvious problems with the assay.  If <3x10
6
 PBMC and 
subject HLA-A2 negative then stimulation was conducted with CMV lysate, 
along with the positive control (SEB) and no antigen background control.   
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2. If >4x106 PBMC stimulation with IE-1 peptide pool and pp65 peptide pool 
were added and an ex-vivo tube (CD28, CD57 and granzyme B) was carried 
out for the HLA-A2 negative subjects.  
3. If > 6 x106 PBMC all assays were included. 
Tubes were vortexed to mix and placed in a 37°C CO2 incubator for 2 hrs. 500μl of 
Brefeldin A (BFA)(Sigma) in 10% FCS/RPMI (concentration 20μg BFA/ml) was 
then added to each tube (to give a final concentration of 10μg BFA/ml), vortexed to 
mix and cells returned to the incubator overnight.  Previous time course assays in 
adult subjects had indicated that optimal cytokine production was seen 12 -14 hours 
after addition of BFA.  Cells were therefore left overnight for ~12 hours and no 
longer than 14 hours.   
Following overnight stimulation PBMC cultures with no antigen, pp65 peptide pool, 
IE-1 peptide pool were divided between 2 tubes to be labelled with either CD4 (A) or 
CD8 (B). Cell suspensions were then centrifuged at 500g for 5 minutes, supernatant 
discarded and the pellet resuspended in residual fluid.  For surface staining 10μl of 
CD4 PerCP Cy5.5 (BD biosciences) was added to CMV lysate, No Ag (A), pp65 
pool (A), IE-1 pool (A) and SEB.  10μl of CD8 PerCP Cy5.5 (BD biosciences) was 
added to matched pp65 MHC class I peptide, No Ag (B), pp65 pool (B), IE-1 pool 
(B).  Tubes were incubated at room temperature for 15 minutes, protected from light.  
Cells were then washed in 2mls PBS/0.1% NaN3 and spun (500g, 5 minutes).  Pellets 
were resuspended in supernatant and 100μl Caltag A added while vortexing. Cells 
were incubated for a further 15 minutes at room temperature, protected from light 
before a further wash. 
Cells were resuspended in residual fluid and 100μl Caltag B added while vortexing. 
Simultaneously 10μl IL-2 FITC (BD biosciences), 10μl TNFα PE (BD pharmingen) 
and 2μl IFNγ APC (BD pharmingen) was added. Samples were mixed and incubated 
at room temperature for 15 minutes protected from light prior to washing, 
centrifuging and resuspending in 4% paraformaldehyde.  Samples were stored 
protected from light at 4°C until acquisition (within 24 hours). 
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o Acquisition 
Cells were acquired using Cellquest software and BD 4-colour FACSCalibur™.  
Initial instrument settings were created using single staining set-up protocols with 
manual compensations.  Given the small number of cells available fine tuning was 
carried out at each analysis if required. 
The lymphocyte population was defined according to forward and side scatter 
characteristics and subsequently the CD4+ or CD8+ cells defined as a subset of this 
population by gating on PerCP Cy5.5+ cells.  Acquisition and storage was then set to 
50,000 CD4+ or CD8+ cell events to enable small changes in CMV-specific 
populations to be detected (i.e. down to approximately 1:1000).  Data were saved 
under the subject number, time point of analysis and stimulating antigen/ex vivo 
protocol prior to transferring to an AppleMac computer for analysis using FlowJo 
software as described further in Chapter 6 of this thesis.    
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CHAPTER 3. 
3. ANALYSIS OF GANCICLOVIR LEVELS IN 
CHILDREN FROM THE UK NATIONAL 
REFERENCE LABORATORY
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3.1. INTRODUCTION 
GCV and its oral prodrug, VGCV, are the most commonly used antiviral drugs with 
activity against HCMV.  Plasma GCV levels have been used to estimate drug 
exposure and to develop suggested doses for treatment and prophylaxis in adults 
(Fishman et al. 2000).  As discussed in the Introduction, measurement of plasma 
GCV levels has also subsequently been used in small groups of children to derive 
equivalent paediatric dosing regimes. 
Therapeutic drug monitoring (TDM) for GCV is available.  The optimal GCV levels 
for ensuring treatment efficacy while avoiding toxicity are, however, largely 
unknown and lacking a firm evidence base. 
3.1.1. Optimal GCV levels and drug efficacy  
Values for MIC and IC50 are derived from CMV grown in vitro on human foreskin 
fibroblasts.  As described in the Introduction, CMV mutates rapidly during multiple 
passages and CMV cultured on fibroblast cell lines may lack large portions of the 
genome which are required for growth on epithelial cells (Wang and Shenk 2005); 
moreover human foreskin fibroblasts are not representative of the cells generally 
associated with CMV disease in vivo.  Caution is therefore needed when applying the 
results of such in vitro assays to the situation in vivo with wild-type CMV infection 
of different cell lines.   
In vivo data has been obtained from specific patient groups but data correlating these 
with clinical efficacy are lacking.  The therapeutic ranges often quoted originate from 
an early study in only 6 adults.  5 bone marrow transplant patients and 1 AIDS 
patient with CMV retinitis or pneumonitis were studied and peak and trough plasma 
concentrations of 4.75-6.2 ug/mL and 0.25-0.63 ug/mL, respectively, recorded.  Drug 
levels achieved have also been found to vary dependent on the patient group being 
studied (Scott, Partovi, & Ensom 2004).   
Lower trough levels (<0.6 mg/L) have been associated with a higher incidence of 
disease progression in a study of CMV retinitis in HIV patients (Piketty et al. 2000). 
Oral GCV prophylaxis is also hypothesised to select for GCV-resistant virus, and 
possible treatment failure, due to the low serum drug levels achieved, (Emery and 
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Griffiths 2000;Limaye et al. 2000).  Other authors have not been able to correlate 
drug levels with clinical or virological efficacy (Fishman et al. 2000;Kimberlin et al. 
2008).   
Despite the lack of data in adult populations, studies so far in children have largely 
strived to show equivalent drug exposure to previous adult studies.  Data correlating 
GCV levels and efficacy in neonates are lacking.  These babies have notable 
differences in PK to adults and may additionally have an impaired ability to 
recognise and control CMV due to a relatively immunological immaturity.    
The relevance of drug levels for clinical outcome, therefore, currently remains 
undefined in all age groups.  The use of TDM is correspondingly somewhat 
contentious and in the adult population generally reserved for those at particular risk 
of toxicity, such as those with renal impairment (Scott, Partovi, & Ensom 2004).   
3.1.2. GCV levels and toxicity  
Data are also lacking to identify a specific threshold at which GCV levels may be 
considered undesirable and toxicity tends to have a high degree of inter-patient 
susceptibility.  Despite toxicity being relatively common, previous reports have 
failed to establish a correlation between GCV levels and clinical toxicity in adults 
(Erice et al. 1987;Fishman et al. 2000). A recent study of VGCV in neonates did, 
however, correlate both Cmax and AUC12 with neutropenia (Kimberlin et al. 2008).   
Although AUC is the parameter reported in many PK studies its measurement is not 
always practical in the clinical setting, particularly in the paediatric age group.  AUC 
has been shown to correlate with both Cmax and trough levels in cystic fibrosis 
patients undergoing transplantation, due to the first-order kinetics exhibited by GCV 
(Snell et al. 2000).   
As GCV is only active once it has been tri-phosphorylated intracellularly whether 
measuring plasma GCV levels is a true reflection of levels of active drug is also 
uncertain and it is possible that phosphorylation varies between individuals and in 
different tissues; similarly clinical virus isolates have been shown to vary in their 
ability to phosphorylate GCV (Crumpacker 1996).   
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There are also possible differences between results reported from PK studies and 
those from samples acquired during routine clinical care.  A rapid decrease in the 
GCV concentration measured in plasma has been reported in blood samples stored at 
room temperature as opposed to on ice, at 0
o
C, prior to centrifugation.  This is 
proposed to be due to increased intracellular transport of drug into erythrocytes at 
room temperature.  If plasma is separated immediately after acquisition, however, 
GCV levels have been reported to remain stable for up to 2 hrs at room temperature 
(Figure 3-1)(Boulieu and Bleyzac 1994).  Other authors have demonstrated in 
experimental models that, after an initial period of equilibration, serum and 
intracellular GCV levels are comparable and stable for 4-6 hours at room 
temperature with diffusion across a concentration gradient hypothesised as being 
responsible for some of the shift in drug between the two compartments (Perrottet et 
al. 2008).  It is therefore conceivable that levels measured in clinical samples, where 
separation of plasma may be delayed, are not comparable with those reported in the 
tightly controlled PK studies from which therapeutic ranges are derived.     
3.1.3. Aims of this Chapter 
Clinical experience and the shortage of evidence for GCV TDM in infants using 
standard dosing regimens led me to hypothesise that drug levels achieved in infants 
may frequently be less than those quoted as optimal in adults.  I therefore reviewed 
the current UK evidence base available by analysing the concentrations of GCV 
found in samples received for TDM of GCV by the UK Antimicrobial Reference 
Laboratory. 
3.2. METHODS 
3.2.1. Study overview 
Serum GCV levels (reported in mg/L) received and analysed by the United Kingdom 
Antimicrobial Reference laboratory in Bristol from 01/11/1999 to 31/3/2007 were 
reviewed. 
The standard advice issued to clinicians for sampling around that time (Antimicrobial 
Reference Laboratory, Guidelines for Users, 10
th
 Edition 2004) recommended that 
separated serum samples (minimum volume 100uL) should be sent.  The
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Figure 3-1  Ganciclovir levels in plasma and blood over time 
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recommended timing of samples was one pre-dose and one post-dose with post-dose 
samples taken either 1 hour after the end of i.v. drug administration or 2 hours after 
oral administration.  This guidance also suggested that GCV assays might be of value 
in patients with renal failure and to monitor oral absorption, particularly in patients 
receiving VGCV.   
Data were anonymised and comprised of date of birth of subject, timing of sample 
acquisition (pre-, post- or random) and GCV level measured in the sample.  No 
clinical data or data relating to dose or formulation of medication were available 
despite laboratory guidance requesting that this information should accompany 
clinical samples. 
Results were analysed in different paediatric age groups and compared to those 
observed in samples from adults (those aged older than 18 years). 
3.2.2. Measurement of ganciclovir levels  
All samples were assayed as described in the Methods of this thesis. 
3.2.3. Data analysis 
In instances where there was no reported GCV detectable in the sample, a value of 
50% of the detection limit for the assay at that time was used for analysis.  Results 
were analyzed in different paediatric age groups and median values compared to 
those from adults using Mann Whitney U test.  
Given literature reporting resistance and decreased efficacy with trough levels below 
0.6mg/L, 2 x 2 contingency tables and Fisher’s exact test were used to compare the 
percentage of individuals in each age group with levels either <0.6 mg/L or ≥0.6 
mg/L.  Similarly the proportion of peak samples above and below 3.0 mg/L (the 
upper limit of the IC50 often quoted from in vitro studies) and those above and below 
7.0 mg/L (the lower reference value for i.v. GCV often quoted) was compared 
between age groups. 
 
 
 
- 80 - 
   
 
3.3. RESULTS 
Specimens were received from 129 patients at 339 time points over the 89 month 
time period.  Only 173 (51%) of samples received at each time point were paired pre- 
and post- levels. 
Specimens were received from 65 patients aged <18 years (50% of all patients), at 
192 different time points (57% of all specimens) 117 (61%) of which were paired 
pre- and post- levels.  Although specimens were received on 95 occasions from 
children aged <6 months, only 10 of these were from 4 neonates (aged <28 days).   
3.3.1. Trough levels 
A total of 199 trough levels were received with 130 (65%) of these being from 
subjects aged <18 years.  Table 3-1 and Figure 3-2 show the distribution of trough 
levels for each of the age categories.   
In those patients aged either <6 months or 6-12 months, there was a significantly 
higher percentage of levels <0.6 mg/L than seen in adults (64.8% and 53.9% 
respectively vs 15.9%; P<0.001).  There was also a trend towards more levels <0.6 
mg/L in those patients aged 1-5 years compared to adults but, possibly due to small 
numbers, this did not reach statistical significance (N=16; 37.5%  vs 15.9%; P = 
0.079).  Those aged 5-18 years had significantly more trough levels <0.6mg/L than 
adults although small numbers may again have influenced results (N=15; 80% vs 
15.9%; P<0.001).   
Correspondingly the younger age groups also had fewer samples with levels that 
might be associated with clinical toxicity with all paediatric age groups having ≤ 7% 
of trough measurements ≥ 6.0 mg/L compared to 19% in adults.   
3.3.2. Peak levels 
198 post-dose levels were received.  Median levels in all age groups were 3.7-5.7 
mg/L (Table 3-1).  Approximately one third of patients aged <18 years had peak 
levels <3.0 mg/L and in infants aged 6-12 months the modal peak level was 2.0-3.0 
mg/L, with nearly 35% of peak levels being <3.0 mg/L.  Although a trend towards 
lower peak levels can be seen in the younger age groups (Figure 3-3) a statistically 
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Table 3-1  Peak and trough ganciclovir levels (mg/L) in different age groups 
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Figure 3-2: Trough levels of ganciclovir in different age groups 
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Figure 3-3: Peak (post-dose) levels of ganciclovir in different age groups 
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significant difference was only found when comparing the median peak levels in 
those aged >18 years with those aged <6 months (5.7 mg/L vs 4.8 mg/L respectively 
P=0.047).  However, the lowest median peak levels were actually found in those 
aged 5-18 years (3.65 mg/L; IQR 2.35-5.63) with 35% of levels being <3.0mg/L.   
3.4. DISCUSSION 
In just over seven years, samples were received on 339 occasions from a total of 129 
patients throughout the UK and although the reasons for TDM were not available, 
this represents one of the largest cohorts reported to date for GCV TDM. In earlier 
studies patient numbers have generally been low (<20) and the patients have either 
had tightly defined disease states or the studies have been conducted under clinical 
trial conditions.  The data presented here may give a clearer picture of the 
concentrations found in samples taken from patients under more typical clinical 
conditions.   
Levels from children accounted for more than half of sampling events received by 
this national reference laboratory, despite the lack of any validated reference values 
for paediatric age groups.  There were significantly more trough levels <0.5 mg/L 
reported in young children compared to adults.  Low trough levels have previously 
been reported in a small study of paediatric transplant patients, with levels <0.5mg/L 
being significantly more common in younger patients (Vethamuthu et al. 2007).  My 
observation that fewer babies <28 days had trough levels <0.5 mg/L when compared 
to the <6 month age group as a whole would be in keeping with the almost exclusive 
renal excretion of GCV alongside known renal immaturity in newborns, leading to a 
corresponding decrease in GCV excretion when compared to older infants.    
Peak GCV levels of >7.0 mg/L (the reference value often quoted for TDM) were 
rarely achieved in any of the age groups studied.  Although a significant difference 
was only seen between median peak levels in those aged <6 months old compared to 
adults the lowest median levels were actually noted in the 5-18 year age group.   
Peak levels were also in keeping with those found in other clinical studies and were 
well above published in vitro values for MIC and IC50 (Fishman et al. 2000;Fletcher 
et al. 1986).  The relatively high frequency of peak levels <3.0mg/L in younger age 
groups would, however, give rise to concerns regarding treatment failure particularly 
if the disease-causing virus had an IC50 at the upper reported range of 3.48mg/L.  
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This may have additional relevance in the neonatal age group where immature host 
immunological responses may further favour viral persistence. 
I cannot offer a full explanation for the lower peak levels and higher proportion of 
trough levels <0.5mg/L seen in 5-18 year olds from these anonymised data which 
lack clinical and pharmacological information. Despite the small numbers included 
these data do suggest that under-dosing may also affect this older paediatric age 
group.   
Trough levels >0.6mg/L have been proposed by some authors as being optimal 
(Emery and Griffiths 2000;Limaye et al. 2000;Piketty et al. 2000).  The lower levels 
reported here and elsewhere raise concerns that paediatric age groups are receiving 
inadequate doses of GCV and/or VGCV and might likewise be susceptible to 
acquisition of resistant virus and treatment failure.   
Although the lower levels seen in the paediatric population may imply that toxicity is 
correspondingly less likely, toxicity tends to have a high degree of inter-patient 
variability and a specific threshold above which GCV levels may be considered 
undesirable has not been described.  Despite the low levels of drug observed here 
studies in neonates have found similar levels of severe neutropenia to those observed 
in adults (Kimberlin et al. 2003).  Interestingly Kimberlin’s study of targeted drug 
dosing to a proposed optimal AUC of 27 mg x h/L, has been one of the only 
published studies to correlate GCV exposure with neutropenia (Kimberlin et al. 
2008).     
The limitations of such retrospectively obtained data must, however, be taken into 
consideration.  These limitations include the possibility that these clinical samples 
may not have been taken within the timeframes required to make them true trough or 
peak values and may additionally have been left for some time prior to plasma 
separation with the potential for inaccurate readings as discussed above.   
A further weakness of this study is the lack of clinical information, making the 
underlying indication for TDM sampling a potential bias.  The relatively high 
proportion of paediatric samples may reflect the fact that almost without exception 
investigations of GCV levels in adult populations over the past two decades have 
failed to correlate levels with either measures of clinical and virological efficacy or 
with neutropenia (a measure of potential toxicity).  These findings have led other 
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authors to challenge the utility of TDM in adult patients, other than in specific sub-
groups (Scott, Partovi, & Ensom 2004).  A possible confounding factor may 
therefore be that levels were only sent from patients in whom there were concerns 
about treatment failure, toxicity or dosing of medication, particularly in adults.  
Interpretation is further limited by the absence of information on the drug 
administered (GCV or VGCV), dose given (including adjustment for renal failure), 
and route of administration.  Given that the oral solution of VGCV only became 
available for use as extemporaneously prepared solutions in the UK around 2006 and 
that oral GCV has also not been available for some time it can reasonably be 
assumed that the majority of younger children received i.v. GCV; this assumption 
cannot be applied to older age groups.   
Although the clinical relevance of the lower levels presented here is therefore 
uncertain the significantly decreased exposure to GCV during standard treatment 
courses when compared to adults is notable. Recent reports have suggested dosing 
algorithms for oral VGCV based on both weight and creatinine clearance (Vaudry et 
al. 2009).  Given that such algorithms do not currently exist for i.v. GCV and the 
wide inter- and intra-patient variability reported in younger children when weight 
alone is used for dosing, the development of such algorithms would seem beneficial.  
In the absence of such data TDM may offer some interim utility to guide GCV 
dosing, particularly in situations where renal function is uncertain or compromised, 
for example in prematurity (Vethamuthu et al. 2007). A role for TDM is therefore 
proposed in younger children particularly if longer treatment courses are being 
considered and during early infancy where rapid changes in renal function occur.  An 
additional role could be proposed for those infants where virological response seems 
inadequate.  Based on existing data and concerns regarding under-treatment a trough 
of 0.5-1.0 mg/L should be targeted.  Although not necessarily translatable to younger 
children the peak GCV reference level used for adults of 7-9mg/L following GCV 
administration (5-7mg/L when using VGCV) are also suggested as an initial goal.  In 
the presence of adequate trough levels and good virological response adjusting dose 
based purely on a mildly suboptimal peak GCV level would not, however, seem 
justifiable based on current evidence.       
The need for dosing algorithms for i.v. GCV, such as those derived for VGCV, seem 
apparent from these data.  Moreover detailed PK/PD studies in different paediatric 
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age groups (and at early gestations) would also be desirable.  In all age groups the 
use of surrogate markers for clinical efficacy (either virological or immunological) 
when designing such trials may help to define the optimal dose.  Until such studies 
are conducted the true utility of TDM with regard to clinical outcomes will remain 
somewhat uncertain.  My observation that the receipt of paired samples in children 
exceeded those received for adult patients shows that obtaining such samples is 
achievable. I would propose that paediatric PK/PD studies should therefore be 
considered a priority alongside those performed in adult patient populations.  
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CHAPTER 4. 
4. DATA FROM CASG #109 (PHASE I/II 
PHARMACOKINETIC TRIAL COMPARING ORAL 
VALGANCICLOVIR SYRUP WITH STANDARD 
INTRAVENOUS GANCICLOVIR)
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4.1. INTRODUCTION 
As described in the Introduction, work carried out in immunosuppressed adult 
patients led to the discovery that CMV had a more rapid half-life than previous 
dogma had dictated (Emery et al. 1999). There have been no previously published 
data relating to viral dynamics of CMV in the paediatric age group.   
Using pre-existing data of blood VL obtained during a PK study of oral VGCV 
treatment in neonates this chapter therefore aims to explore viral dynamics in this 
population.   
Some assumptions must be made in order to apply existing mathematical models to 
this age group.  The equation used for analysis of T1/2 of viral decline requires virus 
to be in steady state prior to treatment commencing.  There have been no studies of 
sequential VL in blood prior to treatment in the neonatal age group, however, older 
data show that the amount of virus in urine (measured using TCID50) is reasonably 
stable for the first 3 months of life in both symptomatic and asymptomatic babies 
(Figure 1-8)(Stagno et al. 1975).  Although it is likely that the majority of 
symptomatic infants will have acquired infection some weeks prior to delivery and 
will therefore have reached steady state some may not have acquired infection until 
later in pregnancy, however, meaning that they may still be undergoing changes in 
viral equilibrium during the course of their primary infection. 
The second assumption is that VGCV has the same efficacy with regards to treating 
CMV in neonates as it does in adults.  Given that the dose of medication actually 
ingested orally in neonates may be more erratic than in adults this needs to be taken 
into consideration.  
The aim was for the results of this analysis to inform the design of a protocol for a 
larger RCT assessing efficacy of longer treatment courses with VGCV.   
4.2. METHODS 
4.2.1. Study overview 
Through collaboration with the US-based CASG data for blood VL (measured by 
CMV DNA PCR) were obtained from a Phase I/II PK study evaluating VGCV in 
neonates (CASG #109).  The primary aim of this ethically approved study was to 
evaluate the dose of oral VGCV giving GCV exposure equivalent to the 6mg/kg bd 
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dose of i.v. GCV previously described for the treatment of cCMV (Trang et al. 
1993;Whitley et al. 1997).  Population PK were used to describe the PK of GCV, 
measured by serum GCV levels, following administration of IV GCV and oral 
VGCV to neonates.  Additional samples were obtained during the study for safety 
monitoring and VL (Acosta et al. 2007;Kimberlin et al. 2008). 
The first 5 subjects were recruited on a regime (Version 1.0) that involved i.v. GCV 
6mg/kg bd for Days 1-4 followed by oral VGCV at a dose of 14mg/kg bd on Days 5 
and 6 and a further five weeks of i.v. GCV 6mg/kg bd with an interruption on days 
35-36 for oral VGCV (Figure 4-1).  Due to recruitment difficulties the protocol was 
subsequently modified (Version 2.0) so that an initial oral dose of VGCV was 
followed by 14 days of i.v. GCV 6mg/kg bd and the treatment course completed with 
oral VGCV.  This enabled more rapid recruitment of the remaining 19 infants.   
Version 2.0 was carried out using a targeted AUC approach with the dose of oral 
VGCV being adjusted according to AUC12 measured following the initial VGCV 
dose to achieve a target AUC of 20-55 mg x h/L.  In this second version 9 babies 
therefore received 14mg/kg, 6 received 16mg/kg and 4 received 20mg/kg VGCV bd.  
It should be noted, therefore, that in Version 1.0 the majority of the treatment course 
was with i.v. GCV whereas in Version 2.0 4 weeks of the 6 week course was with a 
targeted dose of oral VGCV.     
Blood samples for VL were scheduled in both versions of the protocol at baseline 
(day 1) and days 7, 14, 28, 42, 56 and 180.  Samples taken on days 56 and 180 were 
therefore 14 days and 138 days (19.7 weeks) after treatment termination respectively. 
4.2.2. Subjects 
Subjects were all neonates who received antiviral treatment for symptomatic cCMV 
aged 8-34 days at the time of their first blood sample for PK analysis.  Further details 
of these patients are given by Acosta et al (2007) and Kimberlin et al (2008) in their 
publications of the full results of this study.     
In brief, the median age of participants at study enrolment was 27 days (range 9-31), 
46% were female.  All participants were culture positive for CMV from a urine or 
throat swab specimen taken within 30 days of birth but not all had a detectable 
viraemia.    
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Figure 4-1  Schematic representation of study design for CASG Study #109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment duration was 6 weeks in both protocol versions. 
In Version 1.0 6mg/kg of GCV was given i.v. on Days 1-4 with a dose of 14mg/kg oral 
VGCV on Days 5 and 6 followed by a further five weeks of i.v. GCV 6mg/kg bd with an 
interruption on Days 35-36 for oral VGCV.   
In Version 2.0 an initial oral dose of VGCV was followed by 14 days of i.v. GCV 6mg/kg bd 
and the treatment course completed with oral VGCV. 
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4.2.3. Data acquisition and Analysis 
Anonymised data were obtained for all 24 patients in the form of a list of subject 
numbers and dates of sample acquisition along with corresponding whole blood VL 
measurements (copies/ml).   
7/24 (29%) participants had no detectable viraemia at entry to the study.  The VL in 
the remaining 17 participants at each of the study visits is summarised in Table 4-1.  
One subject had undetectable VL at entry and throughout the study period excepting 
a measurement of 1486 copies/ml on day 28 (subject 68).  The remaining 6 subjects 
with no viraemia at study entry had no virus detectable throughout the study period.   
Where VL was expressed as <200 copies/ml the mid-point value of 100 copies/ml 
was taken for analysis to enable log transformation of data.  Log10 VL over time, at 
the actual time of sample acquisition, is shown graphically for each subject in Figure 
4-2.  Samples were not always obtained on the exact day intended according to 
protocol.  Except where specified, specimens were analysed according to the closest 
intended sampling time point.  A calculation of skew indicated that data were 
probably not normally distributed.  Analysis was therefore carried out using non-
parametric methods and using GraphPad prism 5 software. 
Comparison of medians in the same groups at different time points was conducted 
using Wilcoxon matched pairs.  Comparison of medians between different groups 
was performed using Mann-Whitney U test.   
For calculations of T1/2 of virus decline the slope of decline of loge (ln) VL was first 
estimated using segmental regression in GraphPad prism.  X0 constraint for decline 
was set at the point where the phase of most rapid viral decline appeared to end 
(Figure 4-3).  As described earlier (see 1.4.4), the slope derived was then used to 
determine T1/2 in blood by using the formula (-ln2)/slope.   
4.3. RESULTS 
17/24 babies (70.8%) were viraemic at baseline.  Median starting log10 VL in those 
with viraemia was 3.3 log10 (IQR 3.1-4.5).   
Examination of the baseline VL in these babies raised the possibility of 2 distinct 
groups defined by a baseline VL of greater than or less than 4.0 log10 (Figure 4-4).  
These groups were therefore considered separately in some analyses.
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Table 4-1  Viral load in 18 neonates receiving 42 days antiviral therapy. 
 
SUBJECT VIRAL LOAD (copies/ml) taken at specified study day 
 D1 D7 D14 D28 D42 D56 D180 
1 956 <200 <200 412 298 2418 644 
3 1296 756 <200 <200 <200 942 358 
5 530 414 NS <200 <200 724 <200 
53 64828 1414 28800 410 990 1478 12704 
54 651200 108666 527768 9706 3082 16258 974 
55 2264 2210 5888 308 614 692 <200 
56 54692 66414 756 664 448 6452 NS 
58 822 <200 <200 <200 <200 <200 <200 
59 35038 1602 572 <200 528 300 <200 
60 1844 576 430 8694 360 332 <200 
61 31514 3602 4146 2432 1966 31008 1512 
62 1384 647 <200 914 <200 1082 NS 
63 19400 4152 652 3620 4116 223922 796 
64 1772 1486 4682 NS 348 5950 640 
65 31072 3218 2094 3552 NS 3752 <200 
66 776 <200 528 <200 <200 464 492 
67 1584 <200 <200 902 <200 1904 <200 
68 <200 <200 <200 1486 <200 <200 <200 
 
NS                         = No Sample  
Pale shading          = those with undetectable viral load at end of treatment. 
Darker shading     = excluded from analysis. 
 
Viral load in 18 babies with viraemia detected at any time point during a study of treatment 
with 6 weeks antiviral therapy (Kimberlin et al, 2008).   
Viral load was measured using quantitative CMV PCR and reported in copies/ml.   
Treatment was with i.v. ganciclovir or p.o. valganciclovir according to two different 
protocols as summarised in Figure 4-1. 
- 94 - 
Figure 4-2  Log10 viral load over time in 17 viraemic babies treated for 
congenital CMV  
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Viral load, measured using quantitative CMV PCR, is shown plotted at the actual time of 
sample acquisition in 17/24 babies with congenital CMV that were enrolled in a study of 
antiviral treatment and that were viraemic at the onset of treatment.   
 
Two different treatment protocols were utilised as shown in Figure 4-1: subjects 1-5 received 
mainly i.v. GCV for 42 days with oral VGCV 14mg/kg on days 5 and 6, subjects 53-67 
received i.v. GCV days 0-14 followed by varying doses of oral VGCV to achieve a targeted 
AUC of 20-55 mg x h/L to complete 42 days treatment. 
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Figure 4-3  Examples of segmental regression plots of Ln viral load during 
treatment in 15 babies treated for congenital CMV 
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Loge (ln) viral load was plotted in GraphPad prism according to the intended day of 
sampling in the study protocol (Kimberlin 2008).  The slope of virus decline was then 
estimated using segmental regression.  X0 constraint for decline was set at the point where 
the phase of most rapid viral decine appeared to end.  Data is only shown for 15/17 viraemic 
babies included in subsequent analyses of viral half-life.   
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Figure 4-4: Median viral load at baseline, and after treatment in 17 viraemic 
babies treated for congenital CMV  
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Samples for CMV viral load were taken according to protocol (Kimberlin 2008) and are 
shown for baseline (pre-treatment), study day 42 (end of treatment), day 56 (D14 post-
treatment), and day 180 (D138 post-treatment). 
- 98 - 
4.3.1. Viral suppression with treatment 
Only 6/16 subjects (37.5%) who had a sample analysed around day 42 (D42) had 
undetectable viraemia.  However, when log10 VL was plotted at baseline and at the 
end of the treatment course all subjects were shown to have a reduction in VL (Table 
4-2; Figure 4-5).  Median VL at D42 was 2.5 log10 (IQR 2.0-2.8), significantly lower 
than median VL at baseline (p<0.01), with a median decrease in VL at D42 of 1.0 
log10 (IQR 0.7-1.4).   
In the group of babies with baseline VL >4.0 log10 copies/ml median reduction in VL 
was 1.8 log10 copies/ml (IQR 1.4-2.0) compared to only 0.8 log10 copies/ml (IQR 0.7-
1.1) in the 11 subjects with a lower starting VL, a statistically significant difference 
(p=0.02).  6/11 (54.5%) of subjects with a lower starting VL had no virus detectable 
by the end of the treatment course, meaning that they had reached maximal decline.  
Indeed, all babies with undetectable VL at the end of treatment were in the group 
with a starting VL <4.0 log10 and there was a significantly lower baseline log10 VL in 
those with undetectable compared to detectable VL at D42 (3.0 log10; IQR 2.8-3.2) 
vs 4.4 log10 (IQ 3.3-4.8; p<0.01).   
In all 6 subjects with no detectable viraemia at the end of treatment CMV DNA 
became undetectable within 2 weeks of commencing treatment (subject 5 was 
missing a D14 specimen but was undetectable at next sampling).  However, only 3 of 
these 6 subjects had a consistently undetectable VL following the first undetectable 
level; the other 3 subjects had intermittent low level virus detection.  2 further 
subjects had an undetectable VL at some time during treatment (one in the first 2 
weeks of treatment and one at D28). 
4.3.2. Viral load decline 
When considering change in VL during treatment in the group as a whole most of the 
change in VL was observed during the first two weeks treatment (Figure 4-6).  In 
those with a higher starting VL, however, decline continued up to D28 before 
reaching a nadir.   
The median slope of decline in all subjects over 42 days of treatment was calculated 
to be 0.02 log10 copies/day. Decline during the first 14 days was more rapid, 
however, with an observed decrease of 0.07 log10 copies/day. 
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Table 4-2  Change in viral load in 17 babies with congenital cytomegalovirus at 
various time points during and after antiviral treatment 
 
 
Subject Log10 VL 
D1 
Change in 
Log10 VL D1 
to D42 
Change in 
Log10 VL 
D42 to D56   
Change in 
Log10 VL  
D56 to D180 
Change in 
Log10 VL 
D42 to D180  
1 2.98 -0.51  0.91 -0.57  0.33 
3 3.11 -1.11  0.97 -0.42  0.55 
5 2.72 -0.72  0.86 -0.86  0.00 
53 4.81 -1.82  0.17  0.93  1.11 
54 5.81 -2.32  0.72 -1.22 -0.50 
55 3.35 -0.57  0.05 -0.84 -0.79 
56 4.74 -2.09  1.16 MD MD 
58 2.91 -0.91  0.00  0.00  0.00 
59 4.54 -1.82 -0.25 -0.48 -0.72 
60 3.27 -0.71 -0.04 -0.52 -0.56 
61 4.50 -1.20  1.20 -1.31 -0.11 
62 3.14 -1.14  1.03 MD MD 
63 4.29 -0.67  1.74 -2.45 -0.71 
64 3.25 -0.71  1.23 -0.97  0.26 
65 4.49 MD MD -1.57 MD 
66 2.89 -0.89  0.67  0.03  0.69 
67 3.20 -1.20  1.28 -1.28  0.00 
median 3.27 -1.01  0.88 -0.84  0.00 
IQR (3.11-4.50) (-1.36 - -0.71) (0.14 - 1.17) (-1.25 - -0.45) (-0.54 – 0.32) 
 
VL  = viral load 
D     = study day 
MD  = missing data 
IQR = Interquartile range 
 
Data shown is for baseline log10 viral load and change from this baseline value at the end of a 
42 day treatment course (D1 to D42).  Change in viral load between: end of treatment (D42) 
and day 56 (D56), D56 and day 180 (D180) and D42 and D180 are also shown. 
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Figure 4-5: Viral load in 17 babies treated for congenital CMV at baseline, end 
of treatment and 14 days post-treatment. 
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Decrease in viral load during treatment and subsequent rebound following treatment 
discontinuation is shown graphically for 17 babies treated for congenital CMV.  Viral load 
was measured using quantitative CMV PCR at baseline (pre-treatment), at the end of 42 days 
antiviral treatment (end treatment) and 14 days after treatment discontinuation (D14 post). 
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Figure 4-6  Median change in viral load from baseline in 17 viraemic infants 
during and after 42 days treatment for congenital CMV  
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VL = viral load 
High = babies with baseline VL >4.0 log10 copies/ml 
Low = babies with baseline VL <4.0 log10 copies/ml 
D = day of study 
 
D7, 14, 28, 42 = treatment 
D56 = 14 days post-treatment  
D180 = 138 days post-treatment  
 
Change in viral load (log10) from baseline was calculated for all viraemic babies with 
samples available at specified time points.  Median change for all study participants was then 
plotted (all).  Babies with a baseline VL >4.0 log10 copies/ml (high) were then analysed 
separately to those with baseline VL <4.0 log10 copies/ml (low).   
- 102 - 
In order to more accurately estimate viral T1/2, Ln2 of the VL at the exact time point 
of sampling during treatment were used to plot graphs for each subject (Figure 4-3) 
and the phase of most rapid decline used for further calculations of T1/2 as already 
described.  T1/2 during the phase of most rapid decline was thus calculated to be 2.4 
days (IQR 1.9-4.5) (Table 4-3).  
Taking into consideration the more rapid initial decline observed in those with a 
higher starting VL (and shown graphically in Figure 4-6) data from subjects with 
high and low starting VL were also analysed separately.  There was no significant 
difference, however, between the median T1/2 of decline in those with a high baseline 
VL compared to those with VL <4.0 log10 (median 3.86 vs 2.23 p=0.36) (Table 4-3).  
T1/2 during the phase of maximal decline was plotted against baseline log10VL for 
each subject.  There was no obvious correlation between baseline VL and T1/2 using 
standard regression models (Figure 4-7).  
4.3.3. Viral rebound after treatment discontinuation 
After treatment was discontinued an initial rebound in VL was seen in all but 3 
participants who had data available at Day 56 (D56) (Table 4-2).  In the group as a 
whole rebound was to a level similar to baseline (median at baseline 3.27 vs 3.17 
log10 D56 (p=0.06)).  Those with a high starting VL, however, had a VL at D56 that 
was a median of 0.9 log10 lower than at baseline, compared to a median of only 0.1 
log10 decline in those with a low baseline VL (Figure 4-6).  The difference between 
VL at baseline and D56 in those with starting VL >4.0 log10 was still, however, 
statistically non-significant (p=0.1)  
4.3.4. Long-term control of virus 
9/15 (60%) of the subjects with data available still had viraemia detectable at D180.  
All subjects had lower median VL at D180 compared to baseline, with a median 
decrease of 1.2 log10 (IQR 0.7-1.4); at D180 VL was lower than at D56 in all but 3 
subjects (Table 4-2).   
4.3.5. Clinical outcome and association with viral dynamics 
Data for these analyses were limited.  There did not appear to be a relationship, 
however, between starting VL, rate of viral decline or rate of virus rebound between 
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Table 4-3  Viral half life of decline and baseline viral load 
 
  
Subject Baseline 
Log10 VL 
Slope T1/2 
BASELINE VL <4.0 1 2.98 -0.45 1.55 
  3 3.11 -0.19 3.67 
  5 2.72 -0.08 8.50 
 55 3.35 0.02 -39.05 
  58 2.91 -0.32 2.15 
  60 3.27 -0.10 6.75 
  62 3.14 -0.15 4.49 
 64 3.25 -0.06 12.45 
  66 2.89 -0.17 4.04 
  67 3.20 -0.36 1.91 
  MEDIAN 3.13 -0.16 3.86 
  IQR (2.93 - 3.24) (-0.29 - -0.09) (1.97 - 6.18) 
BASELINE VL >4.0 53 4.81 -0.33 2.08 
  54 5.81 -0.15 4.55 
  56 4.74 -0.31 2.23 
  59 4.54 -0.51 1.35 
  61 4.50 -0.29 2.39 
  63 4.29 -0.26 2.69 
  65 4.49 -0.41 1.68 
  MEDIAN 4.54 -0.31 2.23 
  IQR (2.91 - 4.77) (-0.37 - -0.27) (1.88 - 2.54) 
ALL SUBJECTS MEDIAN 3.27 -0.29 2.39 
  IQR (3.11 - 4.52) (-0.35 - -0.16) (1.99 - 4.49) 
 
VL   = Viral load 
IQR  = interquartile range 
T1/2 = half-life of virus decline 
 
The slope of virus decline was calculcated using segmental regression in GraphPad prism as 
described in the methods to this chapter and shown graphically in Figure 4-3.  This slope was 
then used to calculcate virus half-life using the formula (-ln2)/slope. 
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Figure 4-7 Relationship betweten starting viral load and half-lilfe of virus 
decline using standard regression models 
 
A. Linear regression fitted
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B. Exponential growth curve fitted
2 3 4 5 6
0
2
4
6
8
10
R
2
=0.14
Baseline VL (Log10)
T
1
/2
 o
f 
v
ir
a
l 
d
e
c
li
n
e
 (
d
a
y
s
)
 
VL = viral load 
T1/2 = half-life of virus decline 
 
The relationship between starting viral load and virus half-life was scrutinised using 
common methods of regression and using GraphPad prism software.  Two such analyses are 
shown above. 
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days 42 and 56 and either overall mental score or motor developmental score.  When 
the IQ and motor score of those babies who had no virus detectable at D180 was 
compared to those with continued viraemia there was also no appreciable difference 
between the two groups.  There was no apparent association between higher starting 
VL and more severe hearing loss nor did there appear to be an association between 
hearing deterioration and viral decline or rebound.    
4.4. DISCUSSION 
Consistent with other studies only 71% of infants were viraemic at birth, (Bradford et 
al. 2005); others have reported that viraemia is detectable in all babies albeit with 
10% having only low levels of detection (<100 copies CMV DNA per 10
5
 
polymorphonuclear leucocytes) (Lanari et al. 2006). 
63% of babies still had virus detectable in the blood at the end of a 6 week treatment 
course.  This differs from unpublished data from our laboratory which found 66% of 
infants treated with a dose of 5mg/kg GCV bd had no CMV detectable in the urine at 
the end of a course of similar duration and with published data in which undetectable 
levels of virus were reported at the end of treatment in all subjects receiving higher 
GCV dosing regimes (Nigro, Scholz, & Bartmann 1994;Whitley et al. 1997).  Given 
that blood VL is usually found to be a number of logs lower than that found in urine 
one might anticipate that it would be easier to suppress virus to undetectable levels in 
this body fluid after 6 weeks treatment.  Indeed Whitley et al found that of 7 babies 
treated with i.v. GCV all 3 that were positive for CMV in leucocyte culture at 
enrolment were negative after two weeks treatment (Whitley et al. 1997).  It is 
possible that the above discrepancy with previous literature reflects both differences 
in viral dynamics between these two body fluids and a higher sensitivity for detection 
using CMV PCR compared to older culture-based methodology.       
A significant difference was observed in VL at start and end of treatment. The 
median decrease in VL from baseline observed in the group as a whole was 1.0 log10 
(IQR 0.7-1.4) with maximum decrease in VL occurring during the first 2 weeks of 
treatment.  This was the period where GCV was predominantly used for treatment.  
In those with a starting VL >4.0 log10 a greater decrease of 1.8 log10 (IQR 1.4-2.0) 
during 6 weeks treatment was observed and these babies additionally had a more 
rapid and more sustained initial decline in VL over the first 28 days of treatment.  
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Although some of this more prolonged decline may purely be a function of the 
higher starting point this does not fully explain the flattening of viral decline after the 
first 14 days of treatment in other subjects given that 6/11 of those with lower 
starting VL continued to have virus detectable at the end of treatment. 
Starting VL and log10 decrease over the first 14 days of treatment in this group of 
infants are similar to data reported in an adult study of VGCV treatment in transplant 
patients (Table 4-4)(Mattes et al. 2005).  However, in this study all patients receiving 
i.v. GCV had 2 negative CMV PCR results by day 33 of treatment and those 
receiving VGCV had a median time for 2 negative results of 20 days (Table 4-4).   
From the data presented here T1/2 of viral decline in neonates treated for congenital 
CMV is around 2.39 days (1.99-4.49).  This value is comparable to that found in 
groups of GCV-treated adult patients with HIV (2.56 +/-0.36 days); following bone 
marrow transplantation (1.52 +/-0.67 days) and liver transplantation (2.36 +/-1.2 
days) (Emery et al. 1999).  It is also similar to the T1/2 of 2.16 days (range 0.75 to 
6.93) reported in adult solid organ transplant patients given pre-emptive VGCV 
treatment (Mattes et al. 2005). 
Older studies have reported a rapid decline of approximately 2 log10 in viruria 
between the ages of 3 and 9 months in untreated babies after an initial period of 
stability (Stagno et al. 1975).  There are no comparable studies of natural history of 
viraemia in untreated babies with cCMV.  In the absence of a control group of 
untreated participants in this study it is therefore possible that the decrease in blood 
VL over time observed here is not significantly different to that in untreated babies 
and is purely reflecting the natural history of cCMV infection.     
In support of a PD effect of treatment on VL is the subsequent rebound in VL 
observed in this study, as with others, following discontinuation of treatment (Nigro, 
Scholz, & Bartmann 1994;Tanaka-Kitajima et al. 2005;Whitley et al. 1997).  
Rebound in VL in the subjects presented here was not, however, to a level 
statistically different to baseline.  The lower VL at D180 compared to D56 along 
with the continued low level viraemia detectable towards the end of treatment may 
be explained by natural oscillations in VL once steady state has been reached, as 
observed in other viral infections and in CMV-infected adults.  To confirm this 
hypothesis further blood sampling would be needed in the period after treatment in 
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Table 4-4  Comparison of viral load decrease during antiviral treatment for 
CMV in babies and adults 
 
Data are expressed as median (range) 
1 Treatment was continued until 2 consecutive negative CMV PCR results were obtained 
2 These data are expressed as median (interquartile range) due to outliers. 
 
Babies received treatment for congenital CMV disease with a combination of i.v. GCV and 
p.o. VGCV according to two separate protocols (Figure 4-1).  Adult patients were enrolled in 
a study of pre-emptive treatment for CMV infection following solid organ transplantation 
(Mattes 2005).   
 Characteristic Treatment 
iv GCV
1
 VGCV
1
 VGCV - neonate 
Treatment length (days) 16 (1-33) 20 (6-49) 42 
Baseline viral load (log10) 3.55 3.81 3.27 
Half-life, median days  
 
1.73  
(0.87-11.55) 
2.16  
(0.75-6.93) 
2.34  
(2.14-2.71)
2
 
Log10 decrease, genomes/ml     
  Day 7 
 
-0.64  
(-1.79 to 0.57) 
-1.07  
(-1.96 to -0.07) 
-0.78  
(-0.98 to -0.23) 
  Day 14 
 
-1.17  
(-3.07 to 1.07) 
-0.98 
(-2.12 to 0.29) 
-0.95  
(-1.18 to -0.31) 
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order to define VL fluctuations over time.  This persistent low level viraemia may 
also be reflecting immature neonatal immune responses and/or continued virus 
production from sanctuary sites as discussed further in the final chapter of this thesis.       
The results presented here raise a number of areas warranting further investigation. 
1) More information is needed relating to the natural history of blood VL in babies 
with cCMV infection.  This includes data confirming steady state of viraemia at birth 
and trends in blood VL over time in babies not receiving treatment.  Without a good 
knowledge of the natural history of VL it is difficult to evaluate the contribution of 
treatment in suppressing VL and to define target outcome measures. 
2) Taking into consideration the more rapid viral decline noted during the first 7-14 
days in these subjects and that observed during a more intensive sampling study of 
viral dynamics in HIV co-infected patients, more frequent sampling during the first 
1-2 weeks of treatment may allow for more accurate measures of viral half-life. 
3) Further investigation into the different patterns of viral decline is needed.  This 
includes further consideration as to why 5/11 subjects with a low (<4.0 log10) 
baseline VL continued to have virus detectable at the end of a 42 day treatment 
course.  In light of the data relating to potentially subtherapeutic GCV levels 
presented earlier in this thesis whether drug exposure is sufficient to suppress virus in 
this age group should be a primary concern.  The first two weeks of treatment in this 
study was with i.v. GCV and the fact that viral decline in blood during the first two 
weeks of treatment was comparable between this group of neonates and adult data 
would suggest that treatment in the first few weeks of life was adequate (Mattes et al. 
2005).  PK and PD analysis of this study, however, also did not find an overall 
association between any PK parameters and viral suppression (Kimberlin et al. 
2008).  Notably the dose of oral VGCV used later in the study was individually 
targeted and oral bioavailability of drug was shown to increase with postnatal age; 
drug exposure during the latter stages of treatment should therefore have been 
optimal.   There are little data, however, to confirm that the target AUC defined is 
optimal for targeting treatment in neonates.  Moreover factors affecting drug 
availability to CNS compartments in this age group are unknown for both GCV and 
VGCV.  It is therefore possible that differences in PK of VGCV led to the initial 
viral decline observed not being sustained.   
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Less likely is that lower levels of drug exposure during early weeks of treatment at 
the standard GCV dose might encourage the emergence of virus mutations conveying 
drug resistance.  Current data do not support this theory, as discussed in the 
introduction to this thesis.   
These persistent, low levels, of viraemia may alternatively represent low levels of 
continued viral replication in a subset of cells in these infants that are either exposed 
to lower drug levels or possibly with decreased levels of the cellular enzymes needed 
to complete phosphorylation of GCV/VGCV.  This will be explored in more detail in 
the final chapter of this thesis.      
4) The rapid viral rebound after treatment termination observed in neonates is also 
unique to this age group.  If the ‘threshold’ concept described in adult transplant 
recipients applies to these neonates then the rebound back up to baseline noted here 
may have implications for disease progression.  Clinical improvement has, however, 
been documented in previous studies after only 6 weeks i.v. GCV treatment despite 
these observations (Kimberlin et al. 2003).  Maturing neonatal immune responses are 
also likely to be of relevance in ensuring prolonged viral control.  Further studies of 
the immunological response to CMV in neonates may therefore enable identification 
of the key components determining immunological control in this age group.     
5) Key to future therapeutic studies in this age group are data correlating clinical 
outcome with virological response in accessible body fluids.  Whether the inability to 
fully control virus in blood during 6 weeks of treatment has any clinical implications 
or reflects viral replication in relevant cells in the CNS and auditory apparatus 
remains unknown.    
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CHAPTER 5. 
5. THE EUROPEAN CONGENITAL 
CYTOMEGALOVIRUS INITIATIVE AND THE UK 
CMV TREATMENT REGISTRY
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5.1. INTRODUCTION 
5.1.1. The European Congenital CMV Initiative 
It is widely recognised that for uncommon conditions, such as symptomatic cCMV, 
the small number of cases identified by any one centre limits good quality research.  
A group of professionals within Europe with an interest in cCMV was therefore 
established in 2005.  The group included clinicians from the fields of virology, 
obstetrics, neonatology, paediatrics, immunology and epidemiology who had made 
significant contributions to cCMV research over the preceding decades.  It was 
anticipated that the establishment of a collaborative network of interested parties 
within Europe would help address some of the barriers to research by facilitating 
studies involving larger cohorts of affected babies in multicentre studies conducted 
throughout the European Union. 
5.1.2. Rationale for the establishment of a treatment registry for 
congenital CMV 
Our group had experience of working within other successful neonatal infection 
networks, most notably the Paediatric European Network for Treatment of AIDS 
(PENTA, http://www.pentatrials.org/).  This collaboration, established in 1991, 
between paediatric HIV centres in Europe is co-ordinated by the HIV Division of the 
Medical Research Council (MRC) Clinical Trials Unit (CTU) in London along with 
other international organisations.  The large studies made possible through this 
network have led to many notable improvements in the treatment of paediatric HIV 
and significant findings with regards to paediatric dosing of anti-retrovirals 
(Bergshoeff et al. 2005;Burger et al. 2004).   
Within the UK, and also co-ordinated by the MRC CTU, the CHIPS dataset, has 
successfully maintained treatment records that, at the end of March 2009, covered 
93% of the 1560 children identified as HIV infected.  This cohort study has provided 
valuable observational data regarding treatment commencement, drug resistance and 
other follow-up data for HIV-infected children treated in the UK (CHIPS 2013).  
Data originating from this dataset have previously raised important concerns 
regarding underdosing of anti-retroviral medication during childhood which has 
relevance for other paediatric medications (Menson et al. 2006).  Based on the 
- 112 - 
paediatric GCV levels presented earlier in this thesis we had reason for similar 
concerns in relation to the treatment of babies for cCMV.  The use of treatment 
registries, particularly where small numbers of patients are treated with a drug, has 
become increasingly recognised as a valuable pharmacovigilance tool (EMEA 2007).   
In April 2006 the members of ECCI met in Veyrier-du-Lac, France, and agreed 
broad recommendations for clinical management of cCMV.  Given the limited 
evidence-base on which to guide treatment of these babies and the availability of new 
antiviral treatments, such as oral VGCV, it was agreed that a European Registry of 
babies treated for cCMV should be established, in order to monitor treatment of these 
infants while the results of future RCTs were awaited.   
At the time this need was identified oral VGCV solution was not licensed anywhere 
within the European Union (EU), and no published dosing recommendations existed 
for the paediatric age group. Despite this, given the challenges of administering i.v. 
GCV for 6 weeks, case reports of the use of VGCV in neonates using 
extemporaneously prepared solutions were emerging with varying doses and duration 
of treatment reported (Anaizi, Dentinger, & Swenson 2002;Burri et al. 2004;Clark et 
al. 2004;Henkin, Griener, & Ten Eick 2003;Meine Jansen et al. 2005).  The 
publication of such case studies suggesting clinical benefit raised concerns regarding 
emergent publication bias.  Oral VGCV was already known to have been used in 
some neonatal units within the UK and interest in its use was anecdotally increasing, 
particularly in cases where i.v. access was difficult, and in less severely ill babies to 
enable earlier discharge home.  There were therefore concerns that the availability of 
VGCV might lead to the treatment of babies outside the current evidence base for 
benefit, either in older age groups than previously studied, with only mildly 
symptomatic cCMV or for longer durations of treatment (Meine Jansen et al. 
2005;Muller et al. 2008;Schulzke and Buhrer 2006).  Furthermore, although of 
potential benefit through cost savings to healthcare systems, there were also concerns 
that earlier discharge may lead to less frequent review of treated babies, less rigorous 
monitoring of side effects and failure to adjust drug doses for weight-gain during 
treatment.   
I carried out a survey evaluating the views and perception of treatment and its 
success amongst members of the UK CMV parent support group.  Contrary to 
published literature many members of this group felt that, in their experience, 
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medication had not been particularly beneficial and was associated with worrying 
side effects (personal correspondence). Finally, although we were aware of one long-
term follow-up study of outcomes up to puberty in the small cohort of neonates 
studied by Kimberlin et al in their RCT of GCV treatment these data have not been 
published to date and there was no ongoing surveillance in place to follow the large 
numbers of children that would be necessary to identify small increases in outcomes 
such as carcinogenicity.   
The need for larger surveillance data relating to babies treated for cCMV, in addition 
to formal RCTs, was therefore evident.        
5.1.3. Aims of the CMV Registry 
Given that data on symptomatic cCMV had previously been obtained on a large scale 
in both the UK and the US (Demmler 1991;Lynn et al. 2004), the limited resources at 
our disposal and our primary concerns regarding antiviral treatment it was agreed 
that the focus of this registry would be on the short and long term toxicity of 
treatment along with some markers of clinical and virological efficacy.   
The CMV Registry was therefore set up with the primary aims of: 
1) Holding a central register of any babies treated for cCMV in the UK, and 
ultimately Europe, both within and outside of any formal treatment studies. 
2) Developing a national knowledge base of patterns of antiviral usage in cCMV 
and changes over time. 
3) Recording short-term side effects of antiviral usage in cCMV. 
4) Recording possible markers of treatment efficacy, including virological and 
audiological data.   
5) Providing the possibility for longer term surveillance of any potential 
toxicities associated with antiviral usage in this age group both within the 
database itself and by linkage to national cancer registries. 
To pilot the concept and facilitate a more rapid instigation it was agreed that the 
Registry would initially be set-up to recruit babies from within the UK and 
subsequently extended to include other European partners dependent on subsequent 
funding and interest within these countries. 
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5.1.4. Anticipated numbers within the UK 
In the U.K. epidemiological studies estimate around 350 cases of symptomatic 
cCMV per year (Peckham et al. 1983).  A two year British Paediatric Surveillance 
Unit (BPSU) study carried out from February 2001 to February 2003 identified 93 
confirmed cases and a further 69 suspected cases of cCMV.  Of the confirmed cases 
40% had neurological symptoms and 33% of those received treatment, translating to 
approximately 6 cases of treated cCMV per year in the UK (Lynn et al. 2004).   
We anticipated that more babies than this previous estimate would be treated 
annually and eligible for enrolment based on a number of observations.  Firstly the 
publication by Kimberlin et al (2003) gave the first evidence that GCV treatment 
might improve outcome in the most severely affected babies meaning that clinicians 
might now be more likely to treat babies with CNS involvement.  Newer diagnostic 
methods, including rapid CMV PCR and retrospective diagnosis using DBS, were 
emerging and likely to aid confirmation of a diagnosis of cCMV.  A multicentre, 
multinational study of treatment with VGCV of babies with any symptoms of cCMV 
(not just those with CNS involvement) was in the final stages of protocol 
development (NCT00466817).  Selected UK centres were proposed as likely study 
centres and widespread publicity had already commenced, including educational 
talks to clinical groups throughout the UK, to increase the profile of cCMV.  
Anecdotally there was already an increased awareness amongst clinicians of the 
problems associated with cCMV, both antenatally and postnatally, enabling more 
prompt identification of symptomatic babies and initiation of treatment where 
indicated.  We were aware of 4 babies receiving treatment for cCMV in South 
London alone in the year preceding the implementation of the Registry (January-
December 2006).   
UK annual births were around 700,000 in 2007 and using estimates of cCMV 
prevalence at birth of 3-7 per 1,000 live births, 12.7% symptomatic, around 80-350 
babies would be anticipated to be born annually in the UK with symptomatic cCMV 
(Dollard, Grosse, & Ross 2007).  If ~40% of these neonates had CNS signs or 
symptoms, around 32-140 babies per year would be potentially eligible for treatment 
in the UK.  We would anticipate that maybe only 50% of these would be identified 
and treated and a further 50% brought to our attention meaning that the Registry 
would aim to capture 8-35 treated babies annually.   
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We had already established through the CMV Parent Support Group that parents 
were receptive to any research proposals that might inform treatment of cCMV 
(personal correspondence).  Maximal recruitment was proposed by publicising the 
study within neonatology, paediatric infectious diseases, audiology and virology 
networks throughout the U.K.  It was intended that the linked website would 
additionally provide an educational resource for both health professionals and the 
public.     
5.2. METHODS 
The Registry was set up as a web-based database, enabling access from any internet 
connection using a unique username and password.  The use of individual login 
codes enabled audit of the data trail if required.    Local investigators had access to 
data generated from their own institution; only the central study team were able to 
access the complete dataset.   
Our group had experience of successfully using similar databases for other national 
cohort studies and similar collation of data from babies treated for cCMV in many 
centres throughout the UK was therefore felt feasible.  It was anticipated that most 
babies would be treated in tertiary neonatal units with input from paediatric 
infectious diseases specialists, as with the treatment of paediatric HIV and other 
uncommon neonatal conditions.  Capturing the majority of treated babies was 
therefore proposed by the involvement of around 18 key centres throughout the UK.   
Inclusion criteria were defined as:-. 
1) Any baby with confirmed cCMV (diagnostic sample obtained within 21 days 
of life) born between 1/1/2002 and 1/1/2017 AND 
2) Receipt of any treatment for cCMV within the first 5 years of life. 
Treatment and duration were not specified since the Registry aimed to reflect current 
practice and changes over time.  Data were stored in a pseudo-anonymised form 
using a unique study reference number but with inclusion of date of birth and 
hospital number to prevent double entries of the same case from different sites, 
prevent confusion in the case of twins and to facilitate follow-up reminders.  The 
local study team stored more detailed enrolment information enabling retrospective 
identification of each baby registered if required. 
The initial proposal involved clinicians entering baseline data on treated babies as 
soon as they were identified, with reminders automatically generated from the 
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database at one and two years to capture defined follow-up datasets relating 
particularly to neurological and audiological outcomes. 
A set-up grant was successfully obtained through the European Society for Pediatric 
Infectious Diseases (ESPID) which provided funds for development of the database 
through an independent database developer (Dataphiles Ltd).  Hardwear was 
purchased using internal funds made available from St George’s University London 
and the Royal Free Charity.  
5.2.1. Database development and piloting 
A website was initially set-up, as proposed by the ECCI group (www.ecci.ac.uk), to 
act as a platform for the CMV Registry, with a link to the password-protected login 
page.   
An SQL server with 128 bit SSL encryption of the data between the user’s computer 
and the database, giving a level of data protection equivalent to that used by internet 
banking at the time, was subsequently set up.   
A questionnaire containing key demographic data and data relating to disease 
manifestations to be collected was devised.  The focus was to obtain information 
relevant to antiviral drug treatment, including medication formulation and dose, 
reasons for commencing treatment, side effects experienced and any associated 
alterations to treatment along with drug levels and any viral load results.  Proposed 
data collection sheets were sent to a number of neonatologists and general 
paediatricians for comments on acceptability of length and detail of proposed 
questions and any additional/unnecessary data fields.  The data collected are now 
available in the form of an ethically approved ‘Letter requesting information from 
clinicians’ which enables data collection from other units in the case of neonates 
transferred to or from a study site during treatment (Appendix A).  
A separate dataset relating to hearing outcomes was developed in collaboration with 
a trainee in audiological medicine with an interest in cCMV to provide a semi-
quantifiable measure of long-term outcome.  This information is also available in an 
ethically approved ‘Letter requesting information from audiologists’ that can be sent 
to audiological departments to obtain detailed audiolgical data (Appendix B).  This 
form is particularly important as audiology services are often under the auspices of 
different NHS Trusts than acute neonatal and paediatric care. 
- 117 - 
The datasets discussed above were translated into specific questions along with drop-
down menus to closely define data entry options and decrease variability in entries.   
Several rounds of database testing were subsequently performed to identify errors in 
translation of data fields and programming and to refine drop-down menus and data 
entry values permitted (for example format of numbers generated and length of 
additional text allowed).    
During the lengthy period of set-up it was evident that for any data collection to 
commence the proposed follow-up fields would have to be sacrificed in order for the 
project to start recruitment.  It was decided at that point that exporting data from the 
database at regular time intervals (e.g. 6 monthly) would allow clinicians to update 
the database at the time of annual reviews while still enabling the central study team 
to capture changes in outcome over time.  Manual notifications to clinicians would 
therefore be necessary in order to remind them that follow-up data input was due.   
5.2.2. Ethics 
Ethics approval was obtained in February 2007.  With a recent increase in focus 
towards ensuring children are also informed of research that involves them, the ethics 
committee made a requirement that there was some mechanism in place to notify 
children that their data were being held.  This proved challenging in that the central 
research team, to comply with data protection requirements, were unaware of contact 
details of families.  In addition, children with cCMV would be anticipated to have 
varying degrees of disability with many potentially never having sufficient cognitive 
function for this to be relevant.  Ethics approval was therefore granted on the basis 
that parents would be provided with a letter at enrolment to give to their child at an  
undefined time in the future when their child was felt to be able to understand the 
implications of their data being held in the database.      
Due to a change in the regulations since the inception of the idea for such a Registry 
it became necessary for individual parental consent to be obtained for data entry 
meaning that local site research and development (R&D) approval had to be gained.  
As the process of site specific approval and informed consent was necessary even for 
basic data collection it was decided that consent would additionally be obtained for 
surplus clinical samples to be retrieved and stored along with testing of DBS to 
compliment other work in progress in our group.    
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Enquiries were made with both ethics committees and the UK Central Cancer 
Registry (UKACR) regarding processes to facilitate future linkage with cancer 
registries.  As advice was limited and application through the UKACR involved 
securing additional funds it was decided to obtain consent from parents for possible 
future data linkage while not formalising this plan until the Registry was more 
established.   
It was evident early on in study set-up that changes in the ethics requirements for 
such data collection might prove challenging for case ascertainment. 
5.2.3. Approach of sites, local approvals and consent 
An ethically approved advertisement letter was sent out to members of the British 
Paediatric Allergy, Infection and Immunology Group (BPAIIG) encouraging them to 
notify the study team of any treated babies, and asking for expressions of interest 
from those who had already seen cases.  Further eligible babies were identified 
through clinical enquiries to members of the study team.    
I undertook to complete all paperwork required for local site approvals, asking the 
local investigator only to approve drafted documents and provide signatures.  Once 
local site approval had been obtained study files containing all relevant documents 
were sent out along with login details for the Registry.   
Consent could either be obtained from parents at the next out-patient visit or via 
telephone and postal consent (as approved in a later ethics amendment). The postal 
consent option was particularly aimed at increasing recruitment of previously treated 
children that were no longer under regular follow-up with the local study team to 
decrease unnecessary hospital visits for parents and associated out-patient workload 
for local clinicians.       
5.2.4. Ongoing data management 
The Registry was backed up daily and data also manually exported into Excel on a 
regular basis.   
Small amendments and updates were made following set-up, mainly to update the 
website but also to address further technical issues identified during database usage.  
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5.2.5.  Data analysis 
In general median values with IQR were used for summarising linear data as it was 
uncertain in most cases whether a normal distribution was being followed.  
As with my previous analysis of GCV levels, for levels stated as being undetectable 
below a certain level, 50% of this value was entered for analysis.  In addition, for the 
reasons specified in Chapter 3, pre-dose levels above and below 0.6mg/L were 
specifically scrutinised, with >0.6mg/L being the proposed optimal trough value; 
similarly post-dose GCV levels above 7.0mg/L and 5.0mg/L for GCV and VGCV 
treatment respectively were examined. 
5.3. RESULTS 
5.3.1. Site Accrual and numbers recruited 
From February 2007 to May 2010 17 UK sites received R&D approval (14 in 
England; 1 in Scotland and 2 in Wales).   
The median time between application for site approval and approval being obtained 
was 78 days (range 23-169) (measured from date of first submission of documents to 
the local R& D department to date of letter of site approval).   
A further 10 sites were in various stages of approval at the time of writing with 
documentation required for R&D and ethics submission drafted for all of these sites.   
Up to May 2010 27 babies had been enrolled from 10 centres (Figure 5-1; Figure 
5-2).  Although 7 sites had not yet entered data on a baby despite having relevant 
approvals, most of the 10 sites that had entered cases had entered data for more than 
one baby (Figure 5-2).  I was aware of 8 babies treated in approved study sites where 
parental consent was not possible (1 declined due to concerns regarding access to 
data by regulatory agencies; 2 had difficult relationships with clinicians during 
treatment and were not pursued for consent; 1 mother did not formally decline but 
consent was not gained despite several approaches; 3 were contacted by letter and 
declined to get in touch with the study team and in 1 family language constraints 
prevented informed consent).     
During the same time period (February 2007 – May 2010) I had information on a 
further 16 treated babies who would have been eligible for inclusion in the Registry 
(as summarised in Table 5-1 and considered further in the discussion of this chapter). 
- 120 - 
Figure 5-1: Recruitment over time into the UK congenital CMV Treatment Registry 
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Figure 5-2: Number of babies enrolled at each site 
 
 
 
0
1
2
3
4
5
6
7
8
SG CV NE NS AA BS OX RF HE SM
Centre
C
o
u
n
t
 
 
 
 
 
 
 
 
 
 
 
- 122 - 
Table 5-1  Reasons for failed recruitment of babies managed by research team 
but not currently enrolled into Registry 
No. 
 
DoB Centre Symptoms Treatment Reason for failed recruitment 
1 08/02/06 SG CNS + multiple 
systemic 
including PPHN  
GCV, 
Foscarnet 
Retrospective – baby died, parents 
did not respond to invitation letter 
2 01/06/06 SG CNS GCV Retrospective – parents moved; 
no response to invitation letter 
3 14/09/08 SG CNS only GCV, 
VGCV 
Consent not obtained.  
4 21/05/08 SM CNS only GCV Parents declined – (agreed to 
associated study) 
5 Aug 09 SM Subtle CNS GCV Parents transferred care to GOSH, 
not further approached for study 
6 05/08/09 RF CNS only GCV Difficult clinical relationship with 
parents therefore not approached. 
7  HE Partial details – 
CNS.   
?GCV Parents direct correspondence 
with study team.  Verbally happy 
for consent but consent not 
returned. 
8 26/12/07 PM Severe CNS VGCV SSIF prepared. 
Local team not submitted. 
9 02/01/08 W CNS GCV/VGCV SSIF prepared,  
Local team not submitted. 
10 21/4/08 WYo CNS GCV/VGCV SSIF prepared.  Local team not 
submitted. 
11 1/7/08 NH CNS ? SSIF prepared.  Local team not 
submitted. 
12 13/2/09 NM CNS GCV/ 
VGCV 
Parents met, consent not possible 
due to language barrier. 
13 03/09 LB CNS ?GCV SSIF prepared. Local team not 
submitted. 
14 19/05/09 RL CNS (SNHL) GCV, 
VGCV 
Local team expressed interest but 
initial paperwork not completed. 
15 12/6/09 EB CNS VGCV Site paperwork not commenced 
16 8/7/09 BA ? details ? no details Site paperwork not commenced 
17 08/09 GW/B
CH 
CNS + Hepatitis GCV Site paperwork not commenced 
18 09/09 DE  CNS, hepatitis GCV,VGCV Site approvals commenced 
19 11/09 MC ? full details GCV Site to start approvals process 
20 18/01/10 MA CNS GCV Site paperwork not commenced 
21 17/6/09 SH CNS, IUGR GCV, 
?VGCV 
Site approvals commenced  
22 09/08/09 EC CNS GCV SSIF prepared.  Local team not 
submitted 
23 16/04/09 BF CNS ?GCV Site approvals obtained.  Eligible 
baby not yet consented. 
24 19/07/07 BS CNS GCV, 
VGCV 
Local clinicians not able to obtain 
consent.  Language barriers. 
CNS = Central Nervous System 
PPHN= Persistent Pulmonary Hypertension of the Newborn 
IUGR = Intrauterine growth restriction 
SNHL = Sensorineural hearing loss 
SSIF = Site Specific Information Form 
GCV = Ganciclovir  
VGCV = Valganciclovir 
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5.3.2. Baseline demographics of enrolled babies 
The majority of babies (21/27: 78%) were term (≥37/40 gestation)(Figure 5-3); 59% 
were male.  Symptoms and signs of disease are summarised in Table 5-2.  Two 
babies were reported to have no abnormal clinical findings.  CNS symptoms/signs 
were documented in 21/27 babies, with thrombocytopenia and hepatosplenomegaly 
being the next most common clinical findings entered.  Birth weight ranged from 
1000-4000g and was <0.4
th
 Centile (<2.7 Standard Deviations below the mean) in 
5/27 (19%).  OFC at birth was recorded in 22/27 babies and was <0.4
th
 Centile in 
7/22 (32%); in 6/22 (27%) OFC was ≥1 Centile measurement below that of weight.    
Only 8/27 babies currently enrolled were born prior to 2007 (Figure 5-4).  There was 
no obvious over-representation of any particular month (or season) of birth for 
treated babies (data not shown).   
Only 2 babies were reported to have co-morbidities with 1 having co-infection with 
HIV and a further baby having multiple congenital abnormalities (hypospadias; 
bilateral inguinal hernias; branchial cyst). 
5.3.3. Reasons for commencing treatment 
CNS disease was the commonest reason for treatment (22/27 = 81%) (Figure 5-5).  
In 11/22 additional reasons for commencing treatment were also stated including 5 
for high VL, 4 for hearing, 3 for hepatitis and 1 eye problems.  3/5 babies treated 
without CNS disease appeared to have mild, or no clinical symptoms. 
Almost 20% of babies had a high VL stated as a reason for commencing treatment, 
although in only one baby was treatment started purely for this indication; treatment 
was only given for 23 days in this case.  4 (15%) babies had treatment commenced 
for hearing loss and an equal number for hepatitis although these indications were 
always accompanied by others.  A further 4 babies had treatment commenced for 
‘other’ reasons;  2 for petechiae (in one case this was the only apparent reason for 
commencing treatment); one following “advice from tertiary ID team” with no other 
reason or symptoms specified and one for “symptomatic CMV and failure to thrive” 
with hepatitis and eye involvement also documented. 
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Table 5-2  Symptoms and signs at presentation in 27 babies treated for 
congenital CMV 
 
 
Symptom/sign Number (%)  
Central Nervous System 21 (78) 
Hepatitis 5 (19) 
Hepatosplenomegaly 8 (30) 
Pneumonitis 1 (4) 
Thrombocytopenia 18 (67) 
Anaemia 6 (22) 
Neutropenia 4 (15) 
Chorioretinitis 3 (11) 
Skin  10 (37) 
Bowel 1 (4) 
Hearing 15 (56)  
 
Definitions used: 
 
Central nervous sytem:  microcephaly, seizures, abnormal tone, poor suck, abnormal 
neuroimaging consistent with CMV (intracranial calcification, ventriculomegaly, abnormal 
periventricular hyperechogenicity, hyperechogenicity of lenticulostriatal vessels). 
Hepatosplenomegaly:  liver or spleen >4cm below the costal margin 
Hepatitis = ALT (Alanine Transferase) >100 IU/L OR jaundice/raised serum bilirubin 
(conjugated and without other obvious attributable cause). 
Thrombocytopenia = platelet count <100 x 10
9
/L 
Anaemia = Hb <13.5 g/dL 
Neutropenia = Neutrophil count < 0.5 x 10
9
/L 
Skin = petechiae or purpura (or other recognised manifestation of congenital CMV) 
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Figure 5-3: Gestation of babies enrolled  
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Figure 5-4: Number of enrolled babies treated with ganciclovir or valganciclovir 
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Figure 5-5  Indication for treatment in babies with congenital CMV   
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GI    =  Gastrointestinal 
VL   = Viral load 
 
Data showing indication for treatment in 27 babies with congenital CMV as recorded in the 
UK CMV Treatment Registry.  In most babies more than one indication was entered. 
 
 
Figure 5-6  Treatment received 
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Treatment given in 27 babies with congenital CMV as recorded in the UK CMV Treatment 
Registry. 
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5.3.4. Treatment received  
In 16/27 (59%) babies GCV was the sole drug used for treatment (Figure 5-6).  In a 
further 8/27 (30%) of babies GCV was used sequentially with VGCV; GCV was the 
starting drug in all these cases.  In the 8 babies in whom sequential GCV and VGCV 
were used the reason for switching to oral therapy was stated as problems with i.v. 
access in 2 cases (suspected in a 3
rd
 case from correspondence regarding 
management), to enable discharge in 2 cases (and suspected as the reason in a 3
rd
 
case from the same site) and to enable prolonged therapy in one case (suspected as 
the reason in a further case that also received 42 days GCV followed by VGCV).  
VGCV treatment was first documented as used in the Registry in a baby born in 
2006; there was no increase in its use over time (Figure 5-4).  VGCV was used in the 
treatment of a total of 11 babies although it was the sole drug used in only 3 cases 
(Figure 5-6). 
In the majority of babies (24/27) treatment was commenced in the first 30 days of 
life.  Treatment was started at 31 days of age in one baby; the remaining two babies 
in whom treatment was started later were born in 2003.  
The majority of babies (15/27) received a 42 day course of treatment (+/- 2 days) 
(Figure 5-7).  In the 8 babies who received <40 days of treatment 3 were documented 
to have side effects during treatment (2 neutropenia and 1 Staphylococcus aureus 
line sepsis) but in only one of these was it documented that treatment was stopped 
due to side effects (neutropenia).  4 babies received a longer duration of therapy, 
with 2 of these receiving >56 days treatment.  There is no documented reason for the 
longer treatment course in any of these babies.        
The starting dose of GCV was 6mg/kg/dose bd in 16/24 (66%) and 5mg/kg in a 
further 7/24.  In 3/7 in whom a dose of 5mg/kg was commenced the dose was 
subsequently increased to 6mg/kg.   
In 6/11 of those treated with VGCV, the starting dose was 15 or 16mg/kg/dose bd.  
In the other 5 babies the starting dose ranged from 10mg/kg to 40mg/kg bd.  The 
dose was changed in 3 babies receiving VGCV; dose was increased in 2 of these 
babies (one from 15mg/kg to 15.5mg/kg and one from 16mg/kg to 18mg/kg) and 
decreased in one (from 25mg/kg to 15mg/kg bd).    
I am unable to assess from the data currently entered into the Registry how often 
dose was adjusted for increases in weight.  
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Figure 5-7  Duration of treatment 
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Duration of antiviral treatment given in 27 babies treated for congenital CMV and enrolled 
in the UK CMV Treatment Registry 
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5.3.5. Ganciclovir levels  
8 babies had 36 GCV levels recorded; 14 pre- and 16 post-dose levels and 6 untimed.  
No babies had reported renal impairment.  For i.v. GCV median pre- and post- dose 
levels recorded were 0.2 mg/L (IQR 0.1-0.4) and 4.6 mg/L (IQR 2.9-5.1) 
respectively (Figure 5-8A); dose of GCV was 6mg/kg in all instances.  
Corresponding levels for those receiving VGCV were 0.5mg/L (IQR 0.1-0.8) and 
4.0mg/L (IQR 3.0-4.3) pre- and post-dose respectively (Figure 5-8B).  These levels 
were obtained, however, on varying weight based doses of VGCV.  Due to these 
different dosing regimens linear regression was carried out of both the pre- and post-
dose levels (Figure 5-8B).  A strong linear association was demonstrated between 
dose of VGCV and post-dose levels (r
2 
= 0.73) with a weaker association between 
pre-dose levels (r
2 
= 0.58).  In one subject (UKBS3), in whom multiple levels were 
taken, both pre- and post- levels were seen to increase gradually over a 15 day period 
whilst on the same dose of VGCV (12mg/kg bd).   
Trough levels were <0.6mg/L in 4/4 and 6/10 of those receiving GCV and VGCV 
respectively.  Peak levels were >7.0mg/L in 0/6 of those receiving GCV and >5.0 
mg/L in 2/9 (22%) of those receiving VGCV.    
Due to insufficient data it was not possible to describe in any detail the relationship 
between VL and drug levels.  No obvious association emerged in the few patients 
with serial measurements available (Figure 5-9).    
5.3.6. Side effects  
16 side effects were documented in 13 subjects (12 receiving GCV and one VGCV) 
(Figure 5-10).  The commonest side effect documented was neutropenia, which 
occurred in 7/27 (26%) treated babies, followed by line infection which was reported 
in 5/22 (23%) babies receiving i.v. GCV.  In only one baby, however, was the 
treatment course documented to be curtailed due to side effects (the only recipient of 
VGCV that had side effects documented).  In the remaining 6 babies treatment was 
continued but either interrupted for brief periods or switched to VGCV (N=4).  In the 
5 babies with reported line infection 3 had a growth of S. aureus documented, one 
coagulase negative staphylococcus and in one no organism was documented.  In 3 of 
these babies the course was completed with i.v. GCV, in one the course was
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Figure 5-8  Pre- and Post- dose ganciclovir levels following administration of i.v. 
ganciclovir and oral valganciclovir 
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Ganciclovir levels (mg/L) recorded following GCV (A) and VGCV (B) administration in 7 
babies treated for congenital CMV. 
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Figure 5-9  Viral load and ganciclovir levels over time in two subjects treated 
for congenital CMV 
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day 3 to day 22 of life; VGCV 10mg/kg twice daily
day 22 to day 55 of life.
0 7 14 21 28 35 42 49 56
0
2
4
6
8
10
60 120 180 240 300
0
1
2
3
4
5
Blood VL
Urine VL
Pre-dose GCV levels
Post-dose GCV levels
GCV VGCV
Age (days)
L
o
g
1
0
 V
ir
a
l 
L
o
a
d
G
C
V
 le
v
e
ls
 (m
g
/L
)
 
 
Subject UKBS3:  Treated with GCV 6mg/kg twice daily
day 5 to day 15 of life; VGCV 12mg/kg twice daily
 day 15 to day 45 of life.
0 7 14 21 28 35 42 49 56
0
2
4
6
8
10
60 120 180 240 300
0
1
2
3
4
5
Blood VL
Urine VL
Pre-dose GCV levels
Post-dose GCV levels
GCV VGCV
Age (days)
L
o
g
1
0
 V
ir
a
l 
L
o
a
d
G
C
V
 le
v
e
ls
 (m
g
/L
)
 
GCV = ganciclovir 
VGCV = valganciclovir 
VL = viral load 
 
 
- 132 - 
Figure 5-10  Side effects recorded during treatment for congenital CMV  
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Figure 5-11  Source of sample used to diagnose congenital CMV  
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Sample recorded in the UK CMV Treatment Registry as the sample used to make a diagnosis 
of congenital CMV in 27 babies subsequently receiving treatment. 
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completed with VGCV and in one a 37 day course was given with no reason 
specified for this duration of therapy. 
5.3.7. Virology at diagnosis and during treatment 
Most babies had diagnosis confirmed on urine or blood (12/27 and 10/27 
respectively) (Figure 5-11).  Age at time of diagnostic sampling ranged from 1 to 17 
days in 25 babies in whom this was recorded with a median value of 1 day.   
In 3 babies diagnosis was documented to have been made antenatally with 2/3 
specimens being amniotic fluid.   
25 subjects had at least one VL measurement recorded.  13 of these babies were also 
recruited into the Viral Load and Immunology study (VICC) discussed in Chapter 6 
of this thesis.  The detailed analysis of these data, along with those obtained from a 
further 3 babies with detailed VL available but entered in the Registry alone 
(UKCV1, UKBS1, UKBS2), are therefore summarised in more detail in this later 
chapter.   
CMV DNA was detected in blood at baseline (first sample taken after birth and only 
included in analysis if obtained within 7 days of treatment commencing) in 19/23 
(83%) babies in whom samples were recorded; mean VL in these 19 babies was 4.3 
log10 copies/ml (SD 0.68).  Most samples were obtained within the first week of life 
(median day 4; range day 0-27) and there was no apparent decrease in VL with 
increasing age of subjects (data not shown).  8 babies, however, had 2 blood 
specimens analysed prior to, or within 2 days of, commencing treatment (a median of 
10 days between samples; range 6-28 days).  All but one of these babies had a 
decrease in VL over time (mean decrease of 0.82 log10 copies/ml; SD 0.66 
copies/ml).  In the majority of these babies it was thought likely that the VL was 
measured in the same laboratory. 
Virus was detectable in urine in all 17 babies who had results recorded.  13 babies 
had a quantified VL recorded (mean baseline 7.32 log10 copies/ml; SD 1.2).  3 babies 
had 2 specimens analysed prior to, or within 2 days of treatment commencing (1-8 
days between samples).  VL was a mean 0.51 log10 copies/ml (SD 0.43 copies/ml) 
lower at start of treatment compared to baseline. 
VL at the end of the course of treatment was not often reported.  In those with data 
recorded 9/15 (60%) had virus still detectable in the blood and 5/10 (50%) in urine.   
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10/15 babies had a decrease in blood VL recorded during the first 14 days (+/- 4 
days) treatment.  Mean change in VL for all 15 babies was -0.79 log10 copies/ml (SD 
1.14).  All except 2/13 babies had a decrease in VL from baseline to day 42 treatment 
(+/- 4 days), with a mean change in VL of -0.94 log10 copies/ml (SD 0.82).  
When considering urine 11/13 babies had a decrease in VL in the first 14 days (+/- 4 
days) of treatment (mean change -1.66 log10 copies/ml; SD 1.21).  Between days 14 
and 42 all 8 babies with results entered showed a decreased VL with a mean decrease 
of 1.88 log10 copies/ml (SD 0.91).  All 7 babies with values available from day 42 
(+/- 4 days) of treatment had a decrease when compared to baseline with a mean 
decrease of 4.14 log10 copies/ml (SD 1.24).   
Most babies received GCV for the majority of their treatment.  There were therefore 
insufficient data to compare VL decline between those receiving VGCV and GCV.  
5.3.8. Clinical outcome  
Data are still being updated, particularly with regards to hearing outcomes.  9/27 
(33.3%) babies with date of data entry recorded were, however, more than two years 
of age at the time of last data entry.  5 of these were recorded as being asymptomatic. 
10/27 (37.0%) babies with data available were reported to be asymptomatic at the 
time of data last being entered; no babies entered in the Registry are reported to have 
died to date.   
16 babies were recorded as having hearing loss; detailed hearing data is currently 
recorded for 14 of these babies.  Newborn Hearing Screening Programme (NHSP) 
was reported to have detected hearing loss in 8/10 babies with right sided hearing 
loss, data was not entered for the remaining 2 babies.  Similarly 9/11 babies with 
documented left ear involvement were detected by the NHSP, in one baby whether 
hearing loss had been detected at the point of screening was unknown and in the 
remaining baby data was unrecorded.  In 8 babies hearing loss was bilateral when 
last recorded, 3 left sided only and 2 right sided only, in 1 laterality was not recorded.  
Severity of hearing loss was severe to profound in 4/6 and 4/5 babies with data 
available for right and left ears respectively.  In 1 baby progression of hearing loss 
was reported and in one improvement noted.  Data were, however, largely entered as 
‘not recorded’ in this field.  2 babies were noted as having been referred for cochlear 
implantation.   
Detailed neurological outcome data is not currently entered into the Registry.  
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5.4. DISCUSSION 
5.4.1. Number accrued and relation to previous studies 
27 babies treated for cCMV in the UK had been entered into the ECCI Registry from 
10 participating sites up to 1/5/2010.  Summary data available at the onset of this 
study reported approximately 6 babies being treated per year during the two year 
surveillance period (Lynn et al. 2004).  The data currently entered for 2003 would 
imply that the Registry has a fairly low case ascertainment, certainly for earlier years.  
This is not surprising given the comparatively well-established nature of the BPSU 
and the more stringent enrolment requirements for this new treatment Registry. 
Although recruitment has not yet reached the numbers predicted, the enrolment of 7 
babies born in 2008 and 2009 is close to the predicted estimates.  The higher number 
of cases recruited in recent years is likely to reflect improved case ascertainment but 
would also be in support of my hypothesis that more babies would be treated 
following recent evidence particularly as these numbers exceed those identified 
through the more extensive and robust BPSU reporting system.   
The difficulties encountered with ensuring good case enrolment and data collection 
are discussed further below. 
5.4.2. Is treatment in the UK evidence based? 
As one of our initial concerns was regarding the use of antiviral treatment in babies 
in whom there was no evidence base it is interesting to compare the data currently 
entered into this treatment registry with the entry criteria for the only existing RCT 
of treatment for cCMV (Kimberlin et al. 2003).  In this study treatment with 6mg/kg 
bd i.v. GCV was commenced and continued for 42 days duration in neonates aged ≤1 
month with clinically apparent cCMV and evidence of CNS involvement.  
Participants were all ≥1200g in weight and ≥ 32 weeks’ gestation.     
o Basic demographics 
All treated babies currently enrolled in the Registry were ≥32 weeks’ gestation and 
all but one baby was ≥1200g in weight (Figure 5-3).  Treatment was commenced 
within 31 days of age in all but 2/27 babies.  The 2 babies treated outside the age at 
which treatment has been proved effective were both born in 2003. 
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o Clinical symptoms 
22/27 babies were reported to have CNS findings at birth.  In the majority of cases 
treatment was therefore commenced according to existing evidence.  However, in 
nearly 20% of babies treatment was commenced for indications other than CNS 
disease with 2/27 (7%) having no symptoms recorded at birth.  There is therefore a 
notable proportion of babies entered being treated in whom side effects might 
outweigh the currently unproven benefits of such treatment.     
Our comparatively low findings of hepatitis and hepatosplenomegaly (19% and 30% 
respectively) compared to other studies (Table 1-2) is interesting and may be due, in 
part, to recruitment bias as major paediatric liver units are not currently active study 
sites for the Registry.  It is also possible that these babies are not being uniformly 
treated in the UK in keeping with a current lack of evidence that doing so is of any 
benefit. 
It is not currently possible to ascertain from this database how frequently clinicians 
are treating babies with SNHL alone.  Although often considered a CNS 
manifestation of cCMV disease, SNHL may be the only abnormal finding in babies 
with CMV infection making its presence as an indication for treatment contentious 
(Stehel et al. 2008).  Most of the babies included in the Registry did, however, have 
other documented findings of symptomatic CMV. 
o Treatment formulation, dose and duration 
Treatment was commenced with GCV in 24/27 babies and in 8 babies subsequently 
changed to VGCV; difficulty with i.v. access was cited as the reason for this change 
in ~25%.  In other cases the change of medication was to facilitate discharge home or 
to enable prolonged courses of therapy.  Treatment duration was around 42 days in 
16 babies.  7 babies received a shorter course of treatment with side effects reported 
to account for just under half of these.  In 4 babies a longer course of therapy was 
given, with VGCV used in all cases to complete treatment; no information is 
recorded regarding the justification for these longer treatment courses.  The dose of 
GCV used was 5-6mg/kg bd in the majority of babies treated with this drug (21/22).  
Dose of VGCV, however, varied more considerably from 10-40mg/kg bd.  The 
evidence-based VGCV dose of 16mg/kg bd was only published in 2007, however 2 
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of the 6 babies treated with VGCV born in or after 2008 were still commenced on 
alternative doses of medication (Acosta et al. 2007). 
According to my data VGCV is therefore being used frequently both to enable earlier 
discharge and to enable longer treatment courses.  The treatment of a number of 
babies with prolonged courses of VGCV is of some concern given the absence of any 
RCTs reporting any additional benefit from such treatment strategies.  This will 
hopefully be addressed once the results are published of forthcoming RCTs 
(NCT00466817).   
There has not been a noticeable increase in VGCV use over time in babies enrolled 
into the Registry to date.  However, oral VGCV solution gained a manufacturing 
authorisation in the UK in 2009.  Due to the lag between clinical cases being 
identified and recruitment into the Registry an associated increase in VGCV may not 
be observed until late in 2010/2011.  Trends in VGCV use therefore warrant 
continued monitoring.     
It is notable that there are few premature babies included.  Although these babies fall 
outside the dosing evidence available it would be surprising if such neonates were 
being denied treatment if symptomatic.  The current lack of involvement of 
premature neonates is unfortunate as inclusion in such a Registry would allow 
information regarding dosing and safety to be accumulated to inform treatment of 
other similarly affected babies.     
Although treatment in the UK seems to be largely following the evidence available 
there are notable exceptions with regards to the treatment of less symptomatic babies 
and longer courses of treatment along with variable VGCV dosing.  Given that to be 
enrolled in the database clinicians are far more likely to have had contact with the 
study team and discussed treatment options the cases enrolled in the Registry have 
inherent selection bias.  It is therefore even more likely that treatment elsewhere in 
the UK, and Europe, is not so closely in keeping with this published evidence.  The 
only way for this to be addressed it to increase overall case ascertainment as 
discussed further below.   
5.4.3. Pharmacokinetics and pharmacodynamics 
Despite the dose of GCV given being in keeping with that used in previous studies 
10/14 (71%) babies had trough GCV levels <0.6mg/L (Kimberlin et al. 2003;Whitley 
et al. 1997).  Similarly peak drug levels rarely reached those proposed as being 
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therapeutic for adults.  This is consistent with data presented earlier in this thesis and 
raises further concerns that in clinical practice recommended doses of medication are 
associated with underdosing.   
In general the trough GCV levels reported during GCV treatment were less optimal 
than those whilst receiving VGCV.  This may be due to the fact that VGCV dose 
appeared to be adjusted when low GCV levels were documented whereas GCV dose 
generally remained unchanged throughout treatment.  It may also be due to the PK 
changes previously documented in neonates over time whereby increased renal 
excretion of GCV is counter-balanced by increased bioavailability of GCV following 
VGCV administration over the same time period (Kimberlin et al. 2008).  Thus 
VGCV treatment is proposed to give a more stable AUC over 6 weeks’ treatment 
when compared to i.v. GCV.  In support of this latter proposal in one baby (UKBS3) 
in whom serial GCV levels were recorded from specimens taken between days 19 
and 34 of life whilst receiving the same dose of 12 mg/kg bd of VGCV, an increase 
in both pre- and post- levels was observed (Figure 5-9).     
5.4.4. Clinical and virological response to treatment and outcome 
Urine analysis was limited due to laboratories often not reporting a quantitative 
CMV VL.  Although ethical approval permitted retrieval of these specimens in many 
cases samples had been destroyed by the time full consent had been obtained or 
laboratories did not respond to these requests.  Where samples were obtained these 
were often in the form of DNA extracts meaning that accurate comparisons of VL 
were not feasible. 
Consistent with other studies virus was detectable in all urine samples tested at 
baseline but only 83% of blood samples (Bradford et al. 2005;Kimberlin et al. 2003).  
Decrease in VL between two ‘baseline’ measurements (two measurements taken 
prior to or within only a couple of days of starting treatment) in both blood and urine 
indicates that there is some spontaneous control of virus postnatally in both these 
body fluids, as already observed in early culture-based studies of urine (Stagno et al. 
1975).  Given the lower starting VL in blood it is notable that a larger decline prior to 
treatment was seen in this body fluid when compared to urine.  There is currently no 
published literature describing natural history of VL using quantitative CMV PCR of 
blood or urine in untreated babies.  This is important to take into consideration when 
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drawing any conclusions from results of viral decline in either blood or urine from 
uncontrolled treatment studies and attributing this decline to treatment efficacy.   
Most babies in the Registry with results available had a decline in urine and blood 
VL between start and end of treatment but virus was still detectable at the end of 
treatment in 60% and 50% of blood and urine samples respectively. 
Although the Registry holds insufficient data to allow correlations to be made 
between drug levels and viral decline the continued detection of virus at the end of 
treatment raises questions regarding treatment efficacy in this cohort.  The low GCV 
levels observed both here and earlier in this thesis are possibly significant when 
considering that virus is still detectable in a high proportion of blood and urine 
samples in these babies at the end of treatment.   The treatment duration of 6weeks 
should also be questioned particularly taking into account the continued decrease in 
urine VL noted in one baby with samples available during a prolonged treatment 
course.   However, if the threshold theory for symptomatic CMV proposed in adult 
patients is applicable to these babies then transiently decreasing peak VL might be 
sufficient to allow the neonatal immune system to mature and gain subsequent 
virological control.  With this in mind RCTs are essential in evaluating any longer 
treatment courses before exposing babies to unnecessary antiviral agents for 
prolonged periods.   
5/10 (50%) babies with data entered at more than 2 years of age have remained 
asymptomatic; this is consistent with the 50% long term sequelae reported in a meta-
analysis of untreated babies with symptoms at birth(Dollard, Grosse, & Ross 2007).  
This is not therefore consistent with the reported improvement in neurological and 
hearing outcomes with treatment published elsewhere (Kimberlin et al. 2003;Oliver 
et al. 2009).  This may be due to the inclusion in this Registry of less symptomatic 
babies.  It is, however, also possible that less rigorous monitoring of treatment in the 
clinical setting, particularly where VGCV is used, results in suboptimal treatment 
when compared to the constrained scenario of a RCT.   
The data currently available are insufficient to enable any conclusions to be drawn 
with regards to VL and progression of symptoms.  The lack of ability to capture 
follow-up data and record accurate audiological and neurological outcomes in the 
Registry further limits the interpretation of any follow-up data.  It is interesting to 
note the above concerns, however, when considering design of any future treatment 
studies for cCMV and in developing clinical guidelines on treatment.    
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There are currently no deaths reported.  Numbers in the Registry are, however, small 
and we are aware of a number of babies who had passed away and in whom consent 
was not obtained due to concerns about distressing parents further.  This sort of 
recruitment bias is unavoidable in any Registry where consent is required, and limits 
conclusions that can be drawn from this select cohort. 
5.4.5. Safety 
In keeping with other reports, the most common side effect documented was 
neutropenia, observed in 26% of our treated babies, and rarely leading to termination 
of treatment (Kimberlin et al. 2003;Kimberlin et al. 2008).  The relatively few 
reports of neutropenia associated with VGCV use in our cohort may reflect the fact 
that this was generally started later on in the treatment course, when side effects have 
been reported to be less common(Kimberlin et al. 2003).  It is also consistent with 
data emerging from other studies indicating that neutropenia occurs less frequently 
with VGCV treatment (Kimberlin et al. 2008).  Overall the frequency of neutropenia 
(cells <500 cells/mm
3
) reported here is less than grade 3 and 4 neutropenia 
documented in previous RCTs but comparison is limited by the variable neutrophil 
values (<250 up to <899 cells/mm
3
, according to age) involved with reporting 
toxicities in these previous trials.       
Line infections were the commonest reason for switching to VGCV and were 
reported in 5/27 (19%) babies.  Staphylococcus aureus was the reported infective 
organism in 3 out of 4 in whom an organism was recorded.  Given that S aureus has 
been reported to be the infective organism in only around 10% of all episodes of 
neonatal central line infections this trend also warrants further monitoring (Benjamin, 
Jr. et al. 2001).   
5.4.6. Recruitment barriers 
Case ascertainment bias has already been mentioned as a factor limiting 
interpretation of data in a number of areas already discussed above.  Difficulties 
encountered with recruitment, which have a bearing on ensuring widespread 
inclusion of treated babies, is therefore worthy of further discussion.  During the 39 
month period of data collection reported here the study team were aware of a further 
24 babies, who would have been eligible for enrolment (Table 5-1).  In 8 cases 
consent was not possible.  In one of these cases consent was declined due to parental 
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concern regarding regulatory agencies having possible access to clinical notes and 
personal details when monitoring the study. 
Due to many factors, including out-patient capacity and minimising parental 
inconvenience, the anticipated recruitment from a core number of centres with 
paediatric infectious diseases specialist input did not occur.  Most commonly 
telephone advice was sought by managing clinicians regarding evidence and 
recommendations for treatment.  Babies were therefore often treated locally with 
subsequent monitoring of treatment and associated side effects seeming anecdotally 
variable.  This is of particular concern where oral VGCV is being used in the out-
patient setting and where junior team members may be primarily involved with 
monitoring treatment.   
The associated difficulties in gaining numerous site approvals has been a significant 
hindrance to recruitment and a rate-limiting factor in enrolling a significant number 
of babies as highlighted in Table 5-1.  The reported median duration of time of 78 
days from approach to a site’s R&D department to approval is somewhat under-
representative of the time actually taken for submissions as this does not take into 
account the time taken to obtain the Principal Investigator’s approval for the drafted 
site documents prior to initial R&D submission.  In a number of cases this took over 
one year of correspondence and reminders.  At some sites no progress had been made 
with approvals in two years despite numerous contacts including meetings with 
apparently interested paediatricians.  This likely reflects both time constraints for 
NHS clinicians in being able to review these documents and changes in R&D 
funding streams during the period of this study.       
Despite the over-riding principles of multicentre study ethics approval, 3 sites were 
not happy to proceed with approvals until significant amendments had been made to 
study documents or the proposed recruitment methods.  In many cases completion of 
further site specific R&D forms and paperwork were required and further discussion 
was often needed with those involved with the local approval process prior to 
permission being granted to enable one potential recruit to be approached and 
consented.   
The above problems are inherent in any voluntary reporting system, particularly one 
where a complex set of approvals and consent are required.  Indeed, a surveillance 
study of babies exposed pre- and post-natally to anti-retroviral medication (the 
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CHildren exposed to AntiRetroviral Therapy (CHART) study) conducted through the 
well-established NSHPC, but requiring parental consent, likewise achieved only 
33.5% case enrolment.  This would be in keeping with our enrolments in earlier 
study years compared to the currently published information from BPSU and our 
knowledge of clinical cases notified to us.  It is also notable that even well-
established datasets such as the CHIPS/NSHPC described earlier have had to alter 
processes  in recent years and have reported difficulties with ensuring individual 
institution approvals are in place to enable data sharing that was previously 
commonplace for similarly rare conditions (personal correspondence).   
The restrictive nature of recent regulatory changes led to a call for a review of the 
regulation and governance of medical research by the Academy of Medical Sciences 
commissioned by the Health Secretary in March 2010.  Given my experience with 
this multicentre study I submitted evidence relating to how the current approvals 
process has limited data sharing in studying rare conditions such as cCMV which 
necessitate multicentre collaborations.  There is ongoing review of current processes 
in order to ensure that there is a balance between regulatory requirements put in 
place to protect individuals whilst ensuring that the conduct of clinically important 
research is not unduly inhibited. 
5.4.7. Implications of these data  
Despite the limitations noted above data acquired in this registry can still serve a 
valuable role in hypothesis generation and in providing pilot data for more 
scientifically robust studies. The cohort of 27 treated babies described here still 
represents a reasonable sized cohort of treated babies when compared to previously 
published literature for cCMV and raises a number of points warranting future 
consideration as summarised below.  
1) My data would suggest that there is increasing use of antiviral treatment for 
babies with cCMV in the UK.  These babies are treated in multiple different 
centres, often with little experience of managing associated toxicities and 
further follow-up.  In some areas this has been identified as a concern at a 
regional level and addressed by centralisation of referral and treatment.  It is 
suggested that this should be considered throughout the UK while taking into 
consideration associated parental inconvenience and distress at what is 
already a difficult time. In the meantime, the ECCI Treatment Registry 
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provides both a means of reviewing treatment trends within the UK and a 
platform for providing further evidence based information to guide individual 
clinicians. 
2) As originally hypothesised the main reasons for VGCV being used are 
documented as difficulties with i.v. access and to enable early discharge; in 2 
cases it was used to enable a prolonged treatment course.  There remains no 
clinical efficacy data for VGCV when compared to i.v. GCV and both 
clinicians and parents should be aware of this when making treatment 
decisions.  The stable, and more optimal, GCV drug levels observed with 
VGCV are, however, encouraging and may indicate an improved drug 
exposure over time in babies treated with this drug.  It will be of interest to 
monitor trends in VGCV usage in this age group following the marketing 
authorisation of oral VGCV syrup in 2009. 
3) As with our previous data GCV levels documented in the Registry would 
suggest possible underdosing of these neonates based on recorded serum drug 
levels.  The additional data presented here of continued virus detection in a 
significant number of both urine and blood samples at the end of a 6 week 
treatment course would raise further concerns regarding virological efficacy. 
Further work is needed to ascertain whether this is of any significance with 
regards to clinical outcomes.  
4) The lack of a standardised unit for quantifying CMV VL limits conclusions 
that can be drawn from virological data from multiple sites, such as that held 
in the treatment Registry.   Work is in progress to address this using the 
recently described international unit system for reporting VL (nibsc.ac.uk). 
The treatment guidelines mentioned above will in addition hopefully 
encourage clinicians to take samples at similar time points bringing further 
uniformity to date entered.   
5) The data presented here showing decreased VL in both blood and urine of up 
to 1.0 log10 copies/ml between first measurement and treatment 
commencement in babies support the need for RCTs to compare both 
virological and clinical outcomes in these neonates in whom natural history 
data are lacking.  In order to partially address this deficiency a more tightly 
controlled study of CMV VL involving prospective data acquisition and 
sampling of different body fluids at specified time points with centralised 
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analysis of samples was designed and is described further in Chapter 6 of this 
thesis.        
5.4.8. Further work proposed as a result of current data analysis    
The identification of improvements in the database to capture data more accurately 
and make the Registry more user friendly are ongoing.  Translating the audiology 
dataset into such defined menus proved particularly challenging due to the variable 
nature of some of the data captured during audiology assessments. Simplification of 
the audiology datasets would aid interpretation of follow-up outcomes.  Additional 
fields to enable capture of neurological outcomes will also ultimately be of 
importance in ensuring relevant follow-up data is recorded.  The need to make it 
clear whether SNHL is the only indication for treatment would be beneficial in 
assessing outcomes in this specific, and possibly different, group of symptomatic 
babies. Refining the database to enhance capture of data relating to reasons for 
courses of treatment that are longer or shorter than the currently recommended 42 
days would also be informative.      
As an outcome of this data analysis further contact with lead clinicians and site 
approvals for the main paediatric hepatology units is considered a priority along with 
revisiting other means of collating such data.  Eliminating the need for informed 
consent via approval from the Patient Information Advisory Group (PIAG), looking 
at methods of recruiting interested families directly via the website and involving 
sites as participant identification centres (PICs) are all possible means of easing the 
recruitment process and thus increasing case ascertainment.   
In addition the study team has been approached by partners in a number of European 
countries who are keen to share their cohorts of treated babies.  This would lead to 
inclusion of data on over 100 treated babies, providing a more powerful dataset and 
allowing for comparisons of treatment trends between countries.   
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CHAPTER 6. 
6. VIRAL LOAD AND IMMUNOLOGY IN 
CONGENITAL CMV (VICC) STUDY
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6.1. INTRODUCTION 
On reviewing the literature available at the start of my studies it was evident that data 
relating to the natural history of VL in different body fluids in symptomatic and 
asymptomatic infants with cCMV was lacking.  Moreover, studies describing 
immune responses in CMV-infected infants consisted, in the main, of observations 
from single time points, often taken some years after birth, and also often combining 
results from babies with both symptomatic and asymptomatic congenital infection 
(Cauda et al. 1987;Hayashi et al. 2003;Pass et al. 1983b;Pedron et al. 2011).  Few 
studies have documented changes in immunological responses with time or how 
treatment with antiviral agents might alter these responses or evaluated the 
relationship between immune responses and VL in congenitally infected babies. 
A prospective study evaluating VL and CMV-specific immune function at specific 
time points over the first two years of life was therefore designed.  With the known 
inter-lab variations in quantitative measurements of CMV VL, centralisation of 
samples was felt essential in order to provide robust, comparative data in the 
different groups of CMV infected babies (Pang et al. 2009).  Our lab had developed 
methodology for evaluating CMV-specific immune responses in multiple samples 
over prolonged time periods in adult transplant and HIV co-infected patients.   In 
order to be able to draw direct comparisons with adult data I planned to modify these 
techniques, using reduced samples sizes, to define CMV-specific immune responses 
over time in CMV-infected infants.   
CMV IgG avidity is now carried out routinely in adults with suspected primary CMV 
infection but there is limited information on antibody avidity in the neonatal age 
group.  As small amounts of blood are required for antibody assays this prospective 
study also offered an opportunity to study CMV IgG avidity maturation in infants 
over time. 
My investigation of GCV levels in paediatric age groups had raised concerns 
regarding underdosing, but was limited by the lack of associated clinical and 
pharmacological data.  Increased use of VGCV was suspected in the UK with no 
published data on comparative levels of GCV achieved at the start of this study.  This 
study therefore also aimed to provide some PK data of treatment with both GCV and 
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VGCV in babies undergoing treatment along with some PD assessment in the form 
of observed virological response. 
This chapter therefore presents the results of this study which essentially aimed to 
address viral load and immune responses over time in congenitally and postnatally 
infected infants.   
6.2. METHODS 
6.2.1. Study overview 
4 different patient groups were identified for study as defined below 
1. any treated babies 
2. babies with symptomatic cCMV at birth, not receiving treatment   
3. babies with asymptomatic cCMV at birth, not receiving treatment  
4. babies with postnatally acquired CMV infection, not receiving treatment. 
CCMV was defined by CMV detection (by culture or PCR) in any sample acquired 
<21 days of age.  To confirm a diagnosis of postnatal CMV a subject required both a 
sample of urine taken at age <21 days testing negative for CMV followed by a 
subsequently positive sample.  In order for valid comparisons to be made with babies 
with cCMV, postnatally infected babies were only eligible if CMV was identified up 
to 3 months chronological age. 
Sampling was conducted according to pre-defined protocols with a plan for 1-2 years 
follow-up (Appendix C).  In view of the VL analysis presented earlier in this thesis 
and knowledge of viral dynamics in other viral infections the protocol specified 
frequent sampling early in treatment and following discontinuation of drug with the 
aim of more clearly defining viral dynamics in this population.  Due to the 
requirement for fresh PBMCs, samples for cellular immunity were only acquired 
from study sites based around London.  I retrieved and transported all samples 
obtained for cellular immunity directly to the laboratory to ensure no sample loss or 
wastage. 
Full ethical approval was gained in May 2007 and the initial recruitment plan was for 
a total of 45 babies to be included over a period of two years aiming for 20 
symptomatic congenitally infected babies (10 of which to have been treated), 5 
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asymptomatic congenitally infected and 20 postnatally infected babies.  As there 
were no previous data in this field no formal statistical power calculations were 
possible and the aim was therefore for the production of descriptive data which could 
inform future hypothesis-generation.    
6.2.2. Saliva swabs 
At the onset of my studies use of salivary culture as a diagnostic tool in adults was 
described but there was little literature on saliva collection in neonates or of PCR 
detection of CMV in such specimens (Warren et al. 1992;Yamamoto et al. 2006).  
There were no studies to my knowledge evaluating VL in this body fluid.  Initial 
literature searches and discussions with other laboratories led to the investigation of 
the use of cotton swabs in medium or saliva absorbed onto filter paper (Yamamoto et 
al. 2006;Zerr et al. 2000).  The cotton swabs used in previous studies were not 
available in the UK so initial experiments were conducted using filter paper strips 
(Sno-strips®).  Preliminary experiments using gB plasmids suspended in saliva, 
salivary samples from CMV positive healthy subjects and blood samples from 
subjects known to be CMV viraemic, resuspended in saliva following FACS-lysis to 
remove haem contamination, and using various different DNA extraction methods 
failed to give a good yield of CMV DNA from these strips.  Use of nylon flocked 
salivary swabs (Sterilin™) was therefore investigated (Figure 6-1).  These swabs 
have been shown to have better sample release than conventional nylon or polyester 
swabs (94% compared to 25%) and in increased virus detection from nasal and 
nasopharyngeal swabs (Unpublished data, Copan Innovation March 2006 and Daley 
et al. 2006).  Using neonatal flocked swabs, in sterile containers (MicroRheologics™ 
Product code 516C) good DNA yield was found from a swab obtained from a baby 
with asymptomatic CMV and extracted with Qiagen mini-kit™ using their 
recommended buccal swab spin extraction protocol (QIAamp® DNA Mini Kit and 
QIAamp DNA Blood Mini Kit Handbook February 2003).  These swabs were 
therefore evaluated further.             
o Assay set-up 
Salivary swabs were weighed pre- and post- saturating in samples of human saliva.  
Saliva was verified as being close to 1uL = 1ug solution in weight.  Average salivary 
volume retained was thus estimated to be ~27uL per neonatal flocked swab. 
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Figure 6-1 Photograph of flocked salivary swabs (Sterilin™) used for saliva 
acquisition 
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DNA extraction was trialled using a number of different commercial kits available at 
the time with similar DNA yield.  For practical reasons Qiagen DNA minikit™ was 
adopted for use in the study as they were in current use in the diagnostic laboratory.  
PBS was used for the initial step of the extraction procedure following further work 
showing that this gave similar DNA yield to swabs vortexed in virus transport 
medium (VTM) (data not shown).  Swab extractions during early stages of these 
studies were all carried out by hand following the manufacturers’ buccal swab spin 
protocol.  During latter stages, and following further comparisons of DNA yield, 
swab extraction was fully integrated into the diagnostic laboratory protocols as 
further described below.  Swabs were processed using VTM as the solution routinely 
in use in the diagnostic laboratory at the time.     
To investigate stability swabs dipped in PBS spiked with known dilutions of cell-
associated AD169 were left at room temperature for up to one week before 
extraction.  Initial DNA yield from swabs was 2.8-0.5 log10 lower than the starting 
salivary solution when extracted on Day 1 (Figure 6-2).  There was a further decrease 
in CMV DNA yield from swabs extracted on day 1 of acquisition compared to day 5 
but less difference in those extracted on day 8 compared to day 5.  Differences were 
greatest in starting solutions with lower virus concentration (Figure 6-2).             
o Limitations  
A decrease in DNA acquisition from flocked swabs compared to starting solution 
was noted.  It was uncertain whether the use of laboratory preparations of AD169 
accurately mimicked CMV DNA detectable in clinical samples but no other means 
of comparing CMV DNA extraction from fresh salivary solutions compared to swabs 
was available to us.  Variable salivary absorption is likely in clinical samples thus 
potentially further limiting accurate quantification of DNA copy number. The 
protocol for saliva acquisition therefore advised investigators to leave the swab 
inside the baby’s mouth for around 60 seconds to ensure full saturation with saliva; 
this could also be assessed visually.  As obtaining liquid saliva samples from 
neonates is impractical, obtaining swabs offered the best solution available at the 
time despite these limitations. 
In contrast to other liquid samples where only 110uL of starting solution is taken in 
our laboratory for DNA extraction and quantification it is necessary to extract the
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Figure 6-2 CMV viral load detectable in flocked salivary swabs following 
extraction at different time points  
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‘Neat’ is AD169 diluted with saliva followed by direct extraction of nucleic acid from this 
solution. 
For other samples flocked swabs were dipped in this ‘neat’ salivary solution until 
saturated and then extracted on different days following sample preparation.   
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whole 1mL of salivary swab solution to accurately estimate virus quantity present.  
This was subsequently incorporated into standard laboratory protocols.   
The salivary sample protocol also stipulated that samples should be obtained from 
babies at least one hour after a feed to minimise potential contamination with 
maternal CMV DNA in breast feeding mothers.   
6.2.3. Viral load 
CMV VL was quantified using real time PCR in the Royal Free diagnostic 
laboratory, by the laboratory staff, according to standard protocols in use at the time.  
Salivary swabs were processed according to the protocol also described earlier and 
VL adjusted to give an estimated quantity of virus/mL.  Log10 VL was plotted for 
each baby at each defined time point with the allowances for sampling as per 
protocol (Appendix C).  Where VL result was reported as <200 a value of 100 (as the 
mid-point between undetectable and 200) was entered for analysis to enable Log10 or 
Loge transformation of data.   
VL results of treated babies reported here are from 11 babies recruited into this study 
along with 3 babies whose data is recorded solely in the CMV Registry (as discussed 
in Chapter 5) and 3 babies whose samples were received at the Royal Free laboratory 
for clinical management and in whom basic data regarding treatment was known.  
Baseline was considered to be before, or within 7 days of, treatment commencing.  If 
a number of samples were available prior to treatment commencing the sample taken 
closest to the date of drug initiation was used.  End of treatment was considered to be 
date of treatment termination +/- 3 days.  Where VL in different body fluids was 
being compared, however, samples were only considered if taken within one day of 
each other.  It is important to note that day of treatment does not equate to day of life; 
at time point ‘Month 3’ a few babies were still receiving treatment.  Month 3 data 
was therefore omitted from many analyses in these subjects.  Medians were used for 
most VL comparisons, to enable comparison with data presented earlier in this thesis, 
although starting VL appeared more normally distributed in the babies included in 
this study.  
6.2.4. Ganciclovir levels 
Ideally samples were spun and serum separated in the hospital of acquisition to 
prevent sample degradation.  Serum samples were then sent to the Royal Free 
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laboratories where they were frozen at -80
o
C as soon as the study team were aware of 
arrival.  A form was developed to capture details of timing of doses, most recent 
blood creatinine level, most recent weight and whether the sample had been taken 
from a central line (if i.v. drug being given).  Samples were packaged in dry ice and 
sent by courier in one batch towards the end of the third year of the study to the UK 
reference lab where analysis was conducted by the team there according to their 
standard protocols (see 2.3).  Only the unique participant study ID was attached to 
samples along with dates and times of sample acquisition.   
6.2.5.  HLA-A2 Class 1 MHC typing. 
This analysis was carried out by me simultaneously to PBMC extraction in new 
study patients so that at the point of specific antigen stimulation HLA-A2 status had 
been ascertained. 
o Initial set-up 
Although pentamers were available for HLA-A2, -A24, -B7 and -B35 CMV epitopes 
and monoclonal antibody was available for HLA-A2, -A24 and –B7 initial set-up 
focussed on HLA-A2 and HLA-B7 as these were known to be predominant HLA-
types in the ethnic groups anticipated to be most represented in my studies 
(Proimmune handbook 2007).    
Initial assays were conducted using aliquots of samples of blood from subjects with 
known HLA types.  During assay set-up the optimal amount of anti-HLA-specific 
antibody necessary for reliable detection was titrated and the minimum time that 
allowed for effective staining was evaluated by leaving samples incubating for 15, 20 
and 30 minutes prior to analysis (data not shown).  Further work established that 
gating on CD14+ monocytes gave the most accurate reflection of HLA-type.  After 
carrying out anonymised testing of 5 subjects it was established that rapid testing was 
likely to be inaccurate without including additional control samples which would 
increase both sample sizes required and analysis time.  In order to keep testing as 
rapid and accurate as possible the final protocol therefore only involved testing for 
HLA-A2, the most predominant HLA type in Caucasian populations.   
In the final protocol 5uL HLA-A2-FITC conjugated mouse anti-human monoclonal 
antibody (BD pharmingen) was added to 50uL whole blood.  In a separate FACS 
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tube 5uL isotype control mouse IgG2b, , clone 27-35 (BD pharmingen) was added to 
50uL whole blood as a negative control.  5uL anti-CD3 PerCP (BD pharmingen) was 
added to both samples.  Samples were mixed well and then incubated in the dark for 
20 minutes at room temperature before adding 1ml BD FACS™ Lysing solution 
(diluted 1:10 with distilled water) and agitating vigorously.  Cells were left for a 
further 10 minutes prior to washing with 2mls PBS/0.1% NaN3 and centrifuging 
(500g for 5 minutes) at room temperature.  Supernatant was removed and cells 
resuspended in 2mls PBS/0.1% NaN3 prior to a further wash cycle as above.  Cells 
were then resuspended in 200L 2% paraformaldehyde and immediately FACS 
acquired and analysed using a standard acquisition template.  Examples of positive 
and negative results are shown in Figure 6-3. 
o Reliability 
1/5 samples tested falsely negative for HLA-A2 during assay set-up despite altering 
control cut-offs; there were no false positive results.  As the purpose of this assay 
was to identify subjects eligible for further analysis with HLA-A2 specific pentamers 
and peptides false negatives were less concerning than false positive samples and this 
was therefore felt acceptable.   
A concurrent study assessing CMV responses in 24 CMV seropositive adults found 
only one participant assessed as being HLA-A2 positive using the same assay had no 
measurable lymphocyte population staining positive with R-PE fluorochrome-
labelled HLA-A*02:01 matched CMV (NLVPMVATV) pentamers (Proimmune).  
Median CMV-specific CD8 cells were 0.54% (IQR 0.14-1.30).       
o Limitations  
The monoclonal antibody used identifies HLA-A2 but for peptide binding specific 
HLA sub-groups might also be important with HLA*0201 being the HLA type 
associated with the immunodominant CMV NLV peptide incorporated in 
commercially available pentamer preparations.  It would therefore be possible that a 
subject that was HLA*0205, for example, might bind the HLA*A2 monoclonal 
antibody but produce a negative result on pentamer testing thus giving a false 
negative immunological result.  Ideally samples should subsequently undergo more 
detailed, genetic analysis, to determine specific HLA-A2 alleles; this was not 
possible in this study. 
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Figure 6-3 Examples of subjects considered HLA-A2 positive and negative using 
rapid FACS-analysis  
 
A. Example of subject considered HLA-A2 positive 
 
B. Example of subject considered HLA-A2 negative 
 
HLA-A2 status was evaluated using fluorochrome-labelled monoclonal antibody to stain 
whole blood samples. 
 
Samples were stained with either 5uL HLA-A2-FITC conjugated mouse anti-human 
monoclonal antibody (BD pharmingen™) (HLA-A2) or 5uL mouse IgG2b, , clone 27-35 
(BD pharmingen™) (iso control) as isotype control. 
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6.2.6. PBMC phenotyping and stimulation assays 
PBMCs were extracted as described in Chapter 2 of this thesis.  Cells were stained 
according to either the ex-vivo or stimulation protocols also described in Chapter 2.  
Analysis was conducted using FlowJo (Version 8.7.1) software on an Applemac 
computer prior to exporting to Microsoft Excel spreadsheets for further analysis.  
FACS plots were exported to Microsoft PowerPoint and both saved and printed.  All 
data were stored by subject number and sampling time point only.  In all analyses 
initial lymphocyte gates were drawn according to forward and side scatter 
characteristics.   
Ex-vivo analysis of CMV-specific HLA-matched CD8+ T cell populations 
Using the lymphocyte subset the CD8+ cell population was further defined using a 
box plot of the CD8-PerCP Cy5.5+ cells (Figure 6-4). 
HLA-A2 NLV(CMV)+ cells were subsequently identified as a subgroup of these 
CD8+ cells using a further box plot around this easily visible population. Quadrant 
analysis was applied to the CD8+ cells to quantify CD57+ and Granzyme B+ 
subsets.  These quadrants were then copied to the A2-NLV(CMV)+/CD8+ 
population to ensure comparability of subsets between the two different populations.  
Ex-vivo analysis of CMV-specific non-HLA-matched CD8+ T cell populations 
For subjects that were not identified as being HLA-A2+ lymphocyte and CD8+ 
populations were characterised as above.  Quadrants were then drawn characterising 
CD28+ and CD57+ lymphocyte populations.  To further aid correct definition of 
CD57+ lymphocytes histograms were additionally drawn. 
Cytokine producing CD4+ or CD8+ T cells 
Taking the lymphocyte subset the CD4+ or CD8+ cell population was further defined 
(Figure 6-5). Taking either the CD4+ or CD8+ populations IFNγ producing cells 
were defined using a further box plot.  This box was then applied to all CD4 and 
CD8 analyses for consistency.  For IL-2 FITC and TNFα PE analyses a polygonal 
shape was applied to enable elimination of a non-specific staining ‘spur’ present in 
these channels.  This was thought to be due to non-specific staining of PBMCs and 
was noted both in my analyses and those of adult transplant patients (Figure 6-5). 
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Figure 6-4 Gating analysis for ex-vivo PBMC analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PBMCs were extracted and stained according to the protocols detailed in Chapter 2.   Lymphocyte populations were selected and then further defined by 
CD8+ve staining cells.  CMV-specific HLA-A*0201 pentamer (A2 pp65 NLV) positive cells were selected using a further box plot.  Quadrant analysis of 
Granzyme B and CD57 was carried out on CD8+ve cells and then copied to the CD8+/pp65NLV+ population to enable comparison. 
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Figure 6-5:  Gating analysis for intracellular cytokine assays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PBMCs were extracted, stimulated, and stained according to the protocols in Chapter 2.  During FACS analysis lymphocyte populations were first selected 
followed by CD4 or CD8 according to sample type.  Cytokine production was then defined for each cytokine separately (IFNg, IL-2 and TNFa) and these 
settings ideally applied to all samples from a participant at a given time point. 
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In most cases it was possible to define the same cytokine ‘gates’ for both CD4+ and 
CD8+ lymphocyte populations but where these did not adequately define populations 
separate gating was conducted for CD4+ and CD8+ lymphocytes.    
Further analysis was conducted in Excel with ‘no antigen’ negative controls deducted 
as background from any response seen.  Where cytokine production in non-
stimulated ‘no antigen’ controls was greater than that seen in antigen-stimulated 
samples, these ‘negative’ responses were represented as zero response to enable data 
to be presented on a positive axis. 
It was decided that data from all samples would be included, even if it was not 
possible to acquire the intended 50,000 events, in view of the limited number of 
samples and sample size anticipated and the aim to provide descriptive data. 
6.3. RESULTS 
11 sites gained approval between June 2007 and September 2008.  As with the CMV 
Treatment Registry the approvals process ranged considerably between sites with 
one site taking 14 months from initial submission to final approvals.  In 4 of the 11 
sites it was felt feasible to obtain samples for immunological analysis.  In 2 sites it 
proved difficult to ensure samples for VL analysis were received by the Royal Free 
once babies had been recruited. 
6.3.1. Demographics and baseline clinical data 
20 babies were enrolled between May 2008 and April 2010 from 9 sites.  16 of these 
babies had received treatment for cCMV, 1 had symptomatic cCMV but had 
thrombocytopenia and normal cranial USS at birth and therefore was not treated, 2 
were asymptomatic at birth and 1 had postnatal infection. 
Of the 16 babies receiving treatment 13 were also enrolled in the CMV Treatment 
Registry.  Demographics and descriptive data for these 13 babies are therefore more 
fully reported in Chapter 5 of this thesis.   
o Symptoms and severity at baseline 
8/19 (42%) mothers of congenitally infected babies were reported to have been 
diagnosed antenatally; no mothers received treatment.  One of these babies was born 
without symptoms of CMV at birth and was not treated.  The other 7 received 
treatment although 1 baby had no abnormal findings at birth and one had subtle 
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abnormalities on cranial USS only, with no clinical or biochemical/haematological 
abnormalities.        
Of the congenitally infected babies 16/19 were born ≥37/40 with the remaining 
babies being born at 34/40 (2 babies) and 35/40 gestation.  
Of the 17 symptomatic babies 14 had neurological involvement reported at baseline 
with 9 scans reported to be abnormal; 16 received treatment.  Abnormal scan 
findings are summarised in Table 6-1.  9 babies had hearing loss already identified at 
baseline but only one had hearing loss as their only abnormal finding.  5 of these 
babies also had abnormalities noted on neuroimaging; 1 had normal neuroimaging 
and the remaining 3 had no neuroimaging results documented.  10/17 symptomatic 
babies had haematological involvement, with thrombocytopenia predominating; 5 of 
these babies also had skin lesions visible.  Only 3/17 had hepatosplenomegaly and 
3/17 hepatitis with 0/17 having pneumonitis or bowel involvement.  1 baby had 
ophthalmic abnormalities but it was uncertain if these were CMV-related. The 
symptomatic, untreated baby had IUGR (0.4
th
 Centile) with OFC on 2
nd
 Centile and 
thrombocytopenia noted on day 3 which resolved spontaneously by day 23 of life.  
The postnatally infected baby was born at 27/40 birth weight 740g (9
th
 Centile) and 
had CMV detected on NPA on day 88 of life.  Hepatitis was noted on day 37 of life 
which resolved by day 196 and pneumonitis was present from days 124-234 of life 
without treatment being given.   
All except 2 treated babies were commenced on i.v. GCV, with the other 2 treated 
with VGCV exclusively.  3 babies were subsequently switched to oral VGCV 
treatment (1 after 6 weeks; 1 after 3 days following i.v. access difficulties and 1 at 
Day 10 with no reason documented).  Treatment course was 42 days (+/- 1 day) for 
all except 2 babies, one of whom had a prolonged course of treatment of 81 days and 
the other who received only 18 days of treatment, treatment being discontinued once 
no evidence of CNS involvement had been confirmed.   
6.3.2. Clinical follow-up 
Of those congenitally infected with symptoms at birth, 1 of the 9 babies initially 
thought to have hearing loss was reported to have normal hearing at 12 months; 2/9 
had received or were on the waiting list for cochlear implantation.  No babies with 
normal hearing at birth had developed SNHL.  3 babies had neurological sequelae
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Table 6-1  Abnormal neuroimaging findings in 9 babies with congenital 
cytomegalovirus infection and neurological abnormalities reported at birth 
  Subject Neuroimaging  Abnormality 
N1-001 CT scan Intracranial calcification & diffuse white 
matter hypodensity 
M1-001 Antenatal USS Prenatal ventriculomegaly 
 Postnatal MRI Asymmetrical sulci, possible neuronal 
migration defect.  Bilateral (mild) lateral 
ventriculomegaly. 
B1-002 Antenatal MRI  Synechiae posterior horn, lateral 
ventricles bilaterally at 32/40 
 Postnatal MRI Abnormal septations, localised 
ventricular prominence.  
D1-001 Cranial USS and MRI USS: abnormal.  
MRI: bilateral cerebellar malformation, 
diffuse white matter abnormalities, small 
area of polymicrogyria. 
D1-002 Postnatal Cranial USS and  
MRI  
USS: bilateral caudo-thalamic 
subependymal cysts. Cyst left lateral 
ventricle, bilateral calcific lenticulostriate 
vasculopathy. 
MRI diffuse white matter changes, 
frontal cortex possible early 
polymicrogyria. 
D1-003 MRI age 4 months Widespread abnormal white matter and 
polymicrogyria, dysplastic cerebellum. 
Subependymal cysts.   
H1-002 Postnatal Cranial USS Periventricular calcification 
H1-003 Modality unknown Periventricular calcification 
H1-004 CT scan Periventricular calcification 
A1-001 Cranial USS at birth Calcification 
 MRI and CT 4 months Possible white matter changes left 
temporal region. No calcification noted. 
A1-002 Antenatal USS Ventriculomegaly. 
 Postnatal MRI Bilateral perisylvian polymicrogyria.  
Diffuse white matter signal abnormality.  
Small punctate lesions with signals 
suggestive of calcified haemorrhage in 
parietal lobes.  Ventricular septations 
in occipital horns, lateral ventricles.  
Subependymal cysts.   
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documented with 2 of them having significant delay with neurodevelopmental age 
estimated at around 6 months on formal testing at around one year.  One baby had a 
significant retinal scar documented which had not been recorded in earlier 
documentation received.   No seizures were documented.  Overall 9 of the 16 (56%) 
congenitally infected babies with follow-up data available had some kind of 
permanent impairment at 12 months with the majority of these involving hearing.   
At two year follow-up clinical data was available for 17/19 congenitally infected 
children.  In many cases this was through correspondence with parents only as many 
families had moved areas.  Both asymptomatic babies in the study remained 
asymptomatic.  7/17 with hearing data available had continued hearing loss with 2 of 
these likely conductive rather than sensorineural.  1 baby was reported to have new 
hearing loss, but this was suspected to be conductive in nature.  No further babies 
had received cochlear implantation.  9/14 babies with data available had neurological 
impairment with most of these babies having delays in more than one area.  No 
babies had visual loss documented although no further information was available for 
the baby noted to have scarring present at 12 months of age.   
6.3.3. Viral Load 
The main analysis of VL presented here is of 17 babies treated for cCMV in the 
neonatal period.  Data has been pooled from 3 main sources, as described above, 
with the majority (11/17 babies) being part of the VICC study.  Some results were 
available for 4 untreated babies with these small numbers limiting the value of 
detailed comparisons of VL between different patient groups.     
o Viral load in untreated babies 
CMV was only detectable in blood at a low level (log10 2.54 copies/ml) in 1/16 
samples analysed in the 4 babies not receiving treatment for cCMV (Table 6-2); this 
was in the baby that was symptomatic at birth but not treated.   In contrast virus was 
detectable in both urine and saliva at >4.0 log10 from all 4 untreated babies at all time 
points up to 12 months of age (M12).   
The congenitally infected babies had first recorded urine and salivary VL ranging 
4.7-6.9 log10 and 5.8-8.4 log10 respectively.  There was continued viruria at high 
levels on sampling at age 6-12 months (M6-M12) in all 4 untreated babies but in
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Table 6-2  Viral load in different body fluids at specified time points in babies 
with CMV infection not receiving treatment.   
 
BLOOD 
 Time point M2-001 H3-001 M3-001 J4-001 
Baseline  - 2.0 2.0  - 
D14  -  -  -  - 
D28 2.0 2.0  -  - 
M3 2.0 2.0  -  - 
M6 2.5 2.0 2.0 2.0 
M12 2.0 2.0 2.0  - 
M24 2.0 2.0 2.0 - 
 
URINE 
Time point M2-001 H3-001 M3-001 J4-001 
Baseline  - 4.7 6.9  - 
D14  -  -  -  - 
D28 6.5 4.5  -  - 
M3 5.8 5.4  -  - 
M6 5.4 5.2 6.3 8.7 
M12 5.3 5.8  - 6.0 
M24 2.0 4.8 2.0 - 
 
SALIVA  
Time point M2-001 H3-001 M3-001 J4-001 
Baseline  - 7.8 8.4 - 
D14  - -  - - 
D28 5.8 7.6 - - 
M3 8.8 6.4 - - 
M6 5.8 6.0 9.1 8.7 
M12 4.1 4.4 6.0 6.0 
M24 5.3 5.3 2.0  
M2-001 symptomatic at birth, not treated  
H3-001 and M3-001 asymptomatic at birth (age at baseline H3-001 = 8 days, M3-001= 47 
days)  
J4-001 postnatally infected, not treated 
D = day of treatment  M = Month of age 
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only 1/3 babies with samples available at age 24 months (M24).  Urinary VL 
decreased from baseline to M6-12 in 3/4 babies.  
There was a spontaneous decrease in salivary VL observed in all 4 untreated babies 
from first measurement to M12 (decrease of log10 1.7, 3.4, 2.4 and 2.7 respectively).  
Virus was still detectable in saliva, however, in 2/3 subjects with samples received at 
M24, and had increased from the M12 values in both babies.  
o Baseline VL in blood, urine and saliva in treated babies and suppression 
at end of treatment  
In babies treated for cCMV, virus was detectable in 15/17 (88%) of baseline blood 
samples obtained within 7 days of treatment and all of the 15 urine and 8 saliva 
samples.  Mean VL at baseline was 3.8 (SD ± 0.8), 7.7 (± 0.9) and 7.3 (± 1.5) in 
blood, urine and saliva respectively with corresponding median values of 3.8 (IQR 
3.3-4.2), 7.7 (IQR 7.0-8.4) and 7.2 (IQR 6.8-8.3).   
In 6 babies there was more than one blood, and in 5 babies more than one urine, 
sample taken prior to treatment commencing.  In all except one pair of urine 
specimens the samples were analysed in the same laboratory.  In 2/6 blood samples 
both VL were within 0.5 log10 of each other.  In the remaining 4 samples VL varied 
from 0.6-4.3 log10 between samples; in all cases VL decreased over time.  In 2 
patients with more than 2 blood samples taken prior to treatment, VL continued to 
decrease over 21 and 29 days measured.  In 3/5 urine samples where 2 samples were 
obtained prior to treatment a difference of <0.5 log10 was observed.  The remaining 2 
subjects showed decreases of 1.0 and 1.6 log10 over 2 and 23 days respectively.  No 
babies had more than 2 urine specimens analysed prior to treatment.         
At the end of 42 days treatment (or within 3 days of this date) CMV remained 
detectable by PCR in 9 of 14 blood samples (65%), 9 of 12 urine samples (75%) and 
4 of 7 salivary swabs (57%).  Median VL in those babies with virus detectable in 
blood, urine and saliva was 2.8 log10 (IQ 2.5-3.3), 2.9 log10 (IQ 2.7-3.9) and 4.0 log10 
(IQ 3.6-4.7) respectively.   
o Viral decline in blood, urine and saliva and viral half-life calculations 
VL was around 4.0 log10 higher at start of treatment in urine and saliva when 
compared with blood but this difference narrowed during the treatment course 
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(Figure 6-6).  In keeping with this observation VL declined at a greater rate between 
start and end of 42 days treatment in urine and saliva when compared to blood with a 
median change of -1.2 log10 (IQ range -1.8 to -0.9) in 14 paired blood samples 
compared to -4.4 log10 (IQ range -5.5 to -3.8) in 10 paired urine samples and -4.8 
log10 (IQ range –5.2 to -3.9) in 7 paired saliva samples (Figure 6-7).  In 2/14 paired 
blood samples an increase in VL or no change was observed whereas decline was 
noted in all urine and salivary samples during treatment.  
Taking into account observations earlier in this thesis that viral decline appeared to 
be most rapid in the first week of treatment viral decline was analysed separately for 
the first 3 and 7 days of treatment and compared to that over the full 42 day treatment 
course (Table 6-3).  Samples were limited, particularly for decline between days 0 
and 3.  Viral decline over the first 7 days of treatment was nonetheless observed to be 
more rapid in both blood and urine when compared to that observed over the full 42 
days of treatment.  Salivary samples were even fewer but in the one pair of samples 
available there was no difference in the rate of decline between days 0-7 and the full 
42 days treatment.  A more rapid decline was, however, observed during the first 3 
days of treatment compared to over the full treatment course in the 2 babies with 
samples available.   
Virus half life of decline (T1/2) was calculated using segmental regression of plots of 
Ln VL during treatment in GraphPad Prism for each body fluid where sufficient 
samples were available (see 4.2.3).   
Median virus T1/2 in blood of 14 babies with sufficient data available was calculated 
to be 2.4 days (IQR 1.9-3.3).  In 8 of these babies the slope was fitted to viral decline 
during the first 7 days of treatment but in the other 6 subjects maximal decline was 
over a longer time period, in part due to limited sample availability during early time 
points.  Median T1/2 in those babies with viral decline analysed in the first 7 days of 
treatment was 2.1 (IQR 1.4-2.7) days compared to 2.9 (IQR 2.3-3.9) days in those 
with analysis over a longer time period (a non-statistically significant difference).    
Median T1/2 in urine in 14 babies was 2.03 days (IQR 1.29-2.64).  In 7 maximal viral 
decline was noted in the first 7 days of treatment; in these babies median T1/2 was 
observed to be 1.25 days (IQR 0.66-2.46) compared to 2.26 days in the remaining 7 
babies (IQR 1.91-2.75) a difference which was again not statistically significant. 
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Figure 6-6  Mean viral load over time in different body fluids in 17 babies treated for congenital CMV 
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Figure 6-7: Change in Log10 viral load between baseline and end of 42 days 
antiviral treatment in babies treated for congenital CMV  
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VL= Viral Load 
IQR = Interquartile range 
Viral load measured using quantitative CMV PCR before treatment onset and at the end of 
42 days antiviral treatment (+/- 3 days). 
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Table 6-3: Table of median viral decline in blood, urine and saliva at different 
time points during treatment in 17 babies with congenital CMV. 
 
   
 
Body fluid Time point 
 D0-D42 viral decline 
(log10 copies/day) 
(IQR) 
D0-3 viral decline 
(log10 copies/day) 
(IQR) 
D0-7 viral decline 
(log10 copies/day) 
(IQR) 
Blood 0.03 (0.04-0.02)  
N=12 
0.3 (0.5-0.1)  
N= 2 
0.12 (0.16-0.10) 
N=12 
Urine 0.10 (0.14-0.08)  
N= 13 
0.63 (0.85-0.38)  
N= 4 
0.21 (0.3-0.07) 
N= 12 
Saliva 0.11 (0.12-0.07) 
N=7 
0.25 (0.49-0.02)  
N=2 
0.11  
N=1 
 
D= Day of treatment 
N= Number of paired samples available for analysis. 
IQR = Interquartile Range 
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There were only 2 babies with maximum viral decline noted in the first 3 days of life, 
partly due to samples available, these babies had a T1/2 calculated of 0.78 and 0.25 
days.   
Saliva specimens were available during treatment at more than 1 time point for 8 
babies.  In two babies VL increased over the first 7 days of treatment and in a further 
two the first saliva sample was only acquired after day 6 of life; data from these 
babies were therefore excluded in this analysis.  Median T1/2 of viral decline in the 
remaining 4 babies was calculated to be 1.49 (IQR 1.38-2.37).         
Treatment in the group of babies studied above was with i.v. GCV in 11 babies, oral 
VGCV only in 2 and the remaining 4 babies received a mixture of GCV and VGCV, 
all commencing with GCV for at least 6 days.  There was no obvious difference in 
viral decline in those treated with GCV compared to VGCV, although numbers were 
too small to allow meaningful comparisons.   
o Rebound 
Once treatment was stopped rebound of virus was seen within 1 week in 4/8, 6/9 and 
1/5 of those patients with blood, urine and saliva samples available respectively with 
corresponding median increase in VL being 0.52, 1.03 and 2.05 log10.  In samples 
where no rebound was seen virus was undetectable at the end of treatment in 2/4 
blood, 1/3 urine and 2/4 saliva; in the remaining subjects virus was still detectable 
but continued to decrease after treatment discontinuation. 
Based on mean and median values maximal rebound was observed at M3 in blood 
and at M6 in urine and saliva samples (Figure 6-6 and Figure 6-8).  Median VL was 
not significantly different from baseline for blood at M3 (3.78 log10 vs 2.96 log10 at 
baseline and M3 respectively; P=0.3) or saliva at M6 (VL 7.39 log10 and 7.16 Log10 
respectively; p = 0.72).  Urine VL was, however, significantly lower at M6 compared 
to baseline (median 5.94 log10 vs 7.74 log10 respectively; P= <0.01). 
o Long-term viral control 
Data presented here are from all enrolled babies (treated and untreated).  Virus was 
still detectable in 0/10 blood, 9/9 urine and 9/11 saliva samples available at M12 and 
0/6 blood, 4/6 urine and 3/6 saliva samples available at M24. 
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Figure 6-8  Viral load in blood, urine and saliva, during and after treatment in 
17 babies treated for congenital CMV 
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Baseline = start of treatment 
End treatment = end of 42 day treatment course 
D3 and D7 Post = 3 and 7 days after treatment discontinued 
M3, 6, 12 = age 3, 6 and 12 months of life 
Error bars represent median and interquartile range 
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In urine median VL of 9 samples at M12 was 4.83 log10 (IQR 4.53-5.78) and of 6 
samples at M24 was 2.76 log10 (IQR 2.00-3.89), significantly lower than the baseline 
of 7.66 log10 (p<0.01)(Figure 6-9). 
Similarly saliva VL was significantly lower at M12 and M24, measuring 4.40 log10 
(IQR 3.84- 5.13) and 2.76 log10 (IQR 2.00- 5.30) respectively, than the baseline 
median of 7.56 (IQR 6.76-8.44)(p <0.01)(Figure 6-9). 
At M24 there was no association apparent between those with virus detectable and 
whether they were symptomatic or asymptomatic at birth or had ongoing 
abnormalities detectable.  However, none of the babies in this cohort had confirmed 
progressive SNHL.   
o Prolonged treatment 
Only one baby had a course of 81 days treatment (42 days i.v. GCV followed by 39 
days oral VGCV) (Figure 6-10).   In this baby virus continued to be intermittently 
detectable at low levels in blood from day 42 to end of treatment (max 2.6 log10); VL 
continued to decrease in urine from 3.67 log10 on day 42 of treatment to become 
undetectable at day 91 and in saliva became undetectable on day 49 treatment and 
remained undetectable.  7 days after treatment was terminated rebound was observed 
in urine VL up to 1.5 log10 above end of treatment levels with no corresponding 
rebound in blood or saliva VL.  Virus was detectable at high levels at M6 and M12 in 
urine and saliva with no corresponding viraemia.  This baby had no hearing loss but 
significant neurodevelopmental delay at two years of age.    
6.3.4. Ganciclovir Levels 
Most samples were received as whole (unseparated) clotted blood in our laboratory.  
There was therefore significant delay between sample acquisition and separation and 
freezing of serum in most cases.   
31 samples were received from 8 babies, a further 8 samples were sent from 2 babies 
directly to the UK national reference laboratory.  Results were available for 12 pre-
dose, 9 post-dose and 15 random samples; timing was unspecified in 3 samples.  8 
paired samples were available from 5 patients; all babies were aged < 6 months.  
9/12 (75%) of pre-dose samples had GCV levels of <0.5mg/L whilst on treatment 
(Figure 6-11A); 2/3 babies with pre-dose levels 0.5mg/L or above were being treated 
with oral VGCV.  
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Figure 6-9  Viral load in urine and saliva at baseline and over 2 years follow-up 
from 20 babies with congenital CMV (both treated and untreated)  
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Figure 6-10  Viral load during treatment and follow-up in subject N1-001 
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Subject was treated for 81 days with ganciclovir (GCV) followed by valganciclovir 
(ValGCV) and followed up for 2 years to monitor neurodevelopmental and audiological 
outcomes. 
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Figure 6-11  Pre- (A) and Post- (B) dose ganciclovir levels measured in babies in 
the VICC study alongside data from the UK National Reference laboratory. 
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There were no post-dose levels >7.0 mg/L in babies treated with GCV (Figure 
6-11B); Mode post-dose level was 3.0-4.0 mg/L.  1/3 babies being treated with 
VGCV had post-dose GCV level >5.0 mg/L.     
Neutropenia was noted in 2 babies with results available.  Both of these babies had 
low pre- (0.1; 0.2 mg/L) and post-dose (3.7; 3.6mg/L) GCV levels.  There were no 
toxic GCV levels recorded. 
In 4 babies multiple samples were available over time.  In one of these babies, treated 
with GCV, a drop was noted in levels between D7 and D42 of treatment (pre- 0.9 
and 0.1 respectively; post- 6.7 and 3.7 mg/L).  In the other 3 babies values were 
similar at D7 and D42 of treatment; one of these babies received 42 days of GCV, 
one 42 days oral VGCV and the other received 10 days GCV followed by VGCV.  
Drug dose was increased for weight in all 4 subjects.      
There was detailed VL data available for 6 babies with GCV levels analysed.  At the 
end of treatment virus was undetectable in 2/6 (33%), 3/6 (50%) and 4/6 (66%) of 
blood, urine and saliva samples respectively.  Viral decline in the 6 babies with data 
available was not notably different to that of the group as a whole.  There was no 
apparent trend between those babies achieving undetectable VL at the end of 
treatment and GCV levels.     
6.3.5. Cellular Immunity 
Samples were obtained from 8 babies (7 congenitally infected and receiving 
treatment and 1 postnatally infected) at various time points for measures of cellular 
immunity.  More than 1 sample was obtained from 5 babies permitting observation 
of changes over time. 
3 babies were determined to be HLA-A2 positive, 4 were negative and 1 was not 
tested.  Samples were fully acquired (50,000 G2 events +/- 5000 cells) in 67/86 
(78%) CD4 samples and 28/58 (48%) CD8 samples.  As stated earlier all samples 
were included in this analysis.    
o  CMV-specific lymphocyte populations and lymphocyte phenotype in 
CMV-infected infants.   
The mean CD4/CD8 ratio was 2.12 (SD 0.8).  Although not statistically significant, 
CD4/CD8 ratios showed a trend towards decreasing over time with median (IQR) at 
time points D0-14, D28-M3, M6-M12 of 2.2 (1.6-3.3), 2.0 (1.7 - 3.1) and 1.9 (1.4-
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2.1) respectively (Table 6-4).  Most of this decrease could be accounted for by a 
decrease in CD4 percentage over time with median values at D0-14, D28-M3 and 
M6-12 of 62.7% (IQR 53.7-70.1%), 55.3% (IQR 52.8-68.8%) and 53.1% (IQR 47.7-
57.0%) respectively.  CD8 levels, however, remained relatively stable with only a 
small increase at M6-12 to 27.0% from a median of 26.8% at D0-14. 
Analysis of samples from HLA-A2 negative subjects revealed that most CD57+ cells 
were also CD28-, with changes in CD57+ populations mirroring those of 
CD57+/CD28- lymphocytes.  There were insufficient flow cytometer channels to 
examine both CD28 and CD57 populations alongside CMV-specific pentamer 
frequencies.  Changes in CD57+ populations were therefore reviewed alone to enable 
comparison between all patients, with the assumption that most of these cells were 
not expressing CD28. 
Median frequency of CD8+/CD57+ lymphocytes was 27.2% (IQR 15.7-37.8%).  
This is comparable to the proportion of CD8+/CD57+ cells observed in healthy, 
CMV seronegative adults included as controls (Figure 6-12).     
In the 3 patients that were HLA-A2+, median CMV specific Class I MHC restricted 
pp65 (NLV) pentamer frequencies were 0.50% (range 0.02-1.65%).  There was no 
observable increase in proportion of CMV specific lymphocytes over the first year of 
life (Figure 6-13).  In these babies a significantly higher proportion of CMV-specific 
(CD8+/NLV+) lymphocytes were CD57+ compared to the CD8+ population as a 
whole with a median frequency of 71.1% (IQR 60.7-79.5%)(p<0.001)(Figure 6-12).  
There was no difference observed in total percentage of CD8+/CD57+ lymphocytes 
between those subjects that were HLA-A2+ compared to those that were not and no 
association apparent between the frequency of CD8+/NLV+ lymphocytes and total 
CD8+ lymphocytes expressing CD57 (data not shown).  
o PBMC Stimulation assays 
IFNg responses to stimulation with SEB, the positive control, were barely detectable 
or absent in all babies except B1-002 at D0-D14 (Figure 6-14A and B).  This poor 
IFNg response persisted throughout the time frame being studied with maximum 
IFNg-secreting CD4+ T cell frequencies at M6-12 of 1.0%, (median 0.2%) compared 
to maximum IL-2 and TNFa frequencies at this same time point of 8.8% and 9.7% 
respectively (median 2.3% and 2.8%; p <0.05).  Some IL-2 and TNFa production
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Table 6-4: Median CD4 and CD8 T cells and CD4/CD8 ratio at different time 
points in 8 babies with congenital CMV 
    
 
Age Median CD4 % 
(IQR) 
Median CD8 % 
(IQR) 
Median 
CD4/CD8 ratio 
(IQR) 
D0-14 (N=4) 62.7 (53.7-70.1)  26.8 (21.7-32.7) 2.2 (1.6-3.3) 
D28-M3 (N=5) 55.3 (52.8-68.8) 26.6 (21.8-32.5) 2.0 (1.7-3.1) 
M6-12 (N=9) 53.1 (47.7-57.0) 27.0 (26.2-34.8) 1.9 (1.4-2.1) 
 
% = percentage of total lymphocyte number 
IQR = interquartile range 
D = day of treatment 
M= month of life 
N = number of samples included in analysis 
 
 
 
 
 
- 178 - 
Figure 6-12  Frequency of CD57+ lymphocytes in CMV infected infants and 
healthy adults 
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Box plots show interquartile range with line at median; Whiskers show minimum and 
maximum values.  
 
Infants were all CMV-infected and enrolled in the VICC study of viral load and immunity in 
congenital CMV. 
Adult patients were aged 51-70 years (median 60.5 years).  Adults were either positive or 
negative for CMV IgG (CMV +ve or CMV –ve respectively). 
Frequencies shown are CD57+ lymphocytes as a percentage of total CD8+ lymphocytes 
(CD8+) or as a percentage of CMV-specific lymphocytes (CD8+/NLV+) as defined by 
detection of class I MHC HLA-A*0201 pp65 (NLV) restricted pentamer staining. 
 
- 179 - 
Figure 6-13: Frequency of CMV-specific lymphocytes over time in two HLA-A2 
positive babies treated for congenital CMV. 
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CMV specific lymphocytes as a percentage of total lymphocytes (%NLV+/CD8 
lymphocytes) were quantified using FACS analysis of fluorescently labelled HLA-A*0201 
Class I restricted pentamers loaded with CMV pp65 (NLV) peptide (Proimmune) and using 
protocols as described in Chapter 2 and Chapter 6.2.6.   
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Figure 6-14: CD4+ lymphocyte cytokine production in response to stimulation with Staphylococcal aureus enterotoxin B 
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PBMC’s were extracted, stimulated and stained according to protocols detailed in Chapter 2 of this thesis. 
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was seen by CD4+ cells following SEB stimulation at most time points from most 
ies, with median IL-2 and TNFa responses 1.3% (range 0.4-4.4%) and 1.6% (range 
0.1-4.1%) respectively at D0-14 and 0.7% (range 0.0-1.4) and 1.2% (range 1.0-1.5%) 
at D28-M3.    
In contrast CD4+ lymphocyte cytokine responses were <0.1% in all subjects for all 
CMV-specific stimuli at D0-14 (Figure 6-15).  With only one exception the response 
to stimulation with CMV lysate was ≤ 0.1% for any cytokine production at all time 
points.  Maximal CD4+ cytokine response was seen at M6-12 in response to 
stimulation with pp65 peptides with all patients showing some response to 
stimulation with this antigen with median (range) IFNg, IL-2 and TNFa lymphocyte 
frequencies being 0.13% (0.0-0.25%); 0.0% (0.0-0.19%); 0.04% (0.0-0.17%) 
respectively.  There was a general trend towards increased production of all 
cytokines with increasing age.  In contrast to the responses elicited with SEB IFNg 
was the predominant cytokine produced in response to CMV-specific stimulation in 
most cases. In only one infant (D1-002) was IE1 the most potent stimulator of CD4+ 
lymphocyte cytokine production with this baby also showing predominant TNFa 
responses at M6.     
CD8+ T-cell cytokine responses, when elicited, were greater for both IE1 and pp65 
stimulation than those seen in CD4+ lymphocytes.  In keeping with the responses 
observed for CD4+ T-cells responses were generally greater following stimulation 
with pp65, involved IFNg secretion predominantly and increased over time (Figure 
6-16).  In 4 samples only (D1-001 at D42, B1-001 M3, D1-002 at M6 and A1-001 at 
M12) cytokine production was maximal following IE-1 pooled peptide stimulation.  
Median responses following pp65 peptide stimulation for IFNg, IL-2 and TNFa at 
M6-12 were 0.15 % (range 0.0-0.85%), 0.03% (range 0.0-0.25%) and 0.13% (0.0–
0.48%) respectively.  Corresponding results following IE1 stimulation were 0.1% 
(range 0.00-0.83%); 0.04% (range 0.00-0.11%) and 0.04% (range 0.00-0.35%). 
An IFNg response was seen following stimulation with NLV peptide in 7 of 8 CD8+ 
samples from HLA-A2 positive subjects (range 0.06-0.91%).  Somewhat surprisingly 
NLV peptide stimulation produced higher responses than with stimulation with 
pooled peptide preparations.  In keeping with results for stimulation with other 
antigens IL-2 and TNFa production was minimal. 
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Figure 6-15: CD4+ lymphocyte cytokine production following stimulation with CMV-specific stimuli over time 
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PBMCs extracted and stimulated according to protocols described in detail in Chapter 2 of this thesis. 
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Figure 6-16: CD8+ lymphocyte cytokine production following stimulation with CMV-specific stimuli over time 
IE1 CD8 D0-14
D
1-
00
1 
D
0
B
1-
00
2 
D
7
D
1-
00
2 
D
7
B
1-
00
1 
D
14
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
IE1 CD8 D28-M3
D
1-
00
1 
D
42
D
1-
00
2 
D
28
D
1-
00
2 
D
42
B
1-
00
1 
M
3
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
IE1 CD8 M6-M12
J4
-0
01
 M
6
A
1-
00
2 
M
6
B
1-
00
1 
M
6
D
1-
00
2 
M
6
D
1-
00
3 
M
6
B
1-
00
2 
M
6
B
1-
00
1 
M
12
A
1-
00
1 
M
12
J4
-0
01
 M
12
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
pp65 CD8 D0-14
D
1-
00
1 
D
0
B
1-
00
2 
D
7
D
1-
00
2 
D
7
B
1-
00
1 
D
14
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
pp65 CD8 D28-M3
D
1-
00
1 
D
42
D
1-
00
2 
D
28
D
1-
00
2 
D
42
B
1-
00
1 
M
3
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
pp65 CD8 M6-M12
J4
-0
01
 M
6
A
1-
00
2 
M
6
B
1-
00
1 
M
6
D
1-
00
2 
M
6
D
1-
00
3 
M
6
B
1-
00
2 
M
6
B
1-
00
1 
M
12
A
1-
00
1 
M
12
J4
-0
01
 M
12
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
NLV pep D0-14
B
1-
00
2 
D
7
B
1-
00
1 
D
14
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
NLV pep D28-M3
B
1-
00
1 
D
35
B
1-
00
1 
M
3
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
NLV pep M6-M12
B
1-
00
1 
M
6
D
1-
00
3 
M
6
B
1-
00
2 
M
6
B
1-
00
1 
M
12
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
IFNg
IL-2
TNFa
Sample ID
%
 C
D
8
 +
v
e
 c
e
lls
 r
e
s
p
o
n
d
in
g
Day 0-14 of treatment Day 28 of treatment to age 3 months Age 6-12 months
- 184 - 
The responses seen in the only postnatally infected baby (J4-001), who had samples 
available from M6 and M12, were not notably different from those observed in 
congenitally infected babies.   
There was no obvious association between the frequency of CD8+/NLV+ 
lymphocytes on ex-vivo FACS analysis and the frequency of IFNg production by 
CD8+ lymphocytes in response to matched pp65 (NLV) peptide stimulation in the 
small number of samples available (Figure 6-17).   
o Viral load and correlates with CMV-specific T cell responses 
Given that minimal cytokine responses were observed at earlier time points only data 
for responses at M6-12 were scrutinised for any relationship between CD4+ and 
CD8+ lymphocyte responses and VL.  Most subjects had no viraemia at these later 
time points.  There was no obvious trend visible between cytokine responses to any 
stimulus between the 2 patients with viraemia at M6 compared to the 5 patients with 
no viraemia detectable (data not shown).  For urine and saliva, VL was compared to 
IFNg responses observed in CD4+ and CD8+ T cells to all stimuli (Figure 6-18).  
There was a weak association observed between urine VL and IE1 stimulated 
CD8+/IFNg+ (r
2
 = 0.52) and between salivary VL and pp65 stimulated CD4+/IFNg+ 
lymphocyte frequencies (r
2
 = 0.57).  There was a stronger inverse relationship 
observed between the frequency of CD8+/NLV pentamer+ lymphocytes and urine 
VL in the 4 samples evaluable (r
2
 = 0.76).   
6.3.6. Serum IgG Avidity 
52 serum samples were received for CMV IgG analysis (38 from babies and 14 
samples from 8 mothers who agreed for samples to be retrieved or taken as part of 
the study).  Only maternal samples taken closest to their baby’s birth are considered 
further here.  Baby samples taken closest to specific time points were used for 
analysis.     
20/40 (50%) samples had total CMV IgG levels >250 AU/mL (the upper limit given 
routinely by the automated system used in our laboratory); 30/40 (75%) had levels 
>200 AU/mL.  There was no obvious trend over time in total CMV IgG levels with 
some babies showing increasing levels over time (H1-002, H1-003) and others 
decreasing (D1-002, B1-001, H3-001)(Figure 6-19A).  Interestingly the 3 babies with 
lowest IgG levels measured were asymptomatic (K1-001, H3-001, M3-001).
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Figure 6-17: Relationship between CMV specific lymphocyte population and frequency of IFNg production following stimulation with 
CMV-specific peptide 
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CMV specific lymphocytes were defined by percentage of HLA-A2 Class I (NLV) pentamer+/CD8+ lymphocytes in HLA-A2 positive subjects as        
described in Chapter 2. 
IFNg production was measured using FACS analysis of fluorochrome-stained PBMCs following stimulation with NLV peptide, the immunodominant CMV 
peptide in HLA-A2 positive populations as also described in Chapter 2. 
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Figure 6-18  Salivary and urinary viral load and frequency of CMV-specific CD8+ (A) and CD4+ (B) lymphocytes at 6-12 months of age 
in 6 babies with congenital CMV infection following stimulation with CMV specific stimuli. 
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B. CD4+ lymphocyte responses 
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VL = viral load 
Stimulation was with pooled peptides spanning the pp65 and IE1 proteins of CMV (A and B).   
CD4+ lymphocytes were stimulated with whole cell CMV lysate (B) 
In 3 HLA-A2 +ve subjects additional CD8+ responses were assessed following stimulation with HLA-A2 restricted pp65 (NLV) peptide (NLVpep) and 
frequency of MHC Class 1 HLA-A2 pp65 (NLV) restricted pentamer populations were measured (NLVpent). 
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Figure 6-19: Total CMV IgG (A) and CMV IgG (B) avidity measurement over 
time in 16 congenitally infected infants. 
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Mat = maternal serology obtained closest to birth of baby 
M3, M6 and M12 = age 3, 6 and 12 months 
 
Measurements shown are for babies at different time points and, where available, the sample 
from their mother taken closest to the baby’s birth. 
Total CMV IgG was reported as a maximum value of  >250IU and shown here as 250IU. 
Avidity index is a percentage of total CMV IgG as described in more detail in Chapter 2.  
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Table 6-5: Table of total CMV IgG levels and avidity index in 7 mother and 
baby pairs. 
 
All except one baby (J4-001) had confirmed congenital CMV infection; J4-001 had 
symptomatic, postnatally acquired, CMV infection. 
 
 
Subject Day 
of 
baby 
life 
Mat 
IgG 
Mat 
avidity 
index 
Mat 
avidity 
(high/low/ 
equiv) 
Day 
of 
baby 
life 
Baby 
IgG 
Baby 
avidity 
index 
Baby 
avidity 
(high/low
/equiv) 
D1-001 -29 182 77 H 26 231 45 L 
D1-002 -134 168 70 H 25 233.2 36 L 
N1-001 -169 >250 81 H 6 >250 46 L 
B1-001 -16 237 91 H 38 >250 86 H 
M1-001 27 200 66 H 421 >250 Insuff Insuff 
A1-002 -10 >250 74 H 159 >250 83 H 
K1-001 17 100 14 L 15 58.1 37 L 
J4-001 196 102 94 H 196 168.5 NV  L 
J4-001         405 140 42 L 
 
 
H = high avidity 
L = low avidity 
Equiv = equivocal 
Insuff = insufficient sample for analysis 
NV = no value 
 
 
- 189 - 
9 congenitally infected babies had serum samples available from close to birth.  6/9 
were found to have low CMV IgG avidity index, 2 high avidity and 1 equivocal 
measurements; by month 12 0/6 samples analysed had low avidity (Figure 6-19B).  
Of the 6 babies with initially low avidity around birth 2 had high avidity on 
subsequent measurement (M3 and M6), 1 had increased to become equivocal, 1 
remained low; 2 babies had no further samples available for analysis.    
Serum was available from 8 mother and baby pairs.  7 of these babies were 
congenitally infected.  In congenitally infected cases 6/7 of mothers had CMV IgG 
avidity index >70 in the sample taken closest to baby’s birth, consistent with 
infection more than 4 months previously (Table 6-5).  In the related baby samples 
avidity index was <50 in 4; >70 in 2 and not quantifiable in 1 due to insufficient 
sample (Table 6-5).  In all 4 samples with low avidity samples had been taken at <30 
days of life; those with high avidity were acquired at day 38 and day 140.  In the one 
baby with postnatal infection the maternal sample showed a high avidity index with a 
corresponding sample on the same day of life in the baby showing a low avidity.  In 
both samples total measured CMV IgG levels were relatively low.  A subsequent 
sample taken 7 months later in this baby, aged 405 days of life, revealed a similar 
total CMV IgG level and a continued low avidity index (42).   
6.4. DISCUSSION 
The aim of this study was to compare VL and cellular immunity between treated and 
untreated babies and those with and without symptoms.  Understandably 
investigators found it easier to approach parents of babies that received treatment for 
recruitment into this study.  There is therefore an over-representation of babies with 
CNS findings of CMV given that this was the main indication for antiviral treatment 
at the onset of this study.  Only one baby had SNHL with no other findings of 
cCMV.  This is consistent with current uncertainty regarding indications for 
treatment in CMV-infected infants with SNHL alone along with the difficulties in 
acquiring samples early enough in postnatal life to confirm congenital infection in 
otherwise asymptomatic neonates who ‘fail’ NHSP testing.  The 9/16 (56%) of 
babies here that had some evidence of permanent neurodevelopmental or sensory 
impairment on follow-up at 2 years of age is also consistent with figures from other 
studies of babies with symptomatic infection at birth and is a reminder of the 
significant damage associated with this presentation. 
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It also became apparent during the course of the study that fewer neonatal units than 
anticipated were checking for CMV in the neonatal period thus decreasing the 
number of babies that could be enrolled in the postnatally infected group, as 
congenital infection could not be excluded.  In spite of the small numbers of babies 
involved some interesting observations are still possible, particularly in those that 
received treatment.   
6.4.1. Viral load  
The undetectable viraemia in all but one sample obtained from babies not undergoing 
treatment for CMV disease is notable.  Larger numbers would, however, be needed 
before any firm conclusions could be drawn from these data.  Other authors have 
previously commented on the association between symptomatic disease and 
detectable viraemia (Barbi et al. 1996a;Boppana et al. 2005;Lanari et al. 2006).  The 
association between VL and development of symptoms has not, however, been 
maintained when larger numbers of asymptomatic babies are included in analysis 
(Ross et al. 2009).  The negative predictive value of having no CMV viraemia at 
birth, as in our study, does however seem to be of value in predicting good hearing 
outcomes in asymptomatic babies (Ross et al. 2009).      
Others have reported a decrease in VL in both blood and urine with antiviral 
treatment for cCMV.  Systematic follow-up of VL in different body fluids over 
prolonged periods and after treatment termination has not, however, previously been 
reported.  The similarity in salivary and urinary VL both at baseline and in response 
to treatment is striking despite the potential limitations of salivary swab VL 
quantification in neonates when compared to sampling of other body fluids.  
Similarly rebound in VL measured in both urine and saliva was more marked than in 
blood, peaking at around 6 months of life.  Both blood and saliva VL rebounded to 
levels not significantly different to those detected pre-treatment.  In contrast, 
however, urine rebounded to a level significantly lower than baseline.  These 
observations may have significant implications when considering treatment duration 
which will be explored in more detail, alongside results from earlier chapters, in the 
final chapter of this thesis.   
Median T1/2 in blood observed here of 2.4 days (IQR 1.9-3.3) is remarkably similar 
to that calculated in Chapter 4 (2.4 days; IQR 1.99-4.27).  The T1/2 calculated during 
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the first week of life of 2.1 days was not notably different from this value, although 
small numbers limit analysis.  These values in blood are comparable to those 
calculated for CMV viral decline in HIV-infected and liver transplant patients 
described elsewhere (Emery et al. 1999).  This would imply that viral dynamics, and 
thus ability to control CMV in the blood, in congenitally infected babies is similar to 
that observed in immunocompromised adult patient groups and is consistent with 
data relating to viral dynamics of HIV in children where likewise similar dynamics to 
adults have been described (Palumbo et al. 2007).      
Median T1/2 in urine was similarly 2.03 days (IQR 1.29-2.64), however, in contrast 
median T1/2 calculated during days 1-7 of treatment in this body fluid was only 1.25 
days (IQR 0.66-2.46).  Median T1/2 of viral decline in the 4 babies with sufficient 
salivary samples was also shorter at 1.49 days (IQR 1.38-2.37) although small 
numbers may evidently be biasing this analysis.         
Despite the consistency of the results for T1/2 obtained above it is important to 
remember the uncertainty regarding the validity of these calculations in this patient 
group.  My observations that VL decreased spontaneously prior to treatment in the 
few cases where serial samples had been obtained alongside historical tissue culture 
data showing viral decline in the pre-treatment era and a lack of any other natural 
history studies undertaking multiple sampling in untreated infants all raise doubt as 
to whether virus in these babies is truly in steady state.  It is difficult to justify 
multiple sampling in this patient group as unnecessary blood tests provide 
discomfort, raise further parental anxiety and offer no valid prognostic information 
based on our current knowledge.  Possible strategies to address this will be discussed 
in the closing chapter of this thesis.     
There are no published data to my knowledge of viral decline, measured using 
quantitative real-time PCR, in other body fluids.  A number of observations would 
suggest different viral dynamics in urine and saliva compared to blood.  These 
include the shorter T1/2 following treatment initiation, higher starting VL and marked 
rebound up to 6 months of age (3 months after treatment completion) presented here 
along with the long periods of virus detection noted both here and by others (Noyola 
et al. 2000).  There are no current data describing whether there is ongoing viral 
replication in the CNS or inner ear associated with the progressive clinical 
manifestations which are known to occur in these neonates.  If viral replication is 
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ongoing and viral dynamics in these body compartments were shown to more closely 
reflect that of virus infecting the glandular and renal ductal epithelium than in blood 
then treatment focused on maintaining viral suppression in these body fluids could be 
proposed. 
6.4.2. Ganciclovir levels.  
Firstly, the difficulties in interpreting results of samples obtained outside formal, 
rigorously regulated, PK studies should be noted.  The fact that many samples were 
received unseparated from sites and that the time between collection and processing 
of samples was not recorded introduces many possible biases in analysis.   
Despite the low GCV levels observed for all subjects around 1/3 of babies had virus 
undetectable in blood at the end of treatment.  This is comparable to the proportion 
having undetectable viraemia in the PK study described in Chapter 4 of this thesis 
whereby treatment was tailored to a specific AUC (Acosta et al. 2007).  The low 
levels observed throughout this study may therefore be largely attributable to 
deterioration of GCV in these clinical samples as illustrated by studies of sample 
degradation mentioned in Chapter 3 (Figure 3-1) (Boulieu and Bleyzac 1994).  It is 
therefore likely that levels measured in clinical samples, unless processed rapidly, do 
not accurately reflect “true” levels of drug exposure in these babies.  Given that the 
doses of GCV and VGCV used in the babies studied here were generally those 
derived from previous PK/PD studies and that viral decline appears similar in both 
groups studied this is the most likely explanation.  Alternatively, however, given that 
only 1/3 of babies in either study had undetectable VL at the end of the treatment it 
could be argued that the GCV dose thought to be optimal, from early dosing studies 
in severely affected neonates, is in reality insufficient in both these groups of babies.  
It is possible that these less severely ill neonates have better renal function and 
correspondingly higher GCV clearance than those from whom PK data were initially 
obtained.  However, this does not fully explain the reason that few babies treated 
according to the targeted AUC approach in the more recent CASG study remained 
viraemic at the end of treatment.  Further work regarding whether babies are 
receiving correctly targeted therapy needs further consideration whilst taking into 
account the known and frequent associated toxicities of antiviral agents.   
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6.4.3. Cellular immunity  
o T-lymphocyte phenotypic marker expression and CMV-specific 
lymphocyte populations 
The trend in decreasing CD4/CD8 ratios over time observed here was not statistically 
significant but is consistent with the decrease in CD4/CD8 ratios and decreasing 
CD4+, but not CD8+ lymphocytes, reported with age elsewhere in healthy newborns 
(Shearer et al. 2003;Thomas and Linch 1983).  Shearer et al found 52% CD4+ cells 
at birth, decreasing to 46% over the first year of life and CD8+ cells decreasing from 
18% to 17% over the same time period, comparatively lower frequencies than the 
63% CD4+ cells reported here which decreased to 53% at age 6-12 months and 
CD8+ frequencies of 27%.  An increase in total CD8+ T cell percentage in CMV 
infected neonates has also been noted by other authors (Pass et al. 1983a).  Pass et al 
in their study of 48 cCMV infected neonates and 27 healthy controls found a 
significantly higher number of CD8+ T cells and a corresponding significantly lower 
CD4/CD8 T cell ratio in symptomatic, but not asymptomatic congenitally infected 
infants <1 year of age.  Although we also report here a higher CD8+ T cell frequency 
the associated increase in CD4+ T cells led to the observation of a CD4/CD8 ratio 
comparable to healthy neonates.  Due to the limited phenotypic markers being 
identified in this study I am unable to report on what lymphocyte subsets have been 
correspondingly decreased in the infants studied here.  The lack of a control group of 
normal, age-matched neonates further limits drawing conclusions from these data.  
The observation that CD57+/CD8+ lymphocytes were predominantly CD28- is in 
keeping with phenotypic analysis of CD8+ lymphocytes of healthy, CMV 
seropositive adults studied as controls, and by others (Weekes et al. 1999).  My 
observation that a higher proportion of CMV-specific lymphocytes express CD57 
would be in keeping with data suggesting that high levels of terminally 
differentiated, CD57+, lymphocytes are generated as a result of chronic antigenic 
stimulation such as in chronic viral infections and autoimmune disease as described 
in more detail in the introduction to this thesis (1.7.3) (Wang et al. 1997;Wang and 
Borysiewicz 1995).  It is more intriguing why this correlation was not seen in our 
older group of CMV positive subjects.  The CMV positive infants studied here had 
an overall frequency of CD8+ lymphocytes expressing CD57 similar to that seen in 
CMV negative adults.  The lack of a similar association in older CMV-infected 
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adults may be explained by the high proportion of CD8+ lymphocytes dedicated to 
controlling CMV along with other factors coming into play during aging in those 
who have had chronic infection and immune stimulation with CMV over a period of 
many years (Pawelec et al. 2009).      
The median frequency of 71% CD57+/NLVpentamer+/CD8+ T cells is also 
consistent with the elevated CD57+ cell populations observed by Marashi et al 
(2011) in CMV infected adult patients with common variable immune deficiency 
(CVID).  Marashi reported higher proportions of CD57+ lymphocytes in those with 
active inflammation compared to those with no concurrent inflammatory disease.  
Although the data presented here do not allow comparison between symptomatic and 
asymptomatic babies the significantly increased CD57+ lymphocyte population in 
the symptomatic babies studied here would be consistent with the possibility that 
these babies also have ongoing inflammatory disease. 
In the 3 HLA-A2+ subjects studied here the frequency of CD8+ lymphocytes 
recognising the immunodominant NLV peptide ranged from 0.02-1.7% (median 
0.5%).  Some response was noted at all time points in all 3 participants.  This is in 
contrast to data presented by Hayashi et al reporting negligible CMV pp65-
specific/CD8+ T cells in congenitally-infected HLA-A24+ infants (Hayashi et al. 
2003).  Although CMV-specific, NLV pentamer+ lymphocytes were detected in the 
neonates studied here Marashi et al (2011), using the same protocol and reagents, 
reported relatively higher mean frequencies of 4.8% in CVID patients with active 
inflammation; 1.4% in those without inflammation and 0.66% in healthy adults.  
Mattes et al (2008) in their study of CMV in adult renal transplant recipients 
similarly reported median CMV-specific CD8+ lymphocyte frequencies of 1.19% 
(0.27-5.2%) in those patients that developed viraemia in the post-transplant period; 
lower median frequencies of 0.5% (0.03-6.46%) were observed following resolution 
of viraemia.  In contrast significantly lower CMV-specific CD8+ lymphocyte 
frequencies of 0.28% (0.02-3.35%) and 0.37% (0.01-6.92%) were observed in 
subjects that did not develop viraemia at days <50 and >50 post-transplant 
respectively.  The frequency of CMV-specific lymphocytes reported in infants in my 
study is therefore most consistent with healthy adults in Marashi’s CVID studies or 
in post-viraemic, recovering, adult transplant patients.  This is in spite of the 
continued excretion of virus in urine and saliva and clinical progression known to 
- 195 - 
occur in infants with cCMV.  The frequency of CMV-specific CD8+ lymphocytes 
could therefore be considered to be inappropriately low.  The prolonged presence of 
virus in various body fluids in cCMV may thus be a function of inadequate CD8+ 
lymphocyte responses in infants with active infection.       
In further contrast with findings in adult transplant and CVID patients there was no 
correlation between the frequency of CD8+ lymphocytes producing IFNg in response 
to stimulation with NLV-peptide and that of NLV pentamer+/CD8+ T cells (Mattes 
et al. 2008).  Indeed although CMV-specific CD8+ lymphocytes were detected using 
MHC-Class I pentamers, corresponding cytokine responses on stimulation with 
matched (NLV) pp65 peptide were negligible.  CMV infected neonates therefore not 
only have fewer numbers of CMV specific CD8+ T cells but these cells seem to be 
functionally impaired.  This lack of association may be partly attributable to the 
small numbers of viraemic patients studied here when compared to data derived from 
adult patient groups.  In support of this hypothesis the only subject that was viraemic 
at the time of sampling (D1-003 at M6) showed no IFNg response following 
stimulation with NLV-peptide and correspondingly only 0.016% NLV 
pentamer+/CD8+ lymphocytes (the lowest observed in the 8 samples analysed).  
More data in viraemic and non-viraemic infants is needed before this association can 
be fully excluded.     
o CD4 and CD8 T cell cytokine responses  
The high number of samples that were not fully acquired was partly due to the 
limited amount of blood available, compounded by the necessity to split samples into 
CD4+ and CD8+ aliquots to compensate for the limitations of 4-channel flow 
cytometry.  The lower ratio of CD8+ lymphocytes compared to CD4+ also 
contributed to the higher proportion of CD8+ samples which were not completely 
acquired.  Although interpretation of results needs to take this into account the 
selection of 50,000 G2 events was based on an ability to be able to detect 
infrequently (i.e. 1:1000) occurring events such as CMV-specific NLV pentamer+ 
lymphocyte populations.  The acquisition of over 30,000 events in all but 2 samples 
(one of which was a no antigen control sample) therefore still enables valid 
comparison between samples.   
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My finding that SEB stimulation produced little CD4+ lymphocyte IFNg secretion in 
early postnatal life in the neonates studied here is in keeping with studies of non-
specific T-cell activation in response to other antigens in young children which 
likewise have shown impaired IFNg production (Connell et al. 2010).  As IFNg is 
central to the cell mediated response to chronic viral infection and the predominant 
cytokine secreted by CD4+ lymphocytes the absent responses witnessed in these 
younger CMV positive infants is of interest.  Others in our lab, using similar assays 
in adults undergoing liver transplantation, have reported median frequencies of 
CMV-specific CD4+ cells producing IFNg, and IL2 in CMV-PCR positive patients 
of 0.4% (range 0.05-1.96%) and 0.07% (range 0.05-0.08%) respectively following 
stimulation with CMV-lysate (Nebbia et al. 2008). In patients who controlled CMV 
infection (CMV PCR-) cytokine production was significantly higher with median 
IFNg and IL2 responses of 0.97% (0.05-2.9%) and 0.32% (range 0.05-1.2%) 
respectively.  The median IFNg and IL2 secretion observed following pp65 peptide 
stimulation at 6-12 months of age in the non-viraemic infants presented here (0.13% 
(0.0-0.25%) and 0.0% (0.0-0.19%) respectively) is therefore comparatively low.  
Other authors have also documented absent or decreased CD4+ IFNg responses in 
CMV-infected children aged <2 years (Hayashi et al. 2003;Pedron et al. 2011).  The 
observation that this response increased over time and that IFNg emerged as the 
predominant cytokine secreted following CMV-specific antigen stimulation would 
be in keeping with the observation that primary CMV infections are characterised by 
mainly IFNg-secreting effector CD4+ T cells and that this response is diminished in 
young children.  The lack of secretion of other cytokines in response to stimulation 
with CMV-specific antigens observed here is in contrast to the TNFa and IL2 
secretion observed in response to SEB stimulation.  In the context of prolonged virus 
detection in cCMV this observation would be in keeping with the emerging 
significance of polyfunctional T cells in enabling viral control (Nebbia et al. 2008).  
The high VL observed in cCMV infection along with the known immunomodulatory 
properties of CMV may all be contributing to the poor polyfunctional CD4+ T cell 
cytokine responses observed in these infants.  Alternatively, the low responses may 
reflect immunological immaturity.    
CD8+ responses were higher than those observed for CD4+ lymphocytes with 
median CD8+/IFNg cytokine responses of 0.16% (range 0.0-0.85%) reported in the 
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infants studied here.  Although closer to figures reported in adults they remain 
comparatively low.  In adult liver transplant patients CD8+/IFNg+ lymphocyte 
responses in patients having CMV DNA detectable by PCR at any time have been 
reported as 0.4% (range 0.05-2%) following pp65 peptide stimulation with no 
difference between these patients and those not experiencing DNAemia at any time 
point (Nebbia et al. 2008).   
As reported in CMV-infected adults the infants studied here had maximal CD4+ and 
CD8+ cytokine responses in response to stimulation with pp65.  Although Gibson et 
al found IE1 to be possibly more important as an antigenic determinant than pp65 in 
neonates it may be noteworthy that only one baby in their study population had 
symptomatic infection (Gibson et al. 2004).  Somewhat surprisingly cytokine 
responses following stimulation with whole protein CMV lysate were minimal in my 
studies, with pooled pp65 or IE1 peptide stimulation leading to more efficient 
cytokine production.  In further contrast to Gibson’s findings, and that of others, I 
found no notable differences in responses following stimulation with pp65 and IE1 
peptides between HLA-A2+ve and HLA-A2-ve participants.  Given the small 
numbers of participants and the lack of asymptomatic controls it is not possible to 
draw too many conclusions from these data.  However, in summary it would seem 
that congenitally infected neonates are mounting similar responses to 
immunosuppressed CMV positive adult groups but they have fewer CMV-specific 
CD8+ lymphocytes than found in these adult groups and the CD4+ and CD8+ 
lymphocytes are functionally impaired, with respect to cytokine secretion in response 
to CMV antigen.   
It is interesting to note that in perinatal HIV infection, where viral set-point is also 
significantly higher than observed following primary infection in adulthood, 
immature T cell responses have similarly been observed (Sandberg et al. 2003).  This 
may have relevance when considering further treatment studies in neonates and 
would justify the relevance of concomitant immunological monitoring alongside 
such studies as has been successfully employed for studies of perinatal HIV infection 
(www.pentatrials.org).      
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6.4.4. CMV total IgG and IgG avidity  
There were few paired maternal and neonatal samples available for comparing CMV 
IgG avidity;  in 3/5 of these pairs avidity was lower in the infants than in mothers.  A 
previous study, conducted in term neonates, reported a higher mean IgG avidity in 
fetal cord blood of normal deliveries when compared to maternal placental samples 
leading the authors to conclude that high avidity IgG1 is preferentially transcytosed 
via the placental Fc receptor and aids suppression of viral replication in the placenta, 
preventing symptomatic fetal infectionIgG avidity in term neonates (Nozawa et al. 
2009). If this was replicated in a larger cohort it would be intriguing to speculate 
why.  One further study has reported on IgG avidity in premature babies, noting a 
correlation between high avidity anti-CMV-IgG and low CMV viral load (Fedorova 
et al. 2005).  Only one postnatally infected, premature, baby was included in my 
study.  A low IgG avidity was observed for a prolonged period of time in this 
neonate associated with hepatitis and pneumonitis.  Although viraemia was not 
detectable by 6 months of age salivary VL continued to be detectable at 6.0 log10 at 
one year of age.  As serum samples are relatively easy to obtain and process 
differences in IgG avidity in asymptomatic and symptomatic, congenitally infected 
neonates may warrant further investigation. 
6.4.5. Study limitations 
The small numbers of asymptomatic and postnatally infected babies recruited here 
limits meaningful comparison of data between patient groups.  It is hoped that some 
of these deficiencies can be addressed by encouraging recruitment of 
asymptomatic/less symptomatic infants from other studies which are currently 
recruiting or in the process of being set-up.  Ensuring that investigators are aware of 
the need for control data in order to inform treatment strategies for both symptomatic 
and asymptomatic infants will be key to encouraging recruitment into these groups.  
The need to separate samples taken for drug sampling as soon as possible after 
acquisition also needs reinforcing in future studies addressing this area.    
The small numbers of participants and small sample sizes obtainable in neonates 
provided obvious limitations to the cellular immunology data presented here.  My 
assay choice necessitated PBMC separation and stimulation of fresh blood samples 
further limiting eligible participants.  This decision was made following observations 
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by others in our laboratory that thawed frozen PBMCs had diminished cytokine 
responses when compared to freshly extracted PBMCs (unpublished data).  Such 
methodology is feasible when examining large numbers of patients attending one 
institution but may not be optimal when embarking on multicentre studies of 
uncommon diseases.  However, the validity of freezing samples of lymphocytes in 
these neonates where only small samples are available in the knowledge that 
cytokine responses are also diminished could also be challenged.  This clearly needs 
further thought when considering future multicentre collaborative efforts; the data 
presented here may correrspondingly inform future study protocols aiming to 
characterise the key factors in immunological control of cCMV and ultimately those 
associated with neurodevelopmental sequelae. 
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CHAPTER 7. 
7. DISCUSSION
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The aim of this thesis at the outset was to investigate the potential for modern 
virological methodology to define natural history of disease and to inform the design 
of trials.  This chapter discusses the main conclusions of the varied studies presented 
here along with studies already in progress that have been informed by preliminary 
data from work in this thesis and suggested future work.   
7.1. IMPLICATIONS OF DATA IN THIS THESIS FOR TREATMENT 
When considering treatment efficacy, clinical benefit is obviously paramount.  The 
outcomes of most interest in cCMV, namely hearing and neurological outcome, 
require follow-up of a number of years, however, in order to fully assess their 
impact. 
Although the studies described in this thesis are unable to add to the current literature 
regarding long term clinical efficacy, the virological and PK data presented suggest 
that current treatment for cCMV might be inadequate with regards to dose, duration 
and monitoring and that VL measurements could be used as biomarkers to study this 
sytematically.     
7.1.1. Dose. 
Based on the PK and virological data presented here, and by others, it is proposed 
that standard doses of GCV (6mg/kg bd i.v.) and VGCV (16mg/kg bd) may not be 
sufficient in many congenitally infected babies.  Although the VGCV dose now 
commonly used is based on a tightly controlled PK study, doses of up to 20mg/kg bd 
were needed in some babies to achieve the target AUC (Acosta et al. 2007).  The 
higher amount of virus observed in congenitally infected infants along with the 
immune impairments documented both in my studies and elsewhere would also 
question whether higher target drug levels are indicated in infants.  Certainly the 
reported variability in drug dose required to achieve similar AUC, along with 
possible differences in bioavailability where oral drug is being used might suggest 
that individualised dosing is necessary to provide maximal therapeuetic benefit in 
this age group (Acosta et al. 2007). 
In light of the data presented here I would propose that if VL is not decreasing 
steadily, consideration should be made to increasing drug dose, particularly in babies 
with no renal impairment.  Although further work is needed to evaluate validity of 
GCV levels taken in the clinical setting they might have a supporting role in such 
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circumstances to ensure that levels are not already in the high normal range 
particularly in the context of reports of higher Cmax and AUC12 being associated with 
increased neutropenia (Kimberlin et al. 2008). 
7.1.2. Formulation  
Data presented here and published elsewhere indicate that GCV levels are more 
consistently sustained and AUC varies less over time following oral VGCV 
administration than with i.v. GCV (Kimberlin et al. 2008).  However, in sick 
neonates concerns remain regarding ability to fully absorb oral drug and to ensure 
compliance.  PK parameters of relevance for adequate drug exposure in brain 
parenchyma and the auditory system also remain uncertain.  It remains an additional 
challenge to ensure that oral treatment is sufficiently closely monitored to ensure that 
adequate dosing is maintained throughout the treatment course.  In light of the data in 
this thesis I would recommend initiating treatment with i.v. GCV, particularly in 
those with significant disease.   Oral treatment could then subsequently be considered 
once a virological response has been observed.  In less symptomatic babies, 
particularly those who might not historically have received treatment, oral dosing 
could be considered from the outset thus decreasing the risk of side effects associated 
with i.v. drug administration.  Parents should be appropriately informed, however, of 
the limited evidence regarding the clinical efficacy of such an approach.        
7.1.3. Duration 
It is important to note that the 6 week treatment course, derived from the only RCT 
of treatment in cCMV, was not evidence-based but based on prior natural history 
data along with what was thought acceptable to parents when considering 
administration of an i.v. drug (Kimberlin et al. 2003).  This study did, however, show 
improved outcome with treatment.   
My studies and data presented elsewhere, however, clearly show that virological 
control is not achieved in the majority of babies with 6 weeks treatment.  Regardless 
of underlying pathological processes longer treatment courses would potentially both 
decrease direct viral damage and enable normal immunological control to be 
established.  This will be investigated further in a recently completed study 
comparing 6 weeks to 6 months treatment (CASG #112; NCT00466817). 
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7.1.4. Drug Toxicity  
The toxicities reported in the UK CMV Registry are generally in keeping with those 
reported in other studies and rarely led to drug being discontinued.  However, 
neutropenia with GCV administration was possibly less than expected from previous 
reports.  Recent studies have correlated higher Cmax and AUC12 with lower neutrophil 
counts which might further support concerns that the low levels and low toxicity 
found in my clinical studies represent true underdosing of drug in the clinical setting 
(Kimberlin et al. 2008). 
Consistent with other studies, neutropenia was also reported less commonly with oral 
VGCV treatment in the clinical studies presented here which might further support 
its role in treating less severely affected infants (Kimberlin et al. 2008).  It is possible 
that bone marrow toxicity correlates with the peak level of GCV while efficacy 
correlates with either AUC of concentration versus time, or time above a minimum 
value.  This observation could, however, also be explained by the fact that many 
babies included in the studies presented here were having less than the now 
recommended dose of 16mg/kg bd VGCV and VGCV was often used later in the 
treatment course, when neutropenia has also been reported to be less frequent 
(Kimberlin et al. 2003).        
7.1.5. Therapeutic Drug Monitoring 
Despite the concerns regarding accuracy of samples taken in the clinical setting the 
study of UK GCV levels showed comparatively low levels in children compared to 
adults and similar sampling bias should be applicable to samples taken in both 
groups.   
It is interesting to note the higher trough GCV levels observed following VGCV 
administration when compared to i.v. GCV.  Although the recommended target Cmax 
is lower following VGCV dosing (5.0mg/L) when compared to GCV (7.0mg/L) in 
these clinical studies similar Cmax was achieved independent of drug used.  The 
increasing GCV levels with increasing VGCV dose not only support the linear PK 
reported in published literature but also imply that these clinical levels are reflecting 
potentially clinically relevant changes in drug exposure. 
Although early studies of treatment of cCMV showed an association between drug 
dose, virological response and clinical efficacy both my data and other recent PK/PD 
- 204 - 
studies of VGCV use have not been able to correlate measures of quantitative VL 
with any PK parameters (Kimberlin et al. 2008;Nigro, Scholz, & Bartmann 
1994;Whitley et al. 1997).   
7.2. NATURAL HISTORY OF VIRAL LOAD IN CONGENITAL CMV  
In adults CMV VL is successfully used to govern decisions regarding both starting 
and stopping treatment (Atabani et al. 2012).  This thesis provides detailed 
evaluation of virological response to treatment in younger children and the first 
calculations of viral dynamics of CMV in neonates undergoing antiviral treatment. 
7.2.1. Viral dynamics and virological response to treatment in neonates 
o Blood 
Analysis of viral response to treatment in viraemic newborns presented here (16 from 
CASG #109 study (chapter 4) and 14 from the VICC study (chapter 6)) show that 
63% (total 19/30; 10/16 and 9/14 respectively) still had detectable viraemia at the 
end of a standard 6 week treatment course.  This is in contrast to studies in adult 
transplant recipients in whom the majority of patients, with comparable starting VL, 
have no virus detectable within 7 weeks of treatment (Mattes et al. 2005).  Although 
all babies having undetectable viraemia at the end of treatment in the CASG #109 
study had a lower starting VL at treatment onset this did not fully account for the 
high proportion remaining viraemic at the end of treatment.  A nadir in viral decline 
was observed in both studies despite a good initial response to treatment, consistent 
with the ‘levelling off’, observed in classical models of virus decline (Figure 1-3).  
T1/2 of virus decline in blood during the initial stages of treatment from both these 
studies are also almost identical (2.4 (IQR 1.9-4.5) and 2.4 (IQR 1.9-3.3) days 
respectively) and consistent with those observed in adults. This would imply similar 
virus dynamics in these early phases of treatment to those observed in 
immunocompromised adults, who exhibit more complete virological control when 
followed over a longer period.   
Drug resistance or non-compliance are possible explanations for this observation, 
particularly given the low GCV levels also reported in my studies.  Interestingly no 
published data to my knowledge have addressed compliance in adults or children. 
Non-compliance is unlikely in the studies presented here, however, given the 
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predominant use of i.v. GCV in clinical studies, the targeted dose approach used in 
CASG #109 and the fact that VL in the urine and saliva showed continued decline in 
response to treatment (see below).  Data from adult studies and preliminary analysis 
of UL97 sequences in samples obtained during the VICC study would also suggest 
that drug resistance is not likely to be contributing significantly during the short 
courses of treatment described here (unpublished data).   
The prolonged viraemia observed here might alternatively reflect continued virus 
production in ‘sanctuary sites’, with  clearance of virus-infected cells  into the blood 
stream, for example following granulocyte phagocytosis, accounting for persistent 
detection of CMV DNA.  Given the increased neurological morbidity observed in 
cCMV compared to immunocompromised adults the CNS or auditory system would 
be the most obvious sources of such virus reservoirs, possibly explained by poor 
penetration of GCV into the CNS.  An alternative explanation for this persistent 
viraemia might be virus production following reactivation from latency during 
cellular differentiation in these neonates, who are in a rapid phase of growth (Figure 
7-1).   
The data presented here also support other reports that viraemia is rarely detectable 
in asymptomatic babies, or those without CNS symptoms at birth.   
o Urine 
Studies in adult renal transplant recipients have shown that viruria is an independent 
risk factor for CMV disease and prolonged virus excretion in this body fluid in 
infants corresponds with the ongoing pathogenesis observed over the first few years 
of life in cCMV (Cope et al. 1997b).  A shorter T1/2 was observed in urine in the 
VICC study compared to blood.  No comparable T1/2 data for urine have been 
published in adults.    
o Saliva  
A number of large cohort studies have reported on the benefits of using saliva for 
screening with benefits regarding ease of sample acquisition and decreased risk of 
leakage during transport compared to urine (Boppana et al. 2011;Yamamoto et al. 
2006).  None of these larger screening studies have commented on VL.  The data 
presented here show that VL in saliva has similar dynamics to that in urine in a 
number of aspects with persistent detection over time and a shorter T1/2 than blood.  
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Figure 7-1  Proposed model of ongoing viraemia in babies with congenital cytomegalovirus 
 
 
 
 
 
 
 
 
 
 
 
 
The above cartoon shows a postulated mechanism for ongoing viraemia in babies with congenital cytomegalovirus. 
Antiviral drug prevents infected cells from releasing free virus into the bloodstream but the same drug has poor penetration through the blood-brain-barrier 
leading to low efficacy of treatment of infected cells in the central nervous system (CNS).  In addition to virus in the CNS not being killed it is possible that 
virus in latently infected cells within the CNS becomes reactivated, possibly during neuronal differentiation, to give rise to further productively infected cells.  
Virus from these sources is subsequently detectable in the blood following cell degradation or virus release. 
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There are no comparable quantitative data from adult patient cohorts.   
7.2.2. Viral rebound and subsequent control 
Rebound of virus to a level not significantly different from baseline was observed in 
blood in my studies, with a peak at around 3 months observed in the VICC study.  
Similarly saliva was also noted in the VICC study to rebound to a peak level not 
significantly different to baseline at 6 months of age.  In contrast, rebound in urine 
was to a level significantly lower than baseline at around 6 months.  In both the 
CASG #109 study and VICC study viraemia was becoming controlled without 
treatment by around 5-6 months of age.  Virus was spontaneously decreasing in all 
body fluids by one year of age.  It is noteworthy that this virological control 
corresponds with the emergence of CMV specific immune responses also described 
within this thesis.  
7.2.3. Virus persistence in cCMV 
Although the persistent detection of virus in urine of both congenitally and 
postnatally infected children is well described, the reasons for this observation are 
largely unknown.  It may be that the ongoing detection of virus in urine and saliva 
reflects ongoing viral replication permitted by ineffective immunological control 
along with poor inhibition by antiviral drug activity specific to these sites.  This is 
unlikely in the context of the short T1/2 of viral decline observed in both urine and 
saliva compared to blood and the continued decrease in viruria observed during 
prolonged antiviral treatment in the VICC study.   
An alternative explanation for virus persistence is that virus detectable in urine and 
saliva has itself adapted in some way to evade host immunological control in certain 
body compartments.                          
7.2.1. Potential applications of salivary viral load findings 
My work in assessing the use of dry salivary swabs led to approval for funding of a 
targeted screening study (CMV BEST; NCT01162330).  The purpose of this study 
was to evaluate the added benefit of detecting CMV in babies identified as having 
potential SNHL through the UK NHSP.  This study has recently completed 
recruitment and showed that parents found it easier to obtain salivary swabs and that 
these are as sensitive and specific as urine for diagnosing cCMV (Williams et al. 
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2012).  The acceptability of this sampling method offers potential for testing saliva 
as part of the NHSP in the UK to enable early confirmation of cCMV in children 
with hearing impairment.  A larger study to assess feasibility of integrating salivary 
testing for CMV at the point of referral for further audiological investigation is 
shortly due to commence (CMV BEST 2).   
o Utility of saliva as a diagnostic/monitoring sample 
The ease of both acquisition and transport of salivary samples raises the possibility of 
monitoring VL in untreated symptomatic and asymptomatic babies in non-hospital 
settings to further define natural history in these groups particularly in those 
subsequently developing SNHL.  Further data are needed, however, to determine the 
role of possible breast milk contamination in these samples and optimal sampling 
time following breast feeds.   
7.3. RELEVANCE OF OBSERVATIONS HERE FOR CMV DISEASE   
7.3.1. Threshold concept 
Challenging the relevance of ongoing virus detection in the pathogenesis associated 
with cCMV is the prolonged viruria which has also been noted in postnatally 
acquired infection, with no convincing long-term morbidity, alongside the decreased 
duration of excretion noted in asymptomatic cCMV by some authors (Noyola et al. 
2000;Stagno et al. 1975;Vollmer et al. 2004).  Although higher VL in both urine and 
blood have also previously been reported to be associated with disease in cCMV it 
has not yet been possible to identify a critical ‘threshold’ associated with disease.  
Lack of viraemia has, however, consistently been shown to have good NPV for 
disease and the documented clinical response to only 6 weeks antiviral treatment 
might also support the benefits of lowering virus burden, albeit temporarily.  The 
data presented here are the first to describe quantitative VL in urine over time in 
treated infants. It is therefore of note that only urine VL was shown to decrease 
significantly from baseline with treatment in my studies.  Although other authors 
have reported decreased duration of excretion in symptomatic babies it is possible 
that peak viruria at 6 months or AUC might be of greater significance for 
development of sequelae during this critical period of neurological and audiological 
maturation.   
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This concept of a critical threshold of VL during the natural history of disease would 
also be consistent with the higher initial viral inoculum postulated to be received 
during congenital infection following direct transmission of virus into the 
bloodstream via the placenta.  Such direct inoculation has been hypothesised to 
overwhelm host innate immune responses leading to increased susceptibility to organ 
damage.  As postnatally infected babies most commonly acquire infection from 
breast milk there is not only time during primary amplification for immune 
mechanisms to be triggered but also for concomitant transmission of maternal 
antibodies, particularly if breast feeding is ongoing.  Mucosal immunity and other 
innate responses might thus also have an important role in differentiating between 
HCMV pathogenesis following infection acquired via these two different routes.   
7.4. IMMUNOLOGICAL CONTROL AND IMPLICATIONS FOR 
TREATMENT 
Although the most important determinants of immunological control remain debated, 
clinically significant acute CMV disease is observed almost uniquely in those with 
impaired immunological function. 
The data presented here give new information regarding evolving immune responses 
over time in babies with symptomatic cCMV.  These data show that VL decreases, 
without antiviral treatment, at around the same time as CMV specific IFNg responses 
emerge.  This impaired IFNg response is consistent with observations in other 
infections in neonates and is in keeping with the more severe disease often exhibited 
in this age group.  The reported role of IFNg in promoting neural differentiation and 
neurogenesis might be of further relevance to the neurological damage observed in 
these chronically infected neonates (Gonzalez-Perez et al. 2012).  In view of the 
emerging importance of polyfunctional T cell responses in gaining virological 
control in CMV and other chronic viral infections the relative lack of other cytokine 
responses is also of likely importance.   
The relatively diminished CMV-specific pentamers and decreased production of TH1 
cytokines observed in PBMCs here would challenge the suggestion by some authors 
that an overactive immunological response is responsible for the decreased duration 
of virus excretion observed in babies with SNHL attributable to cCMV compared to 
those that do not develop such sequelae (Caviness et al. 2013;Noyola et al. 2000).  
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The relevance of the increased CD57+ cells observed here is uncertain but would 
imply that there is certainly some ongoing antigenic stimulation leading to associated 
immunological recognition and response in these neonates.  It is possible that 
immunological responses in the CNS and inner ear are distinct from those observed 
in PBMCs here.  My observations suggest, however, that ongoing viral replication, 
reflected by prolonged virus detection in saliva and urine, are partly due to immature 
immunological responses to CMV in neonates.  These diminished responses could 
help explain the ongoing audiological and cerebral pathogenesis also observed in 
cCMV.       
7.5. OTHER WORK INFORMED BY THIS THESIS 
7.5.1. #109 analysis 
Work based on my analysis of the CASG #109 data informed the sampling protocol 
for the subsequent CASG study (CASG #112; NCT00466817) evaluating 6 months 
vs 6 weeks treatment with oral VGCV whose results are expected immenently.   
7.5.2. ECCI website and CMV Treatment Registry 
The European collaborations established during the work presented here generated 
interest in an application for FP-7 funding of work to define some of the unknown 
treatment parameters for CMV in the paediatric age group which reached the final 
review stages.  An expansion of the Registry in its current form was incorporated 
into this application to further evaluate PK and PD of GCV in all children and 
preliminary data from work in this thesis formed a large part of the application.  
Furthermore the use of the Registry for ongoing pharmacovigilance, which is 
currently lacking for antiviral treatment in cCMV and considered increasingly 
important by the EMA, was a core component of this application (EMEA 2007).   
A smaller application was subsequently made through other funding streams to 
support the role of the CMV treatment Registry and there is continued European 
interest in unified data sharing.    
7.6. FURTHER WORK PROPOSED 
One of the biggest unknowns when discussing treatment adequacy in this group of 
patients is what the short-term aims of treatment are.  In cCMV not only is there a 
lack of correlation between levels of virus and adverse clinical outcomes but 
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therapeutic agents currently available have their own potentially significant 
morbidities.   
Treatment studies offer a unique opportunity to simultaneously assess clinical 
response whilst also answering questions regarding natural history of disease and 
potential biomarkers.  By incorporating virological and immunological 
measurements into study protocols our overall understanding of the pathological 
processes contributing to long-term damage and their potential reversibility may be 
further evaluated.  In addition unified agreement with regards to what is considered 
to be ‘symptomatic’ disease at birth along with standardised VL measurements and 
recommendations for follow-up would lead to the possibility of combining data from 
smaller studies.   
Obviously the availability of less toxic therapeutic agents would also shift the risks 
of treatment in favour of treating babies born with less obvious disease. 
7.6.1. New drug treatments/studies  
Newer antiviral therapies targeting different parts of the CMV life cycle are in early 
stages of development as summarised in a recent review (Emery and Milne 2011).  
Although EMEA/FDA initiatives will hopefully increase the likelihood of early data 
in paediatric groups the use of such treatments for cCMV are still likely decades 
away.  When evaluating new treatments in the absence of reliable biomarkers the 
need for RCTs in neonates are paramount given the difficulties in assessing SNHL in 
this age group along with the known fluctuations in hearing thresholds which can 
lead to improvement in hearing independent of antiviral treatment.  The difficulties 
in objectively assessing milder neurological involvement at birth also create potential 
bias when assessing treatment response in uncontrolled studies.    
7.6.2. Work to support treatment studies  
o Standardisation of CMV VL 
Sending samples to a central laboratory for CMV PCR is increasingly untenable 
given current market constraints within the NHS.  It is anticipated that the recent 
international standardisation of quantitative CMV PCR will facilitate further research 
relating to natural history of VL and their widespread adoption is eagerly awaited 
(Fryer et al. 2013).  Areas where this would be of particular benefit are in evaluating 
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natural viral decline prior to treatment initiation and enabling comparisons of peak 
VL across sites in babies not entered into ethically approved trials, particularly with 
regards to defining a potential ‘threshold’ for treatment initiation.  The data held 
within the CMV Registry would also have added value if standardisation is widely 
adopted across Europe.   
o Standardised definitions of symptomatic infection  
Inconsistent definition of ‘symptomatic’ infection at birth complicates interpretation 
of currently published data.  It is likely that analysis of data is altered by including all 
babies with evidence of SNHL at birth in the ‘symptomatic’ group from the outset.  
A consistent definition of symptomatic and asymptomatic infection in neonates, 
similar to the consensus published for disease in infected adults would aid future 
collaborative studies (Ljungman, Griffiths, & Paya 2002). 
The need for such definitions also has wider implications for defining which babies 
should be treated antenatally as obstetric practice often aims to treat in utero those 
babies anticipated to have disease warranting treatment postnatally.  Furthermore 
The US Institute of Medicine has assigned the search for a cytomegalovirus vaccine 
as a level 1 priority with one of the main objectives being prevention of symptomatic 
congenital disease (Stratton et al. 2000).  A standard definition of cCMV disease 
would therefore be of additional significance when moving forwards with future 
vaccine strategies.  It is proposed that such work should be a focus of work for the 
ECCI group in coming years.      
Whether carrying out neuroimaging such as MRI on all babies identified as having 
infection at birth might alter our understanding of those more likely to have future 
pathology is also currently uncertain.  Neurological signs/symptoms are difficult to 
elucidate in the early postnatal period and it is possible that CNS disease is under-
recognised at birth.  It is therefore suggested that MRI should be incorporated into 
the protocol of any future studies identifying or evaluating ‘asymptomatic’ neonates.  
Large neonatal imaging studies assessing the prognostic value of MRI in babies with 
perinatal hypoxia (ePrime: NCT 01049594) might also have implications for rarer 
conditions such as cCMV and imaging techniques such as TBBS could warrant 
future investigation as a biomarker for disease.   
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o Monitoring of different body fluids  
Data from adult studies suggests that analysis of clinically accessible samples mirrors 
that of target organs (Bowen et al. 1996;Cope et al. 1997b).  However, which body 
fluid most closely reflects virus dynamics in relevant target organs in cCMV remains 
unknown and remains an important question to address when considering monitoring 
of these babies.  Although monitoring viraemia has historically been considered of 
greatest importance the persistent virus detection in urine and saliva in cCMV and 
differences in virus dynamics described here might suggest that monitoring of these 
body fluids are of greater relevance in this patient group. Genetic sequencing and 
modelling to further define which body compartment detectable virus originates 
from, might assist in assessing the relative merits of monitoring of different body 
fluids and choosing drugs able to penetrate into any identified sanctuary sites.   
It could also be informative to explore differences in natural history and virus 
dynamics between postnatally and congenitally infected infants.   
7.6.3. Maximising treatment efficacy with currently available preparations 
Until newer therapeutic options are available research should focus on maximising 
efficacy of agents currently available. 
o Pharmacokinetics 
The parameters affecting penetration of drug into the CSF and brain parenchyma are 
complex and not well described for GCV (Strazielle and Ghersi-Egea 2005).  There 
are no studies of CSF or brain penetration of GCV in the paediatric age group and 
drug availability to this compartment might also differ in neonates due to differences 
in either the blood-brain barrier and/or transport systems involved.  The most 
important body compartment to target for drug sampling, however, might be the 
inner ear and perilymph.  Although being closely related to the CSF, it is likely that 
drug distribution in the cochlear and other clinically relevant parts of the 
audiovestibular system involves even more complex interactions.  Modelling is 
currently being developed to further assist administration of other intratympanic 
treatments (Salt et al. 2008).  It is tempting to speculate that differences in hearing 
outcome during treatment for cCMV result from factors relating to actual drug 
exposure in these sanctuary sites and experimental strategies addressing GCV 
delivery to the inner ear might be worth pursuing in future.  Given that guinea pig 
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models have been used both for pioneering research into sampling of the 
intratympanic space and as models of cCMV hearing loss utilising these animal 
models could be considered as a first line of investigation.  Sampling of perilymph at 
cochlear implantation might also be a means of obtaining such PK data in children.  
A single oral dose of VGCV administered prior to surgery might enable valuable in 
vivo data to be obtained although the ethics of such a proposal would need careful 
consideration.  It is possible that advances in drug modelling will enable such data to 
be ultimately derived from other more easily measurable parameters in the future.     
There has also been little/no research into the ability of different cell lines to 
phosphorylate GCV monophosphate to its di- and triphosphate and whether neonates 
have altered enzymatic maturity compared to adults. This might also affect drug 
efficacy and could be investigated further initially in ex vivo systems. 
o Formulation 
Some historical comparison between oral VGCV treatment and i.v. GCV will be 
possible from clinical outcomes in the recently completed CASG study of 6 weeks vs 
6 months VGCV treatment in congenitally infected babies (NCT00466817) 
(Kimberlin et al. 2003).  In the absence of a clinical trial directly comparing clinical 
outcomes in GCV compared to VGCV surrogate markers for treatment response and 
drug penetration into clinically relevant areas are even more urgently needed. 
o Duration 
Publication in 2014 of results of the above CASG study (NCT00466817) evaluating 
6 weeks vs 6 months of treatment should inform the debate as to whether a more 
prolonged treatment course is of clinical benefit and whether any short term 
toxicities limit such treatment.  If virological control in urine, rather than blood, is 
found to correlate with morbidity in cCMV then an even longer treatment course of 
up to one year would be indicated based on my data.     
o Therapeutic drug monitoring 
It would be informative to evaluate how delay in separating samples in the clinical 
setting affects reported levels returned.  These data could be obtained by splitting 
adequately sized and timed samples obtained for clinical need into aliquots and 
separating serum at different time points after receipt prior to determining GCV 
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levels.  If separation delay leads to the same decline in levels observed 
experimentally then clinicians and laboratories should be aware of the necessity for 
urgent processing and freezing of such samples to ensure validity of results.   
As discussed earlier whether target levels for the neonatal group should be redefined 
warrants further consideration.    
o Pharmacovigilance and Development of the CMV Treatment Registry 
The use of ECCI as a platform for publishing guidelines to support good practice in 
treatment is ongoing and recent suggested management guidelines published by our 
group are currently accessible through this site (Kadambari et al. 2011).   
The CMV Treatment Registry does not currently hold data on sufficient numbers of 
treated neonates or of sufficient duration of follow-up to allow for any comments 
regarding long-term toxicity.  Collaboration with other European partners with 
cohorts of babies treated for cCMV is, however, planned which would expand this 
dataset.  Data collection proformas have already been shared to facilitate uniform 
data collection whilst formalised funding is sought.  The future amalgamation of 
these cohorts would further inform long-term safety in this patient group and provide 
a potentially powerful tool for ongoing pharmacovigilance as currently supported by 
EMEA guidance (EMEA 2007).  There are currently no other initiatives planned, to 
our knowledge, to monitor these longer term toxicities of treatment making this an 
important longer term goal.     
Preliminary data published by collaborators in Spain indicate that very different 
courses of treatment are being given in this European country (del Rosal et al. 2012); 
it will therefore be of further interest to compare and contrast data from these 
different cohorts. 
7.6.4. Treatment of asymptomatic babies 
The observation that T1/2 in blood from two independent data sources in neonates are 
similar to values obtained in immunologically compromised adults might allow for 
correlates to be made with adult treatment strategies such as that of ‘pre-emptive’ 
therapy.  It might therefore be rational to sample asymptomatic babies regularly and 
only initiate treatment if VL reaches a certain threshold.  Although a recent study has 
shown a reasonable negative predictive value of a VL of 3500 CMV ge/ml, as 
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already discussed there is currently a lack of information regarding a VL ‘threshold’ 
for progression to disease in cCMV (Ross et al. 2009).  Now that an oral drug 
preparation with an acceptable side effect profile is available such regular sampling 
in babies may be considered unacceptable compared to adopting a ‘treat all’ 
approach for those with any virus detectable at birth.  The consistent finding in 
previous studies that having no virus detectable is associated with a decreased 
likelihood of CMV-associated disease would also support this strategy (Boppana et 
al. 2005;Lanari et al. 2006;Ross et al. 2009).  It is evident that an RCT in babies 
without symptoms at birth is needed, particularly in light of the data presented here 
and of other publications which suggest that some clinicians are already opting to 
treat such babies, particularly if a high VL is found at presentation (Gandhi et al. 
2010).   
It is possible that combining parameters such as initial platelet count and 
neuroimaging with VL might assist in defining a group at ‘lower risk’ of long-term 
sequelae.  Targeting treatment to babies not in this low risk group might be a feasible 
future proposal for a RCT in ‘asymptomatic’ babies.  Costs of neuroimaging along 
with the costs of treating those not destined for any long-term impairment (both 
financial, drug-related and psychologically to families) would be needed before 
results of such studies could be adopted into routine clinical practice.      
7.6.5. How to address missing natural history data in untreated groups  
Although serial blood sampling would seem difficult to justify in this age group 
serial, daily, measurements of VL in saliva or urine in untreated babies would be 
feasible.   
It is hoped that studies addressing other areas of cCMV research will increase the 
likelihood of recruiting asymptomatic babies (CMV BEST 2).  Any RCT of 
treatment in asymptomatic babies will obviously offer valuable opportunities for 
contributing to natural history data in this group and would justify any possible 
parental anxiety associated with obtaining such data.  Treatment studies which are 
currently in planning stages to evaluate treatment of older congenitally infected 
children might also contribute to natural history of VL in babies asymptomatic at 
birth, particularly regarding VL at the time of disease progression (NCT01649869).    
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7.6.6. Parallel studies that could inform treatment strategies 
The reasons for continued virus production from sanctuary sites in the face of 
antiviral treatment are possibly key to maximising treatment efficacy in this age 
group.  It is possible that this continued virus detection may be a function of altered 
drug exposure, for example across the blood-brain-barrier, to different levels of 
cellular enzymes needed to complete GCV tri-phosphorylation in different body 
fluids or to diminished immunological control in neonates.  Further studies 
investigating these differences might be informative.                  
o Compartmentalisation 
Coinfection with multiple different virus strains is well documented (Arav-Boger et 
al. 2002;Ross et al. 2011).  Recent data in adults have interestingly shown 
differential viral decline dependent on gB genotype and with mixed compared to 
single genotype infection, however the role of different virus genotypes in clinical 
pathogenesis is as yet undefined (Emery et al. 2012).   
UL144 is a TNF-a receptor homologue located in a hypervariable region of the CMV 
genome.  Some authors have found that genotype C is more commonly found in 
symptomatic infection, although this has not been confirmed by others.  Scrutinising 
UL144 genotype in different body compartments and comparing with TNF-a 
detectable in blood and/or CSF is of potential future interest.   
The application of high-throughput sequencing to model evolution of virus 
populations within a particular body fluid/compartment might provide further insight 
into the origin of virus detectable in blood (Renzette et al. 2011).  Such studies may 
also contribute to our understanding of the origin of virus responsible for persistence 
and rebound observed in cCMV.   
Whether certain virus genotypes have a predilection for different body compartments 
is therefore of potential future interest and further work using samples obtained 
during my studies is in progress.   
o Immunological correlates 
It is tempting to postulate that in neonates, with their maturing immune systems, the 
high VL seen in primary infection pushes the balance in favour of virus causing 
symptomatic disease.   
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In light of conflicting results from my immunological studies and speculation from 
studies of duration of urinary CMV excretion in babies with and without SNHL 
further work to examine immune response in larger numbers of symptomatic and 
asymptomatic babies is warranted.  Sampling of CSF and blood for immunological 
assays alongside VL at enrolment into treatment studies is suggested.  Use of 
immunological techniques which allow for centralisation of samples is likely to be of 
greatest value in enabling inclusion of large enough numbers of babies for 
meaningful comparisons to be made despite the possible limitations of analysing 
frozen samples.  An alternative would be shared protocols to process fresh samples 
in a number of large centres.       
The low CMV Ig avidity noted at birth in symptomatic babies compared to their 
mothers is also of potential interest and warrants further investigation particularly in 
the context of the emerging use of antenatal immunoglobulin both within and outside 
of controlled trials.  Monitoring such changes might also be of utility when 
considering future trials of CMV vaccine or therapeutic antibody in mothers.        
o Defining biomarkers 
The search for biomarkers remains a priority.  Having a surrogate marker for poor 
clinical outcome would enable shortened follow-up periods in therapeutic studies.  
This would ultimately decrease funding needed for such studies and thus facilitate 
the conduct of RCT’s in this patient group.  It is hoped that results of some of the 
studies mentioned earlier in this discussion will add important information regarding 
such biomarkers, particularly in those initially defined as being asymptomatic.  My 
observations of timing of peak VL and virological control should inform such future 
protocols and thus aid future evaluation of VL with clinical outcomes.  
The natural history data presented here suggest that blood sampling at birth followed 
by 3 and 6 months to define peak VL and those remaining viraemic for a prolonged 
period might further inform the published literature on the relationship between VL 
and disease in asymptomatic babies.     
The difference in virus dynamics in urine compared to blood might suggest greatest 
value in investigating this body fluid further as a biomarker for treatment efficacy.  
Additional work evaluating whether peak urinary or salivary VL, or AUC, is of 
relevance for likelihood of disease in these babies is also suggested.   
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In Hepatitis C infection in adults a better early viral response has been associated 
with need for shorter treatment duration to achieve a sustained virological response 
(Manns et al. 2006).  More recently a similar correlation has been shown between 
first phase virus decline and log10 VL reduction in HCMV at day 21 of treatment in 
adult solid organ transplant recipients (Emery et al. 2012).  Although data presented 
in Chapter 4 did not reveal any association between initial viral decline and 
neurological or audiological outcome further work involving larger numbers of 
babies to evaluate whether initial response to treatment correlates with subsequent 
clinical outcome might be of future value.   
When considering the importance of VL and clinical symptoms further data to 
compare and contrast virus dynamics in postnatally and congenitally infected infants 
might also be of benefit.  These data would not only assist in defining natural history 
in these two different groups but might also be informative for evaluating potential 
benefits of treatment in symptomatic postnatally infected neonates. 
Given the individual differences in virus dynamics exhibited in different babies, 
identification of markers of immunological control may further enable treatment 
duration to be individually tailored to take into account differences in immune 
maturation.  Use of a rapid IFNg capture assay (similar to that used to enhance 
diagnosis of TB) might thus be of benefit in monitoring immunological maturation in 
cCMV and in informing treatment duration.  I would therefore suggest that future 
treatment studies could focus on levels of IFNg release following CMV stimulation 
and correlated with virological response to further evaluate this as a biomarker of 
interest.   
I would propose that, in keeping with treatment of other viral infections in adults and 
children, it is likely that treatment will ultimately be tailored according to responses 
involving a number of the above biomarkers rather than follow a prescribed duration 
to maximise efficacy whilst minimising potential toxicity. 
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